ISPE Officers & Board of Directors

Officers
Sonia Hernández-Díaz, FISPE, President
Kiyoshi Kubota, FISPE, President-Elect
John D Seeger, FISPE, Immediate Past President
Alison Bourke, FISPE, Vice President Finance
Tobias Gerhard, FISPE, Vice President Finance - Elect
Mark H Epstein, Executive Secretary

Directors
Morten Andersen
Andrew Bate
Rhonda L Bohn, FISPE
Jennifer B Christian, FISPE
Helga Gardarsdottir
Wan-Ting Huang
Yea-Huei Kao Yang, FISPE
Marie Lindquist
Vincent Lo Re, FISPE
Malcolm Maclure
June Raine
Sabine Straus
Almut G Winterstein, FISPE
Wei Zhou
Stanley A Edlavitch
Lifetime Emeritus

2016 ICPE Scientific Program Committee

Mary E Ritchey, Chair

Core Program Committee
Thamir Alshammary
Andrew Bate
Kathleen Bennett
Kristen Bibeau
Rhonda L Bohn, FISPE
Kimberly Brodovicz
Melissa Castan
Carlos Duran
Mark H Epstein
Josh Gagne
Arlene Gallagher
Tobias Gerhard, FISPE
Robert Hay
Sonia Hernández-Díaz, FISPE
Ken Hornbuckle, FISPE
Jason Hsu
Wang-Tin Huang
Krista Huybrechts
Jessica Jalbert
Olaf Klungel
Kiyoshi Kubota, FISPE
Deborah Layton
J Bradley Layton
Adrian Levy
Vincent Lo Re, FISPE
David Miller
Susana Perez-Gutthann, FISPE
Lisa Pont, FISPE
John D Seeger, FISPE
Ingrid Sketis
Almath Spooner
Darren Toh
Cunlin Wang

Chairs/Co-Chairs & Liaisons

Committees
Archives & History .................. Hugh Tilson, FISPE
Bylaws & Policies .................. Stella Blackburn, FISPE
Frank W May, FISPE
Development .................. Syd Phillips
Kirk Midkiff
Education .................. Joshua Gagne
Darren Toh
Tobias Gerhard, FISPE
Fellowship & Awards .................. John D Seeger, FISPE
Finance .................. Alison Bourke, FISPE
Tobias Gerhard, FISPE
Global Development .................. Kiyoshi Kubota, FISPE
K Arnold Chan, FISPE
Management Oversight .................. John D Seeger, FISPE
Membership .................. Caitlin Knox
Jonathan Schelfhout
Nominating .................. John D Seeger, FISPE
Public Policy & Ethics .................. Yola Moride, FISPE
Corinne de Vries, FISPE
Publications & Communications .................. Kevin Haynes, FISPE
Minah Tadrous
Scholarship .................. Sonia Hernández-Díaz, FISPE
Scientific Program .................. Mary E Ritchey
Strategic Planning .................. Kiyoshi Kubota, FISPE

Councils
Academic .................. Daniel Prieto-Alhambra
Vera Ehrenstein
Government/Regulatory .................. Sabine Straus
Gianpiero Mazzaglia
Industry/Service Providers .................. Susan A Oliveria, FISPE
John Acquavella, FISPE
Student .................. Sze Ling (Celine) Chui
Juan Hincapie Castillo

Special Interest Groups
Adherence .................. Robert Gross, FISPE
Asian Pharmacoepidemiology
Network (AsPEN) .................. Nicole Pratt
Edward Chia-Cheng Lai
Biologics & Biosimilars .................. Veronique Kugener
Amanda Golembesky
BRACE .................. Rachel Sobel, FISPE
Meredith Smith
Alicia Gilsenan
Comparative Effectiveness
Research (CER) .................. Michelle Johnson-Funk
Databases .................. Bing Cai
Rachael Williams
Drug Utilization Research
Katja Taxis
Veronika Wirtz

Medical Device
Irene B Murimi
Chantal Holy
Leyla Sahin

Medicines In Pregnancy
Sara Ephross

Molecular Epi/Biomarkers/Pharmacogenetics
David Pulford
Quan-Ying Yue

Pediatrics
Tamar Lasky, FISPE
Jon Slaughter

Vaccines
Robert T Chen, FISPE

Liaisons
Sabine Straus
Yola Moride, FISPE

International Joint Policy Committee of the Societies of Epidemiology
Yola Moride, FISPE

US FDA
Christian Hampp

Regional Chapters
Elisa Martin-Merino
Danie Prieto-Alhambra
Hisham Aljadhey
Thamir Alshammary
Marcela Jirón

Working Group
Suzanne L West, FISPE

2016 Local Host Committee
Kathleen Bennett, Chair
Stephen Byrne
Caitriona Cahir
Brian Cleary
Grainne Cousins
Eva Flahaven
Paul Gallagher
Janine Glover
Tamasine Grimes
Martin Henman
Carmel Hughes
Emir Hurley
Deirdre McCarthy
Frank Moriarty
Manjoo Sharma
Sarah-Jo Sinnott
Amelia Smith
Susan Spillane
Almuth Spooner
Mary Teeling

Student Chapters
Basel Pharmacoepidemiology Unit, University of Basel, Switzerland & the Boston Collaborative Drug Surveillance Program, Boston University, USA

Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA

Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA

Clinical and Population Health Research Program, Department of Quantitative Health Sciences, University of Massachusetts Medical School, USA

College of Pharmacy, University of Cincinnati, USA

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, USA

Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, USA

Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, India

Harvard University School of Public Health, USA

Health Outcomes and Pharmacy Practice, The University of Texas at Austin, USA

Faculty of Pharmacy, JSS University, Mysore, India

Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island, USA

Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA

Program for Clinical Pharmacy and Pharmaceutical Sciences, National Chen-Kung University, Taiwan

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA

Talla Padmavathi College of Pharmacy, India

Development Committee
Syd Phillips, Chair
Kirk Midkiff, Co-Chair
Dimitri Bennnett
Andrzej Czarnecki, FISPE
Mark Cziraky
Mark H Epstein

Robert Hay
Susan Oliveria, FISPE
Kate Saltus
Nancy Santanello, FISPE
Jasmanda Wu, FISPE
Organizational & Institutional Members

Pharmaceuticals
- GlaxoSmithKline
- Sanofi-Aventis

Service Providers
- RTI Health Solutions

Government/Regulatory Agency
- Department of Epidemiology, Lazio Regional Health Service

Academic Programs
- Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health
- Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Harvard School of Public Health
- London School of Hygiene and Tropical Medicine
- McGill Pharmacoepidemiology Research Unit, McGill University
- National Taiwan University Health Data Research Center
- Russian National Society of Evidence-Based Pharmacotherapy
- Rutgers, The State University of New Jersey
- University of Cincinnati, College of Pharmacy
- University of Massachusetts Medical School
- University of Texas at Austin - College of Pharmacy

The Society expresses its sincere appreciation to the following supporters listed below for their contributions in honor of the 32nd Annual Meeting (ICPE).

Annual Campaign as of August 4, 2016

IN THIS PROGRAM

32nd ICPE Agenda
- Tuesday, August 23 ............................................................. 12
- Wednesday, August 24 .................................................... 12
- Thursday, August 25 ....................................................... 19
- Friday, August 26 ............................................................. 26
- Saturday, August 27 ......................................................... 36
- Sunday, August 28 ........................................................... 46

32nd ICPE Posters
- Poster Guidelines .............................................................. 58
- Poster Session A ............................................................... 59
- Poster Session B ............................................................... 72
- Poster Session C ............................................................... 84

Indexes
- Abstract Index ................................................................. 95
- Advertisers Index ............................................................ 108
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
</table>
Darren Toh
Fadia Tohme-Shaya
Sylvie Tomczyk
Ernese Toth
Gianluca Trifirò
Md Jamal Uddin
Anan Udombhornprabha
Christine Ulbricht
Marianne Ulcickas Yood, FISPE
Krishna Undela
Hisashi Urushihara
Carla Van Bennekom
Patricia van den Bernt
Helene van der Meer
Angela van der Salm
Marleen van Gelder
Myrthe Van Herk-Sukel
Lionel Van Holle
Florence van Hunsel
Robert Vander Stichelen
Vani Vannappagari
Zdravko Vassilev
Sreenivas Phani Veeranki
Anila Verma
Shilpa Viswanathan
David Vizcaya
Nataliya Volkova
Peter Wahl
Cunlin Wang
Florence Wang
Meng-Ting Wang
Shirley Wang
Tongtong Wang
Wei Wang
Ye Wang
Grace Wangge
Daniala Weir
Lisa Weiss
Suzanne L West, FISPE
Anna Westerlund
Bjorn Wettermark
Andrew Wiese
Corinne Willame
James Wilson
Barbara Wimmer
Lesley Wise
Robert Wise, FISPE
Yun Sum Wong
Mollie Wood
Kimberley Woodcroft
Alison Wright
Chuntao Wu
Jasmanda Hsiao-Hui Wu, FISPE
Richard Wyss
Fenglong Xie
Wanning Xu
Fei Xue
Takuhiro Yamaguchi
Huiying Yang
Mo Yang
Yea-Huei Kao Yang, FISPE
Wai Ping Yau
Xibiao Ye

Yizhou Ye
Mellissa Yong
Hongbo Yuan
Zhong Yuan
Emre Yucel
Huifeng Yun
Akeem Yusuf
Jie Zhang
Wei Zhou
Yanmin Zhu
Inge Zomerdijk
ISPE gratefully acknowledges the generous support of the organizations, institutions and programs listed below. Their contributions helped the Society enhance the scientific program content and increase attendance at the 32nd ICPE.

Exhibitors*

- Analysis Group
- BHE Boston Health Economics
- Boehringer Ingelheim
- Clinical Practice Research Datalink (CPRD)
- Department of Clinical Epidemiology, Aarhus University Hospital
- Digital Health Labs
- Dove Medical Press
- Drug Safety Research Unit
- EPID Research
- Eu2P
- Evidera
- HealthCore
- ICON Plc
- IMS Health GmbH & Co
- Japan Medical Data Center
- Kantar Health
- Mapi Group
- Medical Data Vision Co. Ltd.
- Numerus
- Optum
- Oxon Epidemiology
- Pharma
- Quintiles
- RTI Health Solutions
- The Degge Group and DGI, LLC
- Truven Health Analytics
- UBC
- Uppsala Monitoring Centre
- WHO Collaborating Centre for Drug Statistics Methodology

Academic Supporters*

- Center for Drug Safety & Effectiveness, Johns Hopkins University
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women’s Hospital & Harvard Medical School
- ISPE Latin America Chapter
- ISPE Student Council & Student Chapters
- London School of Hygiene and Tropical Medicine
- Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- PhD in Pharmacoepidemiology, RCSI Population Health
- Postgraduate Programme in Pharmacovigilence, Drug Safety Research Unit
- Rutgers, the State University of New Jersey
- School of Pharmacy at University College Cork
- University of Illinois at Chicago
- University of Rhode Island

Annual Meeting Sponsors*

Platinum

- HealthCore

Gold

- Amgen
- Analysis Group
- Bayer Pharma
- BHE Boston Health Economics
- Biogen
- Boehringer Ingelheim
- Department of Clinical Epidemiology, Aarhus University Hospital
- Eli Lilly and Company
- EPID Research
- Evidera
- IMS Health GmbH & Co
- Kantar Health
- Mapi Group
- Merck and Company
- Numerus
- Optum
- Pfizer
- Quintiles
- RTI Health Solutions
- Takeda
- The Degge Group and DGI, LLC
- Truven Health Analytics
- UBC

Silver

- Celgene
- Evalytica
- Proctor & Gamble
- Sanofi Genzyme

Bronze

- Shire

* As of August 4, 2016

Badges

All attendees at the 2016 ICPE must wear their badges to all events and conference-related functions including the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social event. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., courses and guests.
YOUR SUCCESS IS OUR GOAL

APPROVAL ◦ ACCESS ◦ LONGEVITY
Partner with us to help your product hit the mark from start to finish.

Evidera, your global leader in generating and communicating evidence of product value to inform healthcare decision making.

EVIDERA PRESENTATIONS AT ICPE

Pre-Conference Course
Selection of Databases for Pharmacoepidemiology Research
Reynolds M

Symposium
Who to Ask and How? Preference-Based Methods for Benefit-Risk Assessment?
Marsh K, Hillege HL, Ataher Q, Tervonen T

Workshop
What’s in a Code? Algorithm Validation in Drug Safety Studies

Oral Presentation
Development and Validation of an Algorithm for Identifying Pediatric Patients with Type 2 Diabetes in Claims Data

PLUS 5 Posters!

Evidera
evidera.com

Evalytica®
evalytica.com
# Wednesday, August 24, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Welcome Reception/International Chapter &amp; Academic Showcase (3rd floor)</td>
</tr>
<tr>
<td>7:30am</td>
<td>kisses the wave: introduction to therapeutic drug utilization</td>
</tr>
<tr>
<td>8:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>8:30am</td>
<td>Lunch on your own</td>
</tr>
<tr>
<td>9:00am</td>
<td>Propensity Scores in Pharmacoepidemiology (Liffey Mtg Rm 2)</td>
</tr>
<tr>
<td>10:30am</td>
<td>Lunch on your own</td>
</tr>
<tr>
<td>11:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>1:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>7:00pm</td>
<td>Educational Sessions</td>
</tr>
</tbody>
</table>

# Thursday, August 25, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Summary: Biologics and Biosimilars</td>
</tr>
<tr>
<td>7:30am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>8:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>9:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>2:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>4:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>5:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>6:30pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>7:00pm</td>
<td>Educational Sessions</td>
</tr>
</tbody>
</table>

# Friday, August 26, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>8:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>9:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>10:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>11:00am</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>1:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>7:00pm</td>
<td>Educational Sessions</td>
</tr>
</tbody>
</table>
### Saturday, August 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 5:00pm</td>
<td>Speakers’ Ready Room (Liffey Mtg Rm 4)</td>
</tr>
<tr>
<td>7:00am - 6:00pm</td>
<td>Registration Open (Ground Foyer)</td>
</tr>
<tr>
<td>7:00am - 6:00pm</td>
<td>Poster Session B Set-Up (The Forum &amp; 3rd Floor)</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Coffee &amp; Tea (The Forum)</td>
</tr>
<tr>
<td>8:00am - 12:00pm</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>10:30am - Noon</td>
<td>Plenary Session: Multiple Database Study Design (The Auditorium)</td>
</tr>
<tr>
<td>Noon - 1:30pm</td>
<td>ISPE Board of Directors Luncheon (Liffey Mtg Rm 1)</td>
</tr>
<tr>
<td>1:15pm - 1:30pm</td>
<td>2017 ICPE Social Event</td>
</tr>
</tbody>
</table>

### Sunday, August 28, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 3:30pm</td>
<td>Speakers’ Ready Room (Liffey Mtg Rm 4)</td>
</tr>
<tr>
<td>7:00am - 4:30pm</td>
<td>Registration Open (Ground Foyer)</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Poster Session C Set-Up (The Forum &amp; 3rd Floor)</td>
</tr>
<tr>
<td>7:00am - 8:00am</td>
<td>Coffee &amp; Tea (The Forum)</td>
</tr>
<tr>
<td>8:00am - 1:15pm</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>10:00am - 1:15pm</td>
<td>2017 ICPE Social Event</td>
</tr>
<tr>
<td>Noon - 1:30pm</td>
<td>ISPE Board of Directors Luncheon (Liffey Mtg Rm 1)</td>
</tr>
<tr>
<td>1:30pm - 2:00pm</td>
<td>2017 ICPE Adjournment</td>
</tr>
</tbody>
</table>
**EDUCATIONAL SESSIONS: ALL DAY COURSE** *(Ticket required)*

8:00am-6:00pm  
**Pharmacogenomics in the Real World 2.0 (Liffey Meeting Room 2A)**

**Content**
This course will focus on the essentials every pharmacoepidemiologist should know about real world applications of pharmacogenomics including precision medicine, companion diagnostics, the biomarker development pipeline, common genomic observational designs, and the intersection of big data with pharmacogenomics. This course has expanded to include a broader definition of genomic and other biomarkers, including both germ line and somatic changes. There will be short pre-course orientating videos on the ISPE website that will cover basic definitions and concepts in preparation for the main course, allowing the main course to focus more on practical applications. A variety of instructional techniques (including didactic teaching, scenario-based advanced and basic break-out sessions, small group round-table discussions, bring your own question/ask the expert sessions, and an interactive debate) will be used to keep attendees engaged throughout the day-long course.

**Course Directors**
- Amalia M Issa, University of the Sciences in Philadelphia  
- Anke-Hilse Maitland van der Zee, Utrecht University

**Course Faculty**
- Gillian Bartlett, McGill University  
- Bruce Carleton, University of British Columbia  
- Marissa Dolled-Filhart, Merck Research Laboratories  
- Alexander Doney, University of Dundee  
- Kelly Filipski, National Cancer Institute  
- Andrew Freedman, National Cancer Institute  
- Stephen Kimmel, University of Pennsylvania  
- Geoffrey Liu, University of Toronto  
- Colin Palmer, University of Dundee  
- David Pulford, GlaxoSmithKline  
- Wei Zhou, MD, Merck Research Laboratories

---

**HALF-DAY MORNING COURSES** *(Ticket required)*

8:30am-12:30pm  
**Pediatric Pharmacoepidemiology (Wicklow Meeting Room 3)**

**Content**
The increasing use of medications by children and the history of excluding children from clinical trials have created the need for pediatric pharmacoepidemiology, a sub-specialty within pharmacoepidemiology. Unique challenges in studying children, accessing data, defining outcomes, and designing pediatric studies will be discussed. This half-day course will introduce participants who have a good understanding of pharmacoepidemiology to the specific methodologic issues arising in pediatric pharmacoepidemiology and operational approaches used to study medications in children.

**Course Faculty**
- Tamar Lasky, FISPE, MIE Resources  
- Ann W McMahon, U.S. Food and Drug Administration  
- Rachel E Sobel, FISPE, Pfizer Inc.  
- Susan dosReis, University of Maryland School of Pharmacy Department of Pharmaceutical Health Services Research
Real-world insight into drug safety and epidemiology.

Proven epidemiology research expertise powered by one of the largest healthcare data repositories.

HealthCore is on the frontline of observational research aimed at uncovering vital evidence on the utilization, safety and effectiveness of biopharmaceuticals and devices in large, real-world patient populations.

Our multi-disciplinary team of pharmacoepidemiologists brings a broad range of scientific expertise and operational experience to the timely and accurate execution of safety and risk management studies in the post-marketing real-world setting.

The HealthCore Integrated Research Environment (HIRES™) allows for the augmentation of automated claims with clinical data obtained from medical records, electronic health records, physicians, and patients – making it a rare and valuable resource for conducting medical product safety and risk management studies.

- Descriptive epidemiology (natural history of disease, burden of illness)
- Drug and vaccine post authorization safety studies
- Risk management and REMS survey studies
- Active surveillance of new medical products and adverse events
- Development and medical record validation of case-identifying algorithms
- Multi-database study design, coordination, and execution
- Data linkage capability
- Systematic literature reviews
- Strategic consulting

Visit Booth #5 during ICPE to learn about our full-service research solutions or contact us at RWE@HealthCore.com.
HALF-DAY MORNING COURSES (CONT.)

8:30am–12:30pm

Introduction to Pharmacoepidemiology (Wicklow Hall 1)

Content
This half-day course will provide participants with a short introduction to the basic principles and concepts of pharmacoepidemiology. The course includes lectures on cohort studies, case-control studies, and bias & confounding.

Course Faculty
Almut Winterstein, FISPE, University of Florida College of Pharmacy
Jennifer Lund, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
Tobias Gerhard, FISPE, Ernest Mario School of Pharmacy, Rutgers University

Medical Device Epidemiology (Wicklow Meeting Room 4)

Content
This course provides a foundation for medical device epidemiology and its application to the real world. The course will incorporate didactic lectures and interactive case studies that highlight novel medical devices and combination products.

Course Faculty
Colin Anderson-Smits, U.S Food and Drug Administration
Kourtney Davis, GlaxoSmithKline PLC
Chantal Holy, Johnson and Johnson
Katherine Etter, Johnson and Johnson
Jessica Jalbert, LA-SER Group & Weill Cornell Medical College
Mary E Ritchey, RTI Health Solutions
Michael Steinbuch, FISPE, Procter and Gamble

Introduction to the Evaluation of Therapeutic Risk Management Programs (Liffey Meeting Room 3)

Content
This course presents an overview of European and US risk management principles, with a focus on methods and examples for evaluating the effectiveness of risk minimization measures. The didactic section includes speakers from European and US regulatory, industry and research communities to present background, trends in regulatory requirements, and examples of effective evaluation techniques. The workshop section asks participants to work in groups to develop an evaluation plan for one of two health outcomes of interest for a hypothetical product. The groups present their plans from this case study to the “regulatory panel (faculty)” for feedback and discussion.

Course Faculty
Gerald Dal Pan, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Almath Spooner, Health Products Regulatory Authority, Ireland and Vice Chair EMA’s PRAC
Elaine Morrato, Colorado School of Public Health
Meredith Smith, Global Patient Safety at Amgen
Judith Jones, FISPE, The Degge Group, Ltd
Lesley Wise, Takeda Development Centre Europe Ltd
Alicia Gilsenan, RTI Health Solutions
Adherence to Pharmacotherapy (Wicklow Meeting Room 1)

**Content**
This course will provide an overview of measurement issues to be considered when designing and conducting an adherence study. The course will cover the following topics:

- Description of different constructs of adherence that can be measured: initiation, implementation, and persistence.
- Selection of measurement techniques according to the construct being measured.
- Strengths and limitations of commonly used techniques: self-reports, medical/pharmacy electronic data and microelectronic monitoring data, among others.
- Discussion of analysis issues: choice of the duration of an adherence interval, taking multiple drug regimens and switches into account, various approaches to summarizing adherence data from the different techniques, and linking adherence data to relevant outcomes.

**Course Faculty**
- **Robert Gross, FISPE**, University of Pennsylvania Perelman School of Medicine
- **Jacqueline Hugtenburg**, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, Netherlands
- **Niteesh Choudhry**, Harvard Medical School; Center for Healthcare Delivery Sciences, Brigham and Women’s Hospital
- **Jean-Pierre Grégoire, FISPE**, Laval University, Québec City, Canada
- **Petra Denig**, University Medical Center Groningen, The Netherlands

---

It begins with a promise
to discover medicines that make life better.

Since 1876, we have worked tirelessly to discover medicines that make life better, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/promise.
HALF-DAY AFTERNOON COURSES *(Ticket required)*

12:30–2:00pm

**Lunch on Your Own**

2:00–6:00pm

**ISPE Newcomers/Early Stage Investigators Workshop** *(Wicklow Hall 1)*

**Course Faculty**
- Vincent Lo Re III, FISPE, Center for Pharmacoepidemiology Research & Training, University of Pennsylvania
- Caitlin Knox, Quintiles
- Tarek Hammad, FISPE, Merck Research Laboratories
- Sengwee Darren Toh, Harvard Medical School & Harvard Pilgrim Health Care Institute
- Stella Blackburn, FISPE, Quintiles
- Irene Petersen, FISPE, Institute of Epidemiology & Health, University College London
- Quazi Ataher, Pfizer

**Content**
This course is aimed at early stage pharmacoepidemiologists who have been in the field for less than 3 years. Participation will lead to enhancement in skills (i.e., development of mentor-mentee relationships, research presentation, and manuscript writing) that are crucial to early success in pharmacoepidemiology. We will also discuss important aspects of early stage professional development in careers in government/regulatory science, academia, and industry.

**Comparative Effectiveness Research: CER and its Role in Adaptive Licensing** *(Wicklow Meeting Room 4)*

**Course Faculty**
- Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Olaf Klungel, Division of Pharmacoepidemiology & Clinical Pharmacology, University of Utretch
- Danica Marinac-Dabic, FISPE, Division of Epidemiology, Center for Devices and Radiological Health, U.S. Food and Drug Administration

**Content**
Increasingly, regulators are moving towards adaptive licensing, which is the progressive approval or authorization of a medical product characterized by iterative phases of data gathering and regulatory evaluation. Rigorous comparative effectiveness research, which involves generating “real world” evidence about the benefits and risks of medical products, can play a key role in informing adaptive licensing decisions. This year’s course will start with an overview of methodological aspects related to CER and then will narrow the focus to how evidence from comparative effectiveness research can support adaptive licensing.

**Intermediate Database Utilization Workshop: Using Pharmacoepidemiology Database Resources to Address Drug Safety Research** *(Wicklow Meeting Room 3)*

**Course Faculty**
- Gillian Hall, FISPE
- Matthew Reynolds, Evidera
- Brian Sauer, University of Utah
- Elileen Ming, Epi Excellence
- Fergus Caskey, North Bristol, NHS Trust

**Content**
This highly interactive workshop will involve participants in the following topics:
- Examine the use of database resources in pharmacoepidemiology research;
- Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource, workshop will strengthen the concepts discussed through participant interaction;
- Assess the quality of electronic medical record data
- Conduct validation studies through a variety of approaches
- Examine characteristics of available resources for data linkage between pharmacoepidemiology resources particularly to patient registry data resources
HALF-DAY AFTERNOON COURSES (CONT.)

Applying Benefit-Risk Assessment in the Context of Regulatory Submission of New Molecular Entities
(Liffey Meeting Room 3)

Content
- Presentation of Benefit-Risk and patient preference information for regulatory interactions, especially new molecular submissions
- Overview of expectations for developing and presenting the structure and content of Benefit-Risk information
- Quantitative methods for Benefit-Risk assessment
- When and how to use patient preference information to inform regulatory decision-making

Course Faculty
Tarek A Hammad, FISPE, Merck Research Laboratories
Juhaeri Juhaeri, Sanofi
Brett Hauber, RTI Health Solutions
Rebecca Noel, Eli Lilly and Company

Practical Skills in Protocol Writing and Computer Programming Relevant to Pharmacoepidemiology
(Wicklow Meeting Room 1)

Content
Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when executing the studies. This highly interactive course will engage participants in the following topics:

1. Pre-specifying study components in a protocol, including design, analysis, conduct, and reporting of the study, along with a science-based rationale for the choices pertaining to these components.
2. Translating elements of the study protocol into SAS programming

Course Faculty
Christian Hampp, U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Division of Epidemiology II
Jessica Jalbert, LASER Analytica, Weill Cornell Medical College
Chih-Ying (Natasha) Pratt, U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Division of Epidemiology II
Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia
Soko Setoguchi, FISPE, Duke Clinical Research Institute

MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB. BUT THEY BEGIN IN THE HEART.

For more than a century, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400.

Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0102 01/16
Raising the Standard in Pharmacoepidemiology

For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop innovative solutions for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Peri-approval safety studies for IND and NDA submissions and post-approval commitment
- Observational pharmacoepidemiology studies (e.g., claims analysis and chart review, EMR data analysis)
- Prospective drug safety surveillance
- Drug safety monitoring boards
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analyses and meta-analyses for drug safety endpoints
- PMR/PMS and PASS studies
- Strategic responses to drug safety concerns raised by U.S. and ex-U.S. regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Advanced methods in causal inference (e.g., marginal structural models, mediation analysis, high-dimensional propensity score matching)
- Comparative effectiveness research
- Quality of life instrument development and validation
- Mass tort pharmaceutical liability litigation
- Machine learning and ensemble methods
- Natural language processing
EDUCATIONAL SESSIONS:
HALF-DAY MORNING COURSES (Ticket required)

8:30am–12:30pm
Introduction to Drug Utilization Research (Wicklow Meeting Room 3)

Content
This educational session provides an overview of drug utilisation research and presents essential methods used. The session includes interaction with participants, question, and answer sessions and discussion during and at the end of each presentation. At the end of the session, the participant will be exposed to:

• Description of the theoretical framework and practical applications of different methods illustrated using selected examples
• Classification systems used in drug utilisation monitoring and research
• Limitations of data sources and methods
• Interpretation of aggregate and individual-based data, variation and change
• Importance of drug utilisation research for public health and implications for policy decisions

Course Faculty
Katja Taxis, University of Groningen, The Netherlands
Hanne Strom, WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Oslo, Norway
Björn Wettermark, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden
Andrew Gilbert, FISPE, University of South Australia, Adelaide, Australia

PATIENT-CENTERED SOLUTIONS
AT MAPI, PATIENTS ARE AT THE HEART OF EVERYTHING WE DO

Mapi Group believes that listening to patients is the crucial element in improving world health. Our wide range of offerings, including strategic consulting and related services in Epidemiology and Product-Related Risk Management, helps ensure that the voice of the patient is heard throughout the development process.

Visit us at Booth 20 for more information
## Intermediate Pharmacoepidemiology -- Dealing With Unmeasured Covariates (Wicklow Hall 1)

**Content**
Covariates are often poorly measured or not measured at all. Unmeasured confounders produce bias, and they lead to divergent results in studies that ought to be near replicates of one another. Unmeasured intermediates can lead to “effects” that run contrary to simple biological cause. This course will classify the options for dealing with unmeasured covariates in study design and analysis. Students will see and be able to discuss examples of self-controlled case series and matched designs, propensity-balancing for proxy-variable control, and instrumental variable analyses.

**Course Faculty**
- Alexander M Walker, FISPE, World Health Information Science Consultants

## Propensity Scores in Pharmacoepidemiology (Liffey Meeting Room 2)

**Content**
Issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect. Faculty will explain how propensity scores can be used to mitigate confounding through standard observational approaches (restriction, stratification, matching, regression, or weighting). The advantages and disadvantages of standard adjustment relative to propensity score-based methods will be discussed. Details of propensity score methodology (variable selection, use, and diagnostics) will also be discussed.

**Course Faculty**
- John Seeger, FISPE, Optum
- Jeremy Rassen, Aetion

## Pharmacovigilance & Signal Detection (Liffey Meeting Room 1)

**Content**
This half-day course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects and recent advances in the field. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including the EU-ADR project and the US FDA's Sentinel program, aimed at using routinely collected electronic healthcare data to conduct signal detection and prospective medical product safety monitoring. The course will involve lectures with ample opportunities for questions and discussion. Use of social media for signal detection will also be discussed.

**Course Faculty**
- Andrew Bate, Pfizer Ltd
- Gianluca Trifirò, University of Messina & Erasmus University Medical Center
- Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School
- Stephen Evans, FISPE, London School of Hygiene & Tropical Medicine

## Registries and Prospective Cohort Studies (Liffey Meeting Room 5)

**Content**
This course will provide an overview of the theory and practice, including field methods, for the design, execution and interpretation of registries and prospective studies. Topics include regulatory, methodological and logistical challenges and how studies are evaluated for specific purposes. Special applications relating to pregnancy registries, emerging therapies and Post-Authorization Safety Studies will be reviewed, as well as current guides to quality for prospective studies. An interactive case study will be presented to allow attendees to engage in critical reflection.

**Course Faculty**
- Nancy A Dreyer, FISPE, Quintiles
- Christina D Mack, Quintiles
- Sonia Hernández-Díaz, FISPE, Department of Epidemiology, Harvard T.H. Chan School of Public Health
- Deborah Layton, Drug Safety Research Unit, Portsmouth University
HALF-DAY MORNING COURSES (Cont.)

8:30am–12:30pm

Modern Pregnancy Pharmacoepidemiology: Methodological Challenges in Exposure Measurement and Implications for Study Design and Analysis (Wicklow Meeting Room 5)

Content
In this half day course, we will discuss study design and analysis aspects related to exposure in studies of drug utilization and drug safety in pregnancy. The course format will consist of four short methods-focused presentations by faculty with Q&A along with two break-out sessions giving participants the opportunity to discuss and report back on the assigned readings, and a short faculty-moderated session wrap-up.

The content of this course has changed from last year’s. While in 2015 the course provided an overview of issues that are particular to pregnancy safety research, this year the focus will be on specific challenges related to exposure measurement. Some of the topics to be covered include defining the etiologically relevant time window (including issues related to LMP estimation and differential opportunity for exposure), how to define exposure (e.g., number of prescriptions, days supply overlap, patient recall, drug class or individual drugs), how to define the comparator group (e.g., unexposed with same condition, active comparator, exposed during a different time window in pregnancy), dose-response analyses, value of positive controls (i.e., assess known associations between the exposure and an outcome), and sensitivity analysis evaluating potential bias associated with exposure misclassification. Advantages and disadvantages of different approaches will be discussed.

Course Faculty
Andrea Margulis, RTI Health Solutions
Brian Bateman, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School
Krista Huybrechts, FISPE, Brigham and Women’s Hospital and Harvard Medical School
Helle Kieler, Karolinska Institutet

Even with more than 128 years of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 145 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more than 47,500 employees worldwide and a track record built up in more than 128 years, we are continuously dedicated to improving the outlook for a healthier life.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com
### Advanced Topics in Pharmacoepidemiology (Liffey Hall 1)

**Course Instructors/Presentations:**
- Kenneth J Rothman, FISPE, RTI Health Solutions: *The Significance of the ASA Statement on Significance and P-Values*
- Robert Glynn, Brigham and Women’s Hospital and Harvard Medical School: *Competing Risks in Pharmacoepidemiology*

**Content**
This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in:
- Use of drug utilisation information from administrative health data to improve medicines use
- Use of prescribing quality indicators to assess prescribing
- Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention
- Methods for evaluating the effect of clinical or policy interventions
- Interpretation of the evaluation data and dissemination of results

### Advanced Drug Utilization Research (Liffey Meeting Room 1)

**Course Faculty**
- Petra Denig, University of Groningen
- Eimir Hurley, Trinity College Dublin
- Libby Roughead, FISPE, School of Pharmacy and Medical Sciences, University of South Australia
- Lisa Pont, FISPE, Australian Institute of Health Innovation, Macquarie University

**Content**
This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in:
- Use of drug utilisation information from administrative health data to improve medicines use
- Use of prescribing quality indicators to assess prescribing
- Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention
- Methods for evaluating the effect of clinical or policy interventions
- Interpretation of the evaluation data and dissemination of results

### Pharmacoepidemiologic Considerations for Biologics and Biosimilars (Wicklow Meeting Room 3)

**Course Faculty**
- Nancy A Dreyer, FISPE, Quintiles Real World & Late Phase Research and University of North Carolina
- Thijs Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands; Expert at the Medicines Evaluation Board in the Netherlands; Member of the EMA Biosimilars Working Party
- Gianluca Trifirò, University of Messina and Erasmus Medical Center
- Brian D Bradbury, Amgen, Inc. and University of California Los Angeles School of Public Health
- Jaclyn L F Bosco, Quintiles Real World & Late Phase Research and Boston University School of Public Health

**Content**
This interactive workshop will involve participants in the following topics:
- Update on the current landscape of biologics and biosimilars
- Review regulatory guidelines, particularly focused on postmarketing, pharmacovigilance, and risk management requirements for biologics and biosimilars
- Understand challenges and methodological considerations when conducting post-marketing studies of biologics and biosimilars.
- Discuss primary data collection and use of multiple data sources for evaluating comparative safety and effectiveness of biologics and biosimilars.
**HALF-DAY AFTERNOON COURSES (Cont.)**

<table>
<thead>
<tr>
<th>2:00–6:00pm</th>
<th><strong>Epidemiology of Vaccine Safety</strong> (Wicklow Meeting Room 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Content</strong></td>
<td>This half-day course aims to establish an understanding of some of the ways in which vaccine safety is monitored after licensure, including passive surveillance methods, common observational vaccine-safety study designs and methods, active safety surveillance using sequential analysis, and investigation of signals that arise from active surveillance. The course will involve lectures with ample opportunities for audience participation (questions and discussion).</td>
</tr>
</tbody>
</table>
| **Course Faculty** | S Rizwan Ahmad, FISPE, Georgetown University  
Robert T Chen, FISPE, Centers for Disease Control and Prevention  
Steven Bailey, Pfizer  
Patricia Saddier, Merck  
Martin Kulldorff, Harvard Pilgrim Health Institute  
Katherine Yih, Harvard Pilgrim Health Institute |

<table>
<thead>
<tr>
<th><strong>Using Field Studies to Value-add in Pharmacoepidemiology</strong> (Liffey Meeting Room 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Content</strong></td>
</tr>
</tbody>
</table>
| **Course Faculty** | Veronika Wirtz, Boston University School of Public Health  
Katja Taxis, University of Groningen  
Annie Fourrier-Reglat, University Bordeaux  
Lisa Pont, FISPE, Australian Institute of Health Innovation, Macquarie University |

---

**numerus**

**Discover the power of statistics**

Statistical, epidemiological and health economic analyses for drug development

---

**Clinical Development**

Expert statistical design, analysis and reporting of phase I-III trials

**Health Technology Assessment**

Added value for health economics based on sound statistical principals

**Observational Research**

Analytical solutions that utilise the full potential of real world data

**Germany | United Kingdom | Switzerland**

[www.numerus.com](http://www.numerus.com)
HALF-DAY AFTERNOON COURSES (Cont.) (Ticket required)

2:00–6:00pm
Regulatory Pharmacoepi
(Wicklow Hall 1)

Content
• Understand the intent and structure of regulation to protect the Public Health.
• Appreciate the challenges of decision making with weak data.
• Know about practical approaches typically chosen by regulators.
• Recognize the challenges epidemiology faces to provide sufficient information for public health decision making.
• Gain an overview of worldwide challenges for drug regulatory agencies and variation in approaches.
• Know about current strategies to strengthen regulation in the face of these challenges.

Course Faculty
Gerald Dal Pan, Center for Drug Evaluation and Research, Food and Drug Administration
June Raine, Medicines and Healthcare Regulatory Products Agency
Stephen JW Evans, FISPE, London School of Hygiene and Tropical Medicine

6:00–7:00pm
Welcome Reception/International Chapter & Academic Showcase (3rd Floor)

› Sponsored by Optum
• Kathleen Bennett, Chair, 2016 Local Host Committee
• Mary E Ritchey, Chair, 2016 Scientific Program Committee
• Sonia Hernández-Díaz, FISPE, ISPE President

International Chapter & Academic Showcase Participants
› Center for Drug Safety & Effectiveness, Johns Hopkins University
› Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
› Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women’s Hospital & Harvard Medical School
› ISPE Gulf Chapter
› ISPE Latin-America Chapter
› ISPE Student Council & Student Chapters
› London School of Hygiene and Tropical Medicine
› Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
› PhD in Pharmacoepidemiology, RCSI Population Health
› Postgraduate Programme in Pharmacovigilence, Drug Safety Research Unit
› Rutgers, the State University of New Jersey
› School of Pharmacy at University College Cork
› University of Illinois at Chicago
› University of Rhode Island

7:30-9:30pm
Students/Early Career Professionals Meet & Greet
(Ely Bar & Brasserie)

› Registration required -- limited capacity.
Organized by the Student Council. Please contact SISPEchair@gmail.com for more information, and to RSVP.
Real-world insights are driving healthcare decisions on safety, efficacy, effectiveness and value. To develop the evidence you need to satisfy diverse stakeholders, start by integrating therapeutic expertise, real-world data and powerful analytics technology. Harness post-approval research to maximize value, contain costs and drive better outcomes.

Visit us at Booth #12

Learn how at www.quintiles.com/RWLPR
This special session will present the draft guideline, produced by a group of experts from IMI-Protect, EuroDURG and WHO CC for Pharmaceutical Policy and Regulation. The project was selected and funded by the ISPE Strategic Planning Committee under the Society’s Call for Manuscripts Initiative.

Based on a literature search, a review template for CNC DU studies was built to address the main methodological issues, (standardize the information extraction, assess the risk of bias in the exposure estimation of each country or region compared, and evaluate the validity of the comparison between countries or regions). The information gathered was used to develop good practice guidelines for designing, conducting, analyzing and reporting CNC DU studies.

The project leaders will present the results and discuss with the audience whether the following areas were well addressed: reliability and validity of population coverage; drug coverage; drug terminology issues; biases affecting accuracy and precision of exposure estimates. Comments will be collected and embedded in a final draft of the guidelines.

Next steps will be discussed to ensure that standardized guidelines will enhance the validity and reliability of CNC DU studies, and facilitate their peer review, correct interpretation of CNC DU studies, and adequate translation into pharmaceutical policy decision-making. The final draft of the guidelines will be submitted to the ISPE membership for comments consistent with the ISPE Policy Manual and sent to the ISPE Board for action.

Some argue that without representativeness the effects estimated from such studies are applicable only to the patients directly in the study and cannot be extrapolated to other populations, rendering the research essentially useless. Under this view, most pharmacoepidemiology studies conducted to date are invalid. This contentious issue is stirring an important debate in the research community, as evidenced by the more than 30 comments that were published alongside the paper.

A recent, highly publicized paper, “Perils and potentials of self-selected entry to epidemiological studies and surveys,” published in the Journal of the Royal Statistical Society, put forth the argument that all epidemiologic studies should be based on representative samples of a specific patient population. For example, in a study of diabetes treatments, the target population might be all adult type 2 diabetes patients in the United States, and a representative sample could be formed either by randomly selecting patients from the target population into the study or by using a different sampling method, accompanied by sampling weights to adjust estimates for non-random sampling.

While representative sampling is the norm in fields such as survey research, where the focus is on estimating measures that characterize a specific population, it is almost never used in research aiming to estimate causal effects, including both randomized trials and observational studies of treatments. Some argue that without representativeness the effects estimated from such studies are applicable only to the patients directly in the study and cannot be extrapolated to other populations, rendering the research essentially useless. Under this view, most pharmacoepidemiology studies conducted to date are invalid. This contentious issue is stirring an important debate in the research community, as evidenced by the more than 30 comments that were published alongside the paper.

This session will explore the role of representative sampling in pharmacoepidemiology from different perspectives. Dr. Poole will present background on representative sampling, its main methods, and practical issues in its application to pharmacoepidemiology, providing a pharmacoepidemiologist’s viewpoint. Dr. Evans will provide a statistician’s perspective, challenging several of the epidemiologists’ viewpoints. Dr. Kurz will share the views and experience of regulators.
10:30am-Noon  **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

### Meascán de Meds: Utilization and Trends  
**The Liffey A**

**Moderators:** Gianluca Trifirò & Björn Wettermark

- **10:30am**  
  - **Time-Trends and Predictors of Oral Disease Modifying Drug Treatment for Multiple Sclerosis** [1]
    - Rishi J Desai, Mufaddal Mahesri, Eimir Hurley, Joshua J Gagne, Angela Tong, Tanuja Chinis, Sarah Minden, Olga S Matlin, William H Shrank, Niteesh Choudhry. (United States)
  - **Drug Utilization Patterns in Relapsing-Remitting Multiple Sclerosis: A Population-Based Cohort Study** [2]
    - Irene Eriksson, Thomas Cars, Fredrik Pielhl, Rickard Malmström, Björn Wettermark, Mia von Euler. (Sweden)

- **11:00am**  
  - **Psoriasis Patients New to Specialist Care in Sweden 2007-2009: A Two-Year Follow-Up of Treatment Allocation** [3]
    - David Hägg, Marie Eriksson, Marcus Schmitt-Egenolf, Anders Sundström. (Sweden)

### BRACE Yourself  
**The Liffey B**

**Moderators:** Elizabeth Andrews, FISPE & Inge Zomerdijk

- **10:30am**  
  - **Risk Minimization Evaluation in a Distributed Data Network - An IMEDS Evaluation Pilot Assessment of the 2010 Class Label Change for Proton Pump Inhibitors** [7]
    - Rachel E Sobel, Andrew Bate, James Marshall, Gregory Daniel, Troy McCall, Jeffery Brown, Robert F Reynolds. (United States)
  - **The Impact Of Risk Minimisation Measures On The Incidence And Prevalence Of Use Of Strontium Ranelate At The Population Level: Preliminary Results Of A Multi-National Cohort Study Including 5 European Countries** [8]
    - Klara Berencsi, Cristina Reyes Reyes, Lars Pedersen, Preciosa Coloma, Francesco Lapi, Monica Simonetti, Peter Rijnbeek, Miriam C Sturkenboom, Daniel Prieto-Alhambra. (United Kingdom)

- **11:00am**  
  - **Evaluating Patient Knowledge of Risks and Safe Use of Xarelto (Rivaroxaban)** [9]
    - Laurie J Zografos, Kiliana Suzart, Andrea Horvat-Broecker, Montse Soriano-Gabarró, Dan L Wolin, Brian Calingaert, Eric K Davenport, Kelly A Hollis, Elizabeth Andrews. (United States)
### Diabetes: Adverse Events of Cardiovascular Treatment: Head to Toe (Wicklow Hall 2)

**Moderators:** Deb Casso & Yea-Huei Kao Yang, FISPE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00am</td>
<td>Statins and Reduced Risk of Liver Cancer: Evidence for Confounding [15]</td>
<td>Laurel A Habel, Ninah Achacoso, Bruce Fireman, Gary D Friedman. (United States)</td>
<td>Wicklow Hall 2</td>
</tr>
</tbody>
</table>

### Pregnancy and Beyond (Liffey Hall 2)

**Moderators:** Sara Ephross & Kathryn Rough

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30am</td>
<td>Ondansetron Use Among Pregnancies Identified In The Sentinel Distributed Database [19]</td>
<td>Lockwood G Taylor, Patty Greene, Steven T Bird, Marsha E Reichman, Leyla Sahin, Melissa S Tassinari, Susan E Andrade, Katherine Haffenreffer, Darren Toh. (United States)</td>
<td>Liffey Hall 2</td>
</tr>
<tr>
<td>11:00am</td>
<td>Pregnancy Outcomes in Women with Chronic Hypertension Initiated on Labetalol versus Methyldopa [21]</td>
<td>Brian T Bateman, Krista F Huybrechts, Jacqueline Cohen, Helen Mogun, Rishi J Desai, Elisabetta Patorno, Sonia Hernández-Díaz, . (United States)</td>
<td>Liffey Hall 2</td>
</tr>
<tr>
<td>11:15am</td>
<td>Risk Comparison for Prenatal Use of Different Analgesics and Selected Birth Defects [22]</td>
<td>Julia D Interrante, Elizabeth C Ailes, Jennifer N Lind, Marlene Anderka, Marcia L Feldkamp, Martha M Werler, Suzanne M Gilboa, Margaret A Honiein, Cheryl S Broussard. (United States)</td>
<td>Liffey Hall 2</td>
</tr>
<tr>
<td>11:30am</td>
<td>High Exposure to Phthalates from Medications and Male Genital Malformations [23]</td>
<td>Katherine E Kelley, Sonia Hernández-Díaz, Russ Hauser, Allen Mitchell. (United States)</td>
<td>Liffey Hall 2</td>
</tr>
<tr>
<td>11:45am</td>
<td>Language Development in 3 Year Old Children After Prenatal Exposure to Opioids [24]</td>
<td>Eva Skovlund, Marte Handal, Randi M Selmer, Ragnhild E Brandliituen, Svetlana Skurtveit. (Norway)</td>
<td>Liffey Hall 2</td>
</tr>
</tbody>
</table>
Keeping an “I” in Opioid Use (Liffey Hall 1)
Moderators: Paul Coplan & Eileen Ming

10:30am
- Serious Opioid Toxicity in Children with Non-Cancer Pain: A Retrospective Cohort Study [25]
  Cecilia P Chung, S Todd Callahan, William O Cooper, William D Dupont, Katherine T Murray, Kathi Hall, Judith A Dudley, C Michael Stein, Wayne A Ray. (United States)

10:45am
- Long-Acting Oxycodone Co-Prescribing Among US Nursing Home Residents [26]
  Kevin M Fain, G Caleb Alexander, Carlos Castillo-Salgado, David D Dore. (United States)

11:00am
- Doctor/Pharmacy Shopping Measures for Opioid Analgesics and Diagnosed Abuse and Addiction in a US Administrative Database [27]
  Daina B Esposito, M Soledad Cepeda, Ruihuia Yin, Howard Chicoat, Paul Coplan, Stephan Lanes. (United States)

11:15am
- The Role of Socioeconomic Status in Regional Variation of Opioid Utilisation in the Greater London Area [28]
  Ji Hye Bing, Teng-Chou Chen, Li-Chia Chen, Roger Knaggs. (United Kingdom)

11:30am
- Opioid Tolerance Prior to Initiation of High-Dose Oxycodone in Commercially-Insured Adults in the US, 2010-2014 [29]
  Jessica C Young, Jennifer L Lund, Nabarun Dasgupta, Michele Jonsson Funk. (United States)

11:45am
- The Preventable Risk of Fentanyl Prescribing [30]
  Shawn C Bugden, Kevin J Friesen, Cornelius Woelk. (Canada)

According to the World Health Organization (WHO), cardiovascular diseases are the number one cause of death throughout the world. That’s why we’re investigating treatments to manage heart failure, as well as prevent myocardial infarctions and strokes. Which heart patient wouldn’t love to benefit from that? To find out how our innovations are helping to change lives for the better, visit www.bayer.com/cvd1902.
1:30-3:00pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Data Lost and Found** *(The Auditorium)*
Moderators: Til Stürmer, FISPE & Marie Linder

10:30am
- Effects of Expanding the Look-Back Period to All Available Data in the Assessment of Covariates [31]
  Sonja S Nakasian, Jeremy Rassen, Jessica M Franklin. (United States)

10:45am
- Classifying Patient Histories in Medicare Claims: Fixed vs. All-Available Lookbacks [32]
  Mitchell M Conover, Til Stürmer, Charles Poole, Robert J Glynn, Ross J Simpson, Jr., Michele Jonsson Funk. (United States)

11:00am
- Recency of Comorbid Diseases and One-Year Mortality: A Registry-Based Cohort Study in Denmark [33]
  Morten Madsen, Vera Ehrenstein, Henrik T Sørensen. (Denmark)

11:15am
- Avoiding Pitfalls When Combining Multiple Imputation and Propensity Scores [34]
  Emily Granger, Mark Lunt, Jamie C Sergeant. (United Kingdom)

11:30am
- Generalizing Randomized Clinical Trials: Challenges Due to Missing Data on the Target Population [35]
  Jin-Liern Hong, Michele Jonsson Funk, Robert LoCasale, Sara Dempster, Stephen R Cole, Til Stürmer. (United States)

11:45am
- Confounding by Healthcare System Characteristics in Comparative Effectiveness Research [36]
  Jessica M Franklin, Macarius M Donneyong, Rishi J Desai, Mehul D Patel, Panagiotis Mavros, Leona Markson, Caroline McKay, Sebastian Schneeweiss. (United States)

Noon -1:30pm
**Lunch/Poster Session A/Exhibits** *(The Forum)*

**Lunch/Roundtable Discussions** *(Liffey Meeting Room 1)*

Roundtable Discussions
To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Friday and Saturday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

- Gianluca Trifirò
  Role and Responsibilities of Pharmacoepidemiologists in Academia

- Kate Lapane, FISPE
  Medication Issues in Vulnerable Populations

- Stella Blackburn, FISPE
  Adaptive Pathways

Noon-1:30pm
**ISPE Committee/Council Meetings**
(Open to all participants; Lunch available.)
- Membership Committee (Wicklow Meeting Room 3)
- Global Development Committee (Wicklow Meeting Room 4)
- Fellowship & Awards Committee (Wicklow Meeting Room 5)
- Finance Committee (Wicklow Meeting Room 2a)
- Public Policy Committee (Wicklow Meeting Room 2b)
- Student Council *(open to all students)* (Wicklow Meeting Room 1)

12:15-1:15pm
**Spotlight Poster Session** *(3rd Floor; Lunch available)*
- Adherence
- Databases
- Devices
- Pediatrics
CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Bittersweet: Trends and Treatments in Diabetes (The Liffey A)
Moderators: Ken Hornbuckle, FISPE & Rosa Gini

1:30pm
- Preferential Prescribing of Linagliptin to Patients with Renal or Cardiac Disorders in Japan [39]
  Soulamaz Fazeli Farsani, Atsushi Taniguchi, Rie Ikeda, Kimberly G Brodovicz, Dorothee B Bartels. (Germany)

1:45pm
- Estimated Life Expectancy and Cause-Specific Mortality in White, South Asian and Black Patients with Type 2 Diabetes [38]
  Alison K Wright, Evangelos Kontopantelis, Martin K Rutter, Darren M Ashcroft. (United Kingdom)

2:00pm
- Trends In Incidence, Prevalence And Prescribing In Type 2 Diabetes Mellitus [37]
  Manuj Sharma, Irwin Nazareth, Irene Petersen. (United Kingdom)

2:15pm
- Augmentation Patterns Amongst Metformin Initiators with Type 2 Diabetes Mellitus (T2DM) [40]
  Chandrasekar Gopalakrishnan, Sebastian Schneeweiss, John D Seeger, Jun Liu, Elisabetta Patorno. (United States)

2:30pm
- Trends Of Use Of Non-Insulin Antidiabetic Drugs Between 2006-2013 In France [41]
  Mickael Arnaud, Julien Bezin, Bernard Bégaud, Antoine Pariente, Francesco Salvo. (France)

2:45pm
- Antidepressants and the Risk of Type 2 Diabetes Mellitus Among Publicly-Insured U.S. Youth [42]
  Mehmet Burcu, Julie M Zito, Susan dosReis, Fadia T Shaya, Daniel J Safer. (United States)
**Cancer: Around the World in Databases** (The Liffey B)

Moderators: Jason C Hsu & James Kaye

1:30pm
- **Predictors of Induction Chemoimmunotherapy Among Older US Adults with Follicular Lymphoma [43]**
  Laura L Hester, Steven I Park, Jennifer L Lund. (United States)

1:45pm
- **Validation of Claims-Based Definitions of Incident Colorectal Cancer (CRC) in a North Carolina (NC) Medicare Population [44]**
  Monica E D’Arcy, Til Stürmer, Anne Marie Meyer, Michele Jonsson-Funk, Robert Sandler, John Baron, Melissa Troester, Jennifer Lund. (United States)

2:00pm
- **Clinical Outcomes of Stage II and III Breast Cancer Patients in Denmark [45]**
  Deirdre Cronin-Fenton, Anders Kjærsgaard, Mette Nørgaard, Justyna Amelio, Alex Liede, Rohini K Hernandez, Henrik T Sørensen. (Denmark)

2:15pm
- **Post-Diagnostic Statin Use and Breast Cancer Survival: A Nationwide Cohort Study in Scotland [46]**
  Una C Mc Menamin, Chris R Cardwell, Carmel M Hughes, Liam J Murray. (United Kingdom)

2:30pm
- **Low-Dose Aspirin and Survival Benefit in Gastrointestinal Malignancies [47]**
  Martine A Frouws, Esther Bastiaannet, Ruth E Langley, John WK Chia, Myrthe PP Van Herk-Sukel, Hein Putter, Cornelis JH Van de Velde, Johanneke EA Portielje, Gerrit-Jan Liefers. (Netherlands)

2:45pm
- **Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer [48]**
  Anne M Butler, Karynsa Cetin, Rohini K Hernandez, Robert A Overman, Jungin Kim, B Diane Reams, Bradford R Hirsch, Amy P Abernethy, Alexander Liede, M Alan Brookhart. (United States)

---

**At Pfizer**, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Pfizer Epidemiology is proud to support the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Dublin, Ireland.
1:30-3:00pm **CONCURRENT ORAL PRESENTATION SESSIONS**

---

**Playing Catch-up in Pediatric Pharmacoepidemiology** *(Wicklow Hall 2)*

**Moderators:** Susan Oliveria, FISPE & Sudha Raman

1:30pm
- *Birth Cohort Effects on Overall and Subtype-Specific Antibiotic Use Among Infants Born in Denmark 2004-2012* [49]
  - Alan C Kinlaw, Henrik T Sørensen, Jennifer L Lund, Lars Pedersen, Julie L Daniels, Michael D Kappelman, Til Stürmer. (United States)

1:45pm
- *Development and Validation of an Algorithm for Identifying Pediatric Patients with Type 2 Diabetes in Claims Data* [50]
  - Dana Y Teltsch, Richard S Swain, Soulmaz Fazeli Farsani, Kimberly G Brodovicz, Stefan Kaspers, Samuel Huse, Nicholas Sicignano, Beth L Nordstrom, Dorothee B Bartels. (United States)

2:00pm
- *Suicide Trends and Risk Factors in Youth Aged 10-19 Years, Texas, USA* [51]
  - Deanna A Oleske, Denise M Oleske, Sharon M Derrick, Merrill O Hines. (United States)

2:15pm
- *ADHD Treatment and Diagnosis – Importance of Relative Age in Grade in Norway* [52]
  - Øystein Karlstad, Kari Furu, Siri E Håberg, Inger Johanne Bakken. (Norway)

2:30pm
- *Safety of Stimulants in Children with Epilepsy: A Retrospective Cohort Study* [53]
  - Xinyue Liu, Paul Carney, Regina Bussing, Richard Segal, Linda Cottler, Almut Winterstein. (United States)

---

**Patients, Prescriptions, Policy & Pennies** *(Liffey Hall 2)*

**Moderator:** David Martin

1:30pm
- *Potential Impact of Proposed Limits on Clinical Data Collected from Primary Care for a National Research Database* [55]
  - Wilhelmine Meeraus, Jennifer Campbell, Daniel Dedman, Arlene Gallagher, Antonis Kousoulis, Tarita Murray-Thomas, Jessie Oyinlola, Helen Strongman, Rachael Williams, Tim Williams. (United Kingdom)

1:45pm
- *The Impact of State Chemotherapy Parity Laws on Use and Spending for Oral Chemotherapy* [56]
  - Stacie B Dusetzina, Haiden A Huskamp, Aaron N Winn, Ethan M Basch, Nancy L Keating. (United States)

2:00pm
- *Disclosure of Industry Payments to Prescribers: Industry Payments Might Be a Factor Impacting Generic Drug Prescribing* [57]
  - Jingjing Qian, Richard Hansen, Daniel Surry, Jennifer Howard, Zippora Kiptanui, Ilene Harris. (United States)

2:15pm
- *What has Been Achieved Five Years After Approval of New Drugs with the Requirement to Set up Patient Registries? A Follow-Up Study* [58]
  - Carla J Jonker, Marijke HM van den Berg, Arno W Hoes, Peter M Mol. (Netherlands)

2:30pm
  - Mariana F Almas, Pierre Engel, Marieke L De Bruin, Kathryn Starzyk, Blackburn Stella, Dreyer A Nancy. (United Kingdom)

2:45pm
  - Dima Qato, Shannon Zenk, Jocelyn Wilder, Rachel Harrington, Darrel Gaskin, Caleb Alexander. (United States)
Adherence: Staying the Course (Liffey Hall 1)
Moderators: Julie Lauffenburger & Robert Vander Stichele

1:30pm
- Longitudinal Asthma Management Profiles: Visualisation of Patient Histories Using Multiple Data Sources [61]
  Eric H Van Ganse, Sandrine Herbage, Alexandra L Dima, Marijn de Bruin, Nathalie Texier, Flore Jacoud, Maeva Nolin, Laurent Laforest, The ASTROLAB Group. (France)

1:45pm
- Determinants of Antihypertensive Adherence Trajectories Among Older US Adults in the First Year After Initiation [62]
  Jennifer Jones, Carri Casteel, Yvonne Golightly, Laura Loehr, Virginia Pate, Steve Marshall, Til Stürmer. (United States)

2:00pm
- Impact of Statin-Related Media Coverage on the Use of Statins: An Interrupted Time Series Analysis Using UK Primary Care Data [63]
  Anthony Matthews, Emily Herrett, Antonio Gasparinni, Tjerd Van Staa, Ben Goldacre, Laim Smeeth, Krishnan Bhaskaran. (United Kingdom)

2:15pm
- Changes in Statin Adherence in Response to a Myocardial Infarction: The Impact of a Stressful Life Event on Medication Taking Behavior [64]
  Ryan P Hickson, Izabela E Annis, Ley A Killeya-Jones, Gang Fang. (United States)

2:30pm
- Comparative Adherence of Overactive Bladder Agents Among Older Patients [65]
  Samantha Singh, Wayne Khoo, Mina Tadrous, Diana Martins, Muhammad Mamdani, Dean Elterman, Tara Gomes. (Canada)

2:45pm
- Self-Reported Adherence to Different Classes of Antiretroviral Medication as a Predictor of HIV Viral Suppression [66]
  Joseph A Delaney, Robin M Nance, Mari Kitahara, Joseph Eron, Greer Burkeholver, James Willig, Michael Mugavero, Chris Mathewa, Michael Saag, Katerina Christopoulos, Ken Mayer, Susan Heckbert, Heidi M Crane. (United States)

Study Design Considerations to Address Confounding (The Auditorium)
Moderators: Darren Toh & Rob Heerdink

1:30pm
- Instrumental Variable Analysis Using Pooled Data in Pharmacoepidemiology: A Simulation Study [67]
  Md Jamal Uddin, M Abdul Baker Chowdhury. (Bangladesh)
  Andrew McAfee Award for the Best Abstract Submitted by a Researcher or Student living in a Developing Country

1:45pm
- A Reference-Likelihood Alternative to Inverse Probability of Treatment Weighting [68]
  Colin Dormuth. (Canada)

2:00pm
- Variation in Propensity-Adjusted Marginal Estimates of Treatment Effect [69]
  Jessica M Franklin, Wesley Eddings, Robert J Glynn, Sebastian Schneeweiss. (United States)

2:15pm
- The Impact of Study Design and Analysis on “Measurable” and “Un-Measurable” Patient Characteristics in Observational Studies of Glucose-Lowering Drugs in Type 2 Diabetes Mellitus (T2DM) [70]
  Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica Franklin, Kimberly Brodovicz, John Seeger, Dorothee Bartels, Jun Liu, Sebastian Schneeweiss. (United States)

2:30pm
- Calendar Time as an Instrumental Variable in Assessing the Risk of Heart Failure with Antihyperglycemic Drugs [71]
  Mugdha Gokhale, John B Buse, Christina Mack, Til Stürmer. (United States)

2:45pm
- Propensity Score Trimming to Identify the Target Population for Comparative Effectiveness Research [72]
  Robert J Glynn, Til Stürmer. (United States)

3:00-3:30pm
Break/Posters/Exhibits (The Forum)
3:30-5:00pm

PLENARY SESSION

Real World Effectiveness: How Effective is It? (The Auditorium)

Speakers:
- Sarah Garner
  National Institute for Health and Care Excellence
- Elizabeth B Andrews, FISPE
  RTI-Health Solutions
- Tjeerd van Staa
  Health eResearch Centre, Farr Institute for Health Informatics Research
  University of Manchester

Moderator:
- Almath Spooner
  EMA’s PRAC, Health Products Regulatory Authority, Ireland

Health organisations, decision makers and regulators sometimes require information on real world effectiveness of medicines after authorization (post-authorization effectiveness studies, PAES). When evaluating real world effectiveness, observational evidence may be required as randomised controlled trials are inappropriate, impossible or inadequate. Delivering timely decision relevant data is essential; however, because of the potential for bias, it has been suggested that observational studies are only suitable for the study of adverse (non-predictable) effects of drugs and not for measuring their intended effects. Much ongoing research is focused on determining the value of observational studies in effectiveness evaluation and the inference that can be drawn from such analyses. The IMI ‘GetReal’ initiative (www.imi-getreal.eu) is one example that aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process.

This plenary session will focus on the real world effectiveness from different perspectives (decision makers, academics, regulators) and the challenges that are encountered as well as offering thoughts on the how research could and should evolve.

Specific topics covered during this session include:
- Breadth/types of research aims/objectives across perspectives/countries
- Timely and relevant data for decision makers/ regulators etc.
- Generating or retrieving data for effectiveness research (e.g. claims data for outcomes research, electronic health records)
- Methodological considerations of bias and confounding

5:00-6:30pm

SYMPOSIA AND WORKSHOPS

Catch the Wave: Diffusion of Methodological Innovation in Pharmacoepidemiology [73] (The Auditorium)
- Suzanne M Cadarette, Robert W Platt, Joann K Ban, Giulia P Consiglio, Mina Tadrous, Malcolm K Maclure. (Canada)

Patient Engagement in Observational Pharmacoepidemiology Research: Where are We, Where do We Need to be and What are the Steps for Getting There? [74] (The Liffey B)
- Robert F Reynolds, Anne Trontell, Zhanna Jumadilova, Louis Fiore, Liam Smeeth. (United States)

Impact of Pharmacovigilance: From PRAC Strategy to Demonstrable Better Health Protection [75] (The Liffey A)
- Peter Arlett, Marieke De Bruin, Robert Reynolds, Gerald Dal Pan, Saad Shakir, Almath Spooner, Xavier Kurz, June M Raine. (United Kingdom)

Big Data, Big Picture - Data Visualization of Health [76]
(Wicklow Hall 2)
- Alison Bourke, Patrick B Ryan, Noémie Elhadad, Adam Perer. (United Kingdom)

Drug Utilisation In Older Populations: The Irish View On Knowing Right From Wrong [77] (Liffey Hall 2)
(Sponsored by the Drug Utilization Research Special Interest Group)
- Lisa G Pont, Katja Taxis, Veronica Wirz, Paul Gallagher, Stephen Byrne, Annie Fourrier-Reglat. (Australia)

Does Randomization Work? Selection Bias in Pragmatic Randomized Clinical Trials and Unblinded Observational Studies [78] (Liffey Hall 1)
(Sponsored by the CER Special Interest Group)
- Cynthia J Girman, Kourtney J Davis, Liam Smeeth, Sarah Garner, Mary E Ritchey, Corrine De Vries, Andrew W Roddam. (United States)

Exploring Innovative Methods to Conduct Validation Using United States Medicare Administrative Claims Data [79]
(Liffey Meeting Room 2)
- Elizabeth Andrews, Til Stürmer, Leah J McGrath, Michele Jonsson Funk, Jennifer L Lund, Catherine B Johannes, Alicia W Gilsenan, Christopher Powers. (United States)

6:30-7:15pm

Special Interest Group (SIG) Meetings (Open to all participants)

- Adherence (Wicklow Meeting Room 2B)
- AsPEN (Wicklow Meeting Room 3)
- Biologics & Biosimilars (Wicklow Meeting Room 2A)
- BRACE (EcoCem)
- Comparative Effectiveness Research (Wicklow Meeting Room 4)
- Database (Liffey Meeting Room 1)
- Drug Utilization/Health Services Research (Wicklow Meeting Room 1)
- Medical Devices (Liffey Boardroom 3)
- Medications in Pregnancy (Liffey Meeting Room 3)
- Molecular Epi/Biomarkers/ Pharmacogenetics (Liffey Meeting Room 5)
- Oncology (Liffey Boardroom 1)
- Pediatrics (Wicklow Meeting Room 5)
- Vaccines (Liffey Meeting Room 2)

7:15-9:00pm

PDS Editorial Board (Spencer Hotel)
(By Invitation Only)
8:00-9:30am **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Psychotropics in Pregnancy (The Liffey A)**
Moderators: Janet Hardy & Caitlin Knox

8:00am
- **Antidepressant Medication and the Risk of Pregnancy-Induced Hypertension** [402]
  Loes F ter Heijne, Nelly Zakiyah, Jens HJ Bos, Eelko Hak, Catharina CM Schuing-Veninga. (Netherlands)

8:15am
- **Gestational Exposure to SSRIs and Risk of Preeclampsia in Pregnancy: A Study from the Norwegian Mother and Child Cohort Study Accounting for Time-Varying Severity of Depressive and Anxiety Symptoms** [403]
  Angela Lupattelli, Molly Wood, Olav Spigset, Kate Lapane, Hedvig Nordeng. (Norway)

8:30am
- **Continuation of Atypical Antipsychotic Medications During Pregnancy and the Risk of Gestational Diabetes** [404]
  Yoonyoung Park, Sonia Hernández-Díaz, Brian T Bateman, Jacqueline Cohen, Elisabetta Patorno, Helen Mogun, Krista F Huybrechts. (United States)

8:45am
- **Is There a Dose-Response Relation Between the Use of Lithium in Early Pregnancy and the Risk of Cardiac Malformations?** [405]
  Elisabetta Patorno, Krista Huybrechts, Brian Bateman, Helen Mogun, Rishi Desai, Sonia Hernández-Díaz. (United States)

9:00am
- **Associations Between Treatment with Selective Serotonin Reuptakeinhibitors (SSRIs) Before and After Pregnancy** [406]
  Loes F ter Heijne, Nelly Zakiyah, Jens HJ Bos, Eelko Hak, Catharina CM Schuing-Veninga. (Netherlands)

9:15am
- **Risk Of Neurodevelopmental Disorders Following Prenatal Valproate Exposure: An Observational Cohort Study Using The Health Improvement Network** [407]
  Cormac J Sammon, Rachel L McCrea, David P Osborn, Stephen JW Evans, Phillip J Cowen, Irwin Nazareth, Irene Petersen. (United Kingdom)

---

**Better Health, Brighter Future**

**Takeda**

For more than 230 years, we have been serving society with innovative medicines and helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

We continue to transform the future of healthcare by unifying our strengths around the world. We are a diverse organization committed to working with local communities to fully understand their needs and deliver industry-leading solutions with a sense of urgency, dedication and unparalleled efficiency.

Our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world.

©2015 Takeda Pharmaceutical International Co. All rights reserved.

To learn more, visit us at TakedaPIC.com.
8:00-9:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Pay Attention to Pain: ADHD and Pain Treatment DUS (The Liffey B)
Modemators: Judith Jones, FISPE & Mina Tadrous

8:00am
- Frequency and Predictors of Analgesic Prescribing in US Nursing Home Residents with Persistent Pain [408]
  Kevin M Fain, G Caleb Alexander, David D Dore, Carlos Castillo-Salgado. (United States)

8:15am
- Prevalence and Trends of Analgesic Medication Utilisation in Patients Undergoing Total Joint Replacement Surgery [409]
  Maria CS Inacio, Kara Cashman, Nicole L Pratt, Marianne H Gilliam, Stephen E Graves, Elizabeth E Roughead. (Australia)

8:30am
- Global Utilization of Attention Deficit Hyperactivity Disorder Medications – Preliminary Results [410]
  Sudha R Raman, Kenneth KC Man, Anick Berard, Takoua Boukhris, Yea-Huei Kao Yang, Kiyoshi Kubota, Hidefumi Nakamura, Chien-Chou Su, Miriam CJM Sturkenboom, Ian CK Wong. (United States)

8:45am
- Prescribing Trends of Attention-Deficit Hyperactivity Disorder (ADHD) Medications in UK Primary Care, 1995-2015 [411]
  Christel Renoux, Ju-Young Shin, Sophie Dell’Aniello, Emma Fergusson, Samy Suissa, CNODES Canadian Network for Observational Drug Effect Studies. (Canada)

9:00am
- Drug Utilization of Lisdexamfetamine Dimesylate in European Countries [412]
  Birgit Ehlken, Dorothea von Bredow, William A Blumentals, Barbara Thun, Jacco Keja, Tricia Maxwell. (Germany)

9:15am
- Treatment Patterns in Adults with Newly Treated Attention Deficit/Hyperactivity Disorder [413]
  Yanmin Zhu, Wei Liu, Yan Li, Paul S Kubiulis, Almut G Winterstein. (United States)
Psychotropic Trends on Populations from a Multinational Perspective (Wicklow Hall 2)
Moderators: Yola Moride, FISPE & Maire O’Dwyer

8:00am
- Psychotropic Medicine Use in Australia (2006 to 2014); Annual Incidence, Prevalence and Patterns of Use [414]
  Jonathan Brett, Benjamin J Daniels, Emily Karanges, Sallie-Ann Pearson, Carl Schneider. (Australia)

8:15am
- Incidence of Mood and Anxiety Disorders and Psychotropic Use in Spouses of Dementia Patients: A Population-Based Study [415]
  I Fan Kuo, Andrew Basham, Heather Prior, Silvia Alessi-Severini, James Bolton, Alan Katz, Shahin Shooshtari. (Canada)

8:30am
- Sustained Use of Benzodiazepines and High Dose Escalation in a Canadian Population [416]
  Silvia Alessi-Severini, James M Bolton, Murray W Enns, Matthew E Dahl, Dan Chateau, David M Collins, Jitender Sareen. (Canada)

8:45am
- Antidepressant and Benzodiazepine Co-Initiation and Subsequent Long-Term Benzodiazepine Use in Adults with Depression, United States 2001-2014 [417]
  Greta A Bushnell, Til Stürmer, Bradley N Gaynes, Virginia Pate, Matthew Miller. (United States)

A Sticky Subject: Diabetes Safety (Liffey Hall 2)
Moderators: James Lewis, FISPE & Christian Hampp

8:00am
- Final Results of a Large Multi-National Postmarketing Safety Study Evaluating Use of the Oral Anti-Diabetic Drug Saxagliptin and Risk of Five Outcomes [420]
  Vincent Lo Re III, Dena M Carbonari, Craig W Newcomb, M Elle Saine, Jason A Roy, Serena Cardillo, Kevin Haynes, Stephen E Kimmel, Peter P Reese, David J Margolis, Andrea J Apter, K Rajender Reddy, Harshvinder Bhullar, Arlene M Gallagher, Daina B Esposito, Brian L Strom. (United States)

8:15am
- Use of Incretin Agents and Risk of Acute and Chronic Pancreatitis: A Population-Based Cohort Study [421]
  Lotte M Knapen, Ronaldus GPJ de Jong, Johanna HM Driessen, Yolande C Keulemans, Nieltje P van Erp, Marie L de Bruin, Hubert GM Leufkens, Sander Croes, Frank de Vries. (Netherlands)

8:30am
- Use of Non-Insulin Blood Glucose Lowering Drugs and the Risk of Acute Pancreatitis [422]
  Gwen MC Masclee, Ingrid Leal, Lorenza Scotti, Giorgia De Berardis, Irene Bezemert, Miguel Gil, Anita McGrogan, Niklas Schmedt, John D Seeger, Gianluca Trifirò, Serena Pecchioli, Manel Pladévall-Vila, Mark M Smits, Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana A Romio. (Netherlands)

8:45am
- Metformin and Cancer Risk in Type 2 Diabetes: An Application of Marginal Structural Models with Inverse Probability of Treatment Weights in the Clinical Practice Research Datalink [423]
  Ruth E Farmer, Deborah Ford, Liam Smeeth, Nishi Chaturvedi, Richard Kaplan, Krishnan Bhaskaran. (United Kingdom)

9:00am
- Impact of Glycaemic Control on Risk of Infections in 69 318 Patients with Type 2 Diabetes: A Population-Based Cohort Study [424]
  Anil Mor, Olaf M Dekkers, Jens S Nielsen, Henning Beck-Nielsen, Henrik T Sørensen, Reimar W Thomsen. (Denmark)

9:15am
- Estimated Effects of Treatment Changes on Emergency Care Utilization in a Cohort of Patients with Type 1 Diabetes [425]
  Richard S Swain, G Caleb Alexander, Dana Y Teltsch, MAJ Christina L Cristaldi, Janet T Holbrook, Jodi B Segal. (United States)
8:00am

**Broken & Torn** (Liffey Hall 1)

**Moderators:** Daniel Prieto-Alhambra & Andrew Roddam

- **8:00am**
  - **35-Year Trends in First-Time Hospitalizations for Hip Fracture and Subsequent 0-30 and 31-365 Days Mortality: 1980-2014 [426]**
    - Alma B Pedersen, Vera Ehrenstein, Szimonetta Szepigeti, Astrid Lunde, Anna Westerlund, Ylva Trolle Lagerros, Grethe S Tell, Henrik Toft Sørensen. (Denmark)
  - **Association of Gout Diagnosis with Increased Risk of Joint Replacement: A Population-Based Cohort Study of Older Adults [427]**
    - Sylvie Perreault, Alyssa B Klein, Robert Morlock. (Canada)
  - **Validation of Fracture Risk Assessment Tool Using Real-World Data [428]**
    - Inbal Goldshtein, Yariv Gerber, Sophia Ish-Shalom, Moshe Leshno. (Israel)

- **8:45am**
  - **Total Hip and Knee Replacement Among Incident Osteoarthritis and Rheumatoid Arthritis Patients Within the UK Clinical Practice Research Datalink (CPRD) Compared to Hospital Episode Statistics (HES): A Validation Study [429]**
    - Samuel Hawley, Antonella Delmestri, Andrew Judge, Christopher J Edwards, Cyrus Cooper, Nigel K Arden, Daniel Prieto-Alhambra. (United Kingdom)

9:00am

- **Modular versus Monobloc Neck Stems Primary Total Hip Arthroplasty Survivorship. Result of a Prospective Series of 324,108 THA at 6-Years Follow-Up [430]**
  - Sandrine Colas, Assia Allalou, Rosemary Dray-Spira, Mahmoud Zureik. (France)

9:15am

- **Incidence and Trends in ACL Reconstruction Among Commercially-Insured Individuals in the United States, 2002-2013 [431]**
  - Mackenzie M Herzog, Stephen W Marshall, Virginia Pate, Jennifer L Lund, Jeffrey T Spang. (United States)

8:00am

**Identification and Validation of Outcomes** (Liffey Meeting Room 2)

**Moderators:** Helga Gardarsdottir & Richard Wyss

- **8:00am**
  - **A Comparison of Methods for Estimating Values for Sparse and Irregularly Spaced Continuous Outcome Measures in Electronic Health Record (EHR) Data [432]**
    - Therese M Sheppard, William G Dixon, Robyn Tamblyn. (United Kingdom)
  - **A Comparison Of Structured Data Query Methods Versus Natural Language Processing To Identify Metastatic Melanoma Cases From Electronic Health Records [433]**
    - Paul R Dexter, Jinghua He, Lawrence Mark, David Haggstrom, Charity Hilton, Joel Martin, Jarod Baker, Jon Duke, Siu L Hui, Xiaochun Li. (United States)
  - **Additive versus Multiplicative Survival Models: Prediction and Understanding of Effect Modification [434]**
    - Shirley V Wang, Jessica M Franklin. (United States)

- **8:45am**
  - **Validity of Cardiac Examination, Procedure, and Surgery Codes in the Danish National Patient Registry [435]**
    - Kasper Adelborg, Jens Sundbøll, Troels Munch, Trine Froslev, Henrik T Sørensen, Hans E Bøtker, Morten Schmidt. (Denmark)
  - **Validity of Cardiovascular Diagnoses in the Danish National Patient Registry [436]**
    - Jens Sundbøll, Kasper Adelborg, Troels Munch, Trine Froslev, Henrik T Sørensen, Hans E Bøtker, Morten Schmidt. (Denmark)
  - **Validation of Cardiovascular Events and Covariates in CPRD GOLD Using Questionnaires to General Practitioners (GPS) [437]**
    - Andrea V Margulis, Cristina Varas-Lorenzo, Christine L Bui, Lisa J McQuay, Ryan Ziemiecki, Maria Reynolds, Cristina Rebordosa, Manel Pladevall-Vila, Joan Fortuny, Elena Rivero-Ferrer, Estel Plana, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Arana. (Spain)

9:30-10:00am

**Break/Posters/Exhibits** (The Forum)
PLENARY SESSION

Patient Voice in Clinical and Pharmacoepidemiologic Research
(The Auditorium)

Speakers:
- Derick Mitchell, Science and Industry (IPPOSI)
- Rachel Lynch, FibroIreland
- Irene Petersen, FISPE, University College London and Aarhus University
- Cindy Girman, FISPE, CERobs Consulting, LLC and UNC Chapel Hill

Moderator:
- Ken Hornbuckle, FISPE, Eli Lilly and Company

This plenary session will focus on current efforts to include the patients’ voice in clinical and pharmacoepidemiologic research. Speakers will be asked to comment on patient engagement as it relates to benefit-risk, safety and pharmacoepidemiology studies. Specific topics covered during this session include:

- Evolving paradigm (including, how should pharmacoepidemiologists leverage patients’ voice in their research and how to increase patient awareness of the importance of the health data for research)
- Patient engagement in study development (including, refinement of study objectives, selection of study design, outcome definitions and recruitment strategy) and implementation
- Patient engagement in interpretation, communication and dissemination of study findings

Lunch/Poster Session B/Exhibits
(The Forum)

Roundtable Discussions
(Liffey Meeting Room 1)

To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Friday and Saturday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

- Libby Roughead, FISPE, Building Sustainable Research Collaborations
- Thomas MacDonald, FISPE, Experimental Medicine
- Ryan Kilpatrick, Positioning Epidemiologists for Success in Working for or with Biopharma

ISPE Committee Meetings
(Open to all participants; Lunch available.)

- Education Committee (Wicklow Meeting Room 3)
- Development Committee (Wicklow Meeting Room 4)
- Publications Committee (Wicklow Meeting Room 2a)
- Bylaws Committee (Wicklow Meeting Room 2b)

Spotlight Poster Session
(3rd Floor; Lunch available)

CV Effectiveness: How to Fix a Broken Heart
(The Liffey A)

Moderator: Monteserrat Soriano-Gabarro

1:00pm
- Calcium Intake and 10 Year Risk of Incident Coronary Artery Calcification in the Multi-Ethnic Study of Atherosclerosis [438]
  Bridget Kruszka, Ka He, Joseph A Delaney, Gregory L Burke, Alvaro Alonso, Diane Bild, Matthew J Budoff, Erin D Michos, John JB Anderson. (United States)

1:15pm
- Model Observational Bridging Study on the Effectiveness of Ezetimibe Upon Cardiovascular Outcomes [439]
  Jean Dallongeville, Denis Getsios, Jean Ferrières, Lucien Abenhaim, Michel Rossignol Rossignol, Lamiae Grimaldi-Bensouda, Billy Amzal. (United Kingdom)

1:30pm
- Clinical Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors [440]
  Katsiaryna Bykov, Sebastian Schneeweiss, Macarius M Donneyong, Yaa-Hui Dong, Niteesh K Choudhry, Joshua J Gagne. (United States)

1:45pm
- Effectiveness of Recommended Drug Classes in Secondary Prevention of Acute Coronary Syndrome in France [441]
  Julien Bezin, Rolf Groenwold, Sanni Ali, Régis Lassalle, Anthonius de Boer, Nicholas Moore, Olaf Klungel, Antoine Pariente. (France)

2:00pm
- Treatment with Carvedilol, Bisoprolol or Metoprolol Tartrate and the Risk of Mortality and Hospital Readmission Among Older Adults with Heart Failure [442]
  Sylvie Perreault, Simon de Denus, Michel White, Brian White-Guay, Marc Dorais, Marie-Pierre Dubé, Jean-Lucien Rouleau. (Canada)

2:15pm
- Real-Life Statin Use and LDL-Cholesterol Reduction in a General Population: A Retrospective Study of Primary Care Electronic Medical Records [443]
  Maria García-Gil, Marc Comas-Cufí, Eli León-Paz, Lía Alves-Cabratos, Anna Ponjoan, Ruth Martí, Jordi Blanch, Rafel Ramos. (Spain)
1:00-2:30pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Antipsychotic Use Across the Life Span** *(The Liffey B)*  
Moderators: Wendy Camelo Castillo & Deborah Layton

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00pm</td>
<td>Psychotropic Medications and the Risk of Neonatal Withdrawal [444]</td>
<td>Krista F Huybrechts, Brian T Bateman, Sonia Hernández-Díaz, Rishi J Desai, Kathryn Rough, Helen Mogun, Elisabetta Patorno</td>
<td>United States</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Mortality Risk of Second-Generation Antipsychotic (SGA) Augmentation for Adult Depression [446]</td>
<td>Tobias Gerhard, T Scott Stroup, Christoph Correll, Brian L Strom, Cecilia Huang, Zhiquiang Tan, Stephen Crystal, Mark Olfson</td>
<td>United States</td>
</tr>
<tr>
<td>1:45pm</td>
<td>Comparative Safety of Antipsychotic Medications in Hospitalized Myocardial Infarction Patients [447]</td>
<td>Yoonyoung Park, Brian T Bateman, Dae Kim, Sonia Hernández-Díaz, Elisabetta Patorno, Robert J Glynn, Helen Mogun, Krista F Huybrechts</td>
<td>United States</td>
</tr>
</tbody>
</table>

---

**Transforming the language of life into vital medicines**

At Amgen, we believe that the answers to medicine’s most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com

*Amgen is a proud sponsor of the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Epidemiologic research at Amgen focuses on benefiting patients with grievous illnesses and advancing knowledge in our field.*
1:00-2:30pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

### To Take or Not to Take? (Wicklow Hall 2)
**Moderators:** Katja Taxis & Zhen-Fang Lin

- **1:00pm**
  - Medication Taking Behaviour and Adverse Health Outcomes in Community Dwelling Older Patients [450]
    - Caitriona Cahir, Tom Fahey, Conor Teljeur, Kathleen Bennett. (Ireland)
- **1:15pm**
  - Adherence to Anti-Hypertensive Medication in the Elderly: A Prospective Cohort Study [451]
    - Paul Dillon, Paul Gallagher, Susan Smith, David Williams, Derek Stewart, Gráinne Cousins. (Ireland)
- **1:30pm**
  - Too Many, Too Few, Or Too Unsafe? Impact Of Inappropriate Prescribing On Mortality, And Hospitalisation In Community-Dwelling Adults, Aged 80 And Older [452]
    - Maarten Wauters, Monique Elseviers, Bert Vaes, Jan Degryse, Robert Vander Stichele, Thierry Christiaens, Majda Azermai. (Belgium)

### Drug-Induced Kidney and Liver Injury (Liffey Hall 2)
**Moderators:** Judy Kelly & Susana Perez-Gutthann, FISPE

- **1:00pm**
  - Acetaminophen Overdose-Related Morbidity and Mortality in Canada [456]
    - Samina Aziz, Andrew Slot, Vincent Punch, Lucye Galand, Steven McFaul, Lisa Lange, Marc Berthiaume. (Canada)
- **1:15pm**
  - Comparative Hepatotoxicity of Echinocandins in Hospitalized Patients (pts): A Retrospective Cohort Study [457]
    - Francis Vekeman, Lisa S Weiss, Jalal Aram, Raluca Ionescu-Itu, Shahrazad Moosavi, Yongling Xiao, Wendy Y Cheng, Rachel Bhak, Margaret Tawadrous, Mei Sheng Duh. (Canada)
- **1:30pm**
  - Detection and Quantification of Flucloroxacin-Induced Liver Injury: A Population-Based Cohort Study [458]
    - Kevin Wing, Krishnan Bhaskaran, Louise Pealing, Adrian Root, Liam Smeeth, Tjeerd P van Staa, Olaf H Klungel, Robert F Reynolds, Ian Douglas. (United Kingdom)
1:00-2:30pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Biologics: “Miracle Drug”** (Liffey Hall 1)  
**Moderators:** Mary Anthony & Timothy Beukelman

- **1:00pm**  
  - The Risk of Hospitalized Infection Associated with New Use of Abatacept versus TNF Inhibitors in Juvenile Idiopathic Arthritis [462]  
  Timothy Beukelman, Fenglong Xie, Melissa M Mannion, Long Chen, Jie Zhang, John Baddley, Kenneth G Saag, Jeffrey R Curtis. (United States)
- **1:15pm**  
  - In Search of Predictors of Erythropoiesis-Stimulating Agents (ESAs) Resistance: A Population-Based Study [463]  
  Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marciànò, Jenny Bolcato, Roberta Pirolo, Alessandro Chinellato, Achille P Caputi, Gianluca Trifirò. (Italy)
- **1:30pm**  
  - Comparative Effectiveness and Safety of Erythropoiesis-Stimulating Agents (Biosimilars versus Originators) in Clinical Practice: A Population-Based Cohort Study [464]  
  Francesco Trotta, Valeria Belleudi, Fusco Danilo, Laura Amato, Alessandra Mecozi, Flavia Mayer, Massimo Sansone, Marina Davoli, Antonio Addis. (Italy)

**A Methods Coddle** (The Auditorium)  
**Moderators:** Robert Platt & Edmore Chamapiwa

- **1:00pm**  
  - Baseline and Time-Varying Determinants of Statin Adherence [468]  
  Chintan Dave, Abraham Hartzema, Haesuk Park, Almut Winterstein. (United States)
- **1:15pm**  
  - Determining Prescription Durations from the Parametric Waiting Time Distribution [469]  
  Henrik Støvring, Anton Pottegård, Jesper Hallas. (Denmark)
- **1:30pm**  
  - Assessing and Reducing the Impact of Drug Exposure Measurement Errors Due to Non-Adherence: A Simulation Study [470]  
  Yishu Wang, Michal Abrahamowicz. (Canada)

- **1:45pm**  
  - Comparative Safety and Effectiveness of Denosumab versus Zoledronic Acid in Patients with Osteoporosis: A Cohort Study [465]  
  Nam-Kyong Choi, Daniel H Solomon, Theodore N Tsacogianis, Joan E Landon, Hong Ji Song, Seoyoung C Kim. (United States)
- **2:00pm**  
  - A Real World Comparison of Methods for Assessing Dosing Patterns of Biologic Therapies for Psoriasis [466]  
  Ireny YK Iskandar, Richard B Warren, Ian Evans, Kathleen McElhone, Caroline M Owen, A David Burden, Catherine H Smith, Nick J Reynolds, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)
- **2:15 pm**  
  - Trends in the Utilization of Biologics for Inflammatory Bowel Disease in the United States [467]  
  Chao Chen, Abraham Hartzema. (United States)
# ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY

## ANNUAL MEETING

### Call to Order & Presidential Address
- Sonia Hernández-Díaz, FISPE, ISPE President

### Financial Report
- Alison Bourke, FISPE, Vice President, Finance

## AWARDS CEREMONY

The Ronald D. Mann Best Paper Awards for Manuscripts Published in *Pharmacoepidemiology and Drug Safety (PDS)* 2015, Volume 24:

**First Prize**
- **Domperidone, Cytochrome P450 3A4 Isoenzyme Inhibitors and Ventricular Arrhythmia: A Nationwide Case–Crossover Study.** *Pharmacoepidemiol Drug Saf* 2015: 24; pages 841-848
  - Hung-Lin Chen and Fei-Yuan Hsiao

**Honorable Mentions**
- **Alcohol Misuse, Genetics, and Major Bleeding Among Warfarin Therapy Patients in a Community Setting.** *Pharmacoepidemiol Drug Saf* 2015: 24; pages 619-627
  - Joshua A Roth, Katharine Bradley, Kenneth E Thummel, David L Veenstra and Denise Boudreau

- **Exposure to Systemic Antibacterial Medications During Pregnancy and Risk of Childhood Cancer.** *Pharmacoepidemiol Drug Saf* 2015: 24; 821-829
  - Natalie C Momen, Jørn Olsen, Mika Gissler, Helle Kieler, Bengt Haglund and Jiong Li

**Presenters**
- Brian L Strom, FISPE, Editor-In-Chief
- Sean Hennessy, FISPE, Regional Editor for the Americas
- Hubert G M Leufkens, FISPE, Regional Editor for Europe
- Byung Joo Park, FISPE, Regional Editor for Asia-Pacific and ROW

### 32nd ICPE
- **Mary E Ritchey,** Chair, 2016 Scientific Program Committee
- **Kathleen E Bennett,** Local Host Committee
- **Lisa Gai Pont,** FISPE, Spotlight Poster Sessions
- **J Bradley Layton,** Spotlight Poster Sessions
- **Vincent Lo Re,** FISPE, Newcomer Track
- **Kristen B Bibeau,** Luncheon Roundtable Discussions
- **Jessica Jalbert,** Luncheon Roundtable Discussions

**The Andrew McAfee Award**
(Submitted by an academic researcher or student residing in a developing country)
- Md Jamal Uddin, Shahjalal University of Science & Technology

**The John Snow Award**
(Submitted by a female academic researcher or student residing in a developing country)
- Sze Ling Celine Chui, The University of Hong Kong

### Student Awards
- **Third Best Abstract:** Xiaojuan Li, University of North Carolina at Chapel Hill
- **Second Best Abstract:** Nakyung Jeon, University of Florida

**The Stanley A. Edlvitch Award & Oral Presentation**
(Submitted by a student/post-doc)
- Rebecca Burne, McGill University
- New Statistical Methods for Using Validation Subsamples to Adjust for Time-Dependent Unmeasured Confounders in Marginal Structural Cox Models [474]
  - Rebecca Burne, Michal Abrahamowicz. (Canada)

### Induction of ISPE Fellows (FISPE)
- John F Acquavella
- Krista F Huybrechts
- Tamar Lasky
- Danica Marinac-Dabic
- Irene Petersen
- Maribel Salas
- Rachel E Sobel
- Jasmanda H Wu

### BOARD TRANSITION

**Retiring Board Members & Officers**
- Rhonda L Bohn, FISPE
- Jennifer B Christian, FISPE
- Yea-Huei Kao Yang, FISPE
- Alison Bourke, FISPE, Vice President Finance
- John Seeger, FISPE, Immediate Past President

**Induction of New Board Members**
- Dorothee Bartels, Industry/Service Provider (Europe/Africa)
- Lisa Gai Pont, FISPE, Academic (Asia/Pacific)
- Jennita Reefhuis, Government/Regulatory (Americas)
- June Raine, Government/Regulatory (Europe/Africa)
- Rachel E Sobel, FISPE, Industry/Service Provider (Americas)

**Installation of 2016-2017 Officers**
- Tobias Gerhard, FISPE, Vice President Finance
- Jesper Hallas, FISPE, President Elect
- Sonia Hernández-Díaz, FISPE, Immediate Past President
- Kiyoshi Kubota, FISPE, President

### Adjournment
**3:30-4:00pm**

**Break/Posters/Exhibits** (The Forum)

**4:00-5:30pm**

**SYMPOSIA AND WORKSHOPS**

**Perspectives from Causal Inference in the Era of Big (Healthcare) Data [475]** (The Auditorium)
- Susan Gruber, Michele Jonsson Funk, Robert Platt, James M Robins, Mireille Schnitzer, Til Stürmer, Alexander M Walker. (United States)

**Making Optimal Use of Routinely Collected Data from United Kingdom Electronic Health Records [476]** (The Liffey B)
- Ian J Douglas, Stephen J Evans, Laurie Tomlinson, Rohini Mathur, Krishnan Bhaskaran, Caroline Minassian, Sara Thomas, Rachel Williams, Wilhelmine Meeraus, Jenni Quint, Janet Valentine, Liam Smeeth. (United Kingdom)

**Using “Big Data” in Early Safety Evidence Gathering and Targeted Surveillance for Newly Launched Medicines: Is It the Right Time Now? [477]** (The Liffey A)
- Hu Li, Andrew Bate, Joshua Gagne, Jim Slattery, Ken Hornbuckle, Stephen Motsko. (United States)

**What's in a Code? Algorithm Validation in Drug Safety Studies [478]** (Wicklow Hall 2)
- Beth L Nordstrom, Sheila Weiss, Stephan Lanes, Cunlin Wang. (United States)

**The Epidemiological Approach to Rare Disease Research: Challenges and Opportunities [479]** (Liffey Hall 2)
- Mary E Ritchey, Jessica J Jalbert, Alicia Gilseinan, Theodore Lystig, Michael Peng, Tzuyung D Kou, William Blumentals. (United States)

**The Role of Evidence Synthesis in Drug Safety Evaluation and Regulation [480]** (Liffey Hall 1)
- Simone Pinheiro, Wei Liu, Michael Nguyen, Marc Poitras, Yoshiaki Uyama, Peter Arlett. (United States)

**A Discussion of Data Requirements and Methodologic Considerations for Evaluating the Real-World Effectiveness and Safety of Biosimilar Medicines [481]** (Liffey Meeting Room 2)
- Veronique Kugener, Michael Kelsh, Brian Bradbury, Thyjs Giezen, Jaclyn Bosco, Gianluca Trifirò, Amanda Golembesky. (United States)

**5:30-6:15pm**

**ISPE Council Meetings** (Open to all participants.)
- **Academic Council** (Liffey Meeting Room 1)
- **Government/Regulatory Council** (Wicklow Meeting Room 3)
- **Industry/Service Providers Council** (Wicklow Meeting Room 4)
- **Student Council & Chapters** (Wicklow Meeting Room 5)

**7:30-11:30pm**

**Social Event (Guinness Storehouse)**

Located in the heart of the St James’s Gate Brewery is the Guinness Storehouse. Home to the black stuff since 1759, this massive seven-storey building, a former Guinness® fermentation plant, has been remodelled into the shape of a giant pint of Guinness®. A visit will teach you everything you ever wanted to know about this world famous beer. The highlight for many visitors is the Gravity Bar®, symbolically the “Head of the Pint”, where visitors can enjoy unparalleled panoramic views of Dublin city – views that are all the better with a pint in hand.

A FACT: Guinness is the perfect diet drink. A pint of the good stuff contains only 198 calories. That’s less than most light beers, wine, orange juice or even low fat milk.

TONIGHT, the Guinness Storehouse will host ISPE. Join us for entertainment, food, dancing and a pint of the black stuff.

Full ICPE registration includes:
- Admission to the Storehouse by badge or ticket (guests)
- Food
- Entertainment
- Transportation. Buses will shuttle between the CCD and the Storehouse, with the first bus departing from the CCD at 6:30pm; and from the Storehouse to ISPE meeting hotels

A cash bar will be available.
7:00-8:00am
Coffee & Tea
(The Forum)

Poster Session C
Set-up
(The Forum & 3rd Floor)

7:00am-4:30pm
Registration
(Ground Foyer)

7:30am-3:30pm
Speakers’ Ready Room
(Liffey Meeting Room 4)

8:00am-1:45pm
Exhibits/Posters
(The Forum)

8:30-10:00am CONCURRENT SESSIONS: CONTRIBUTED PAPERS

From Eve to... (The Liffey A)
Moderators: Andrew Margulis & Colin Anderson-Smits

8:30am
- Effect of Concomitant Use of Tamoxifen and Selective Serotonin Reuptake Inhibitors on Mortality [791]
  Macarius M Donneyong, Katsiaryna Bykov, Pauline Bosco-Levy, Yaa-Hui Dong, Gagne Joshua. (United States)

8:45am
- The Effect of BMI on Unintended Pregnancy Rates Amongst Users of Combined Oral Contraceptives [792]
  Anja Bauerfeind, Clare Barnett, Do Minh Thai, Klaas Heinemann. (Germany)

9:00am
- Unwanted Pregnancies in Women Using Intrauterine Devices: Final Results from the EURAS-IUD 5-Years Study [793]
  Klaas Heinemann, Sabine Moehner, Suzanne Reed, Thai Do Minh. (Germany)

9:15am
- Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD 5-Years Study [794]
  Klaas Heinemann, Sabine Moehner, Thai Do Minh, Suzanne Reed. (Germany)

9:30am
- Comparative Risk of Serious Infections During Pregnancy in Patients Treated with Immunomodulatory Agents [795]
  Rishi J Desai, Brian T Bateman, Krista F Huybrechts, Elisabetta Patorno, Sonia Hernández-Díaz, , Yoonyoung Park, Helen Mogun, Seoyoung C Kim. (United States)

9:45am
- Venous Thromboembolism Risk Following New Use of NSAIDs in U.S. Women [796]
  Tracy L Kinsey, Robert J Glynn, Michele Jonsson Funk, Charles Poole, Ross J Simpson, Jr., Til Stürmer. (United States)

8:30am
- Effect of Concomitant Use of Tamoxifen and Selective Serotonin Reuptake Inhibitors on Mortality [791]
  Macarius M Donneyong, Katsiaryna Bykov, Pauline Bosco-Levy, Yaa-Hui Dong, Gagne Joshua. (United States)

HEALTHIER IS HERE
Big data can transform our perception of health care — as long as we have the ability to interpret it. As a health services and innovation company, Optum® powers modern health care by combining data and analytics with technology and expertise. We embed substantive knowledge and context into our applications and data products, adapting epidemiologic principles to big data to arrive at actionable insights.

Visit us at booth #25
optum.com/epidemiology
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30am</td>
<td><strong>My Achy Breaky Heart: Diabetes and CVD</strong> (The Liffey B)</td>
<td><strong>Moderators:</strong> Cynthia Girman, FISPE &amp; Gillian Caughey</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>8:30am</td>
<td><strong>Relationship Between Glycaemic Burden and Micro- and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus [797]</strong></td>
<td>Jetty A Overbeek, Rients PT van Wijngaarden, Joris Diels, Agata Schubert, Huub Straatman, Hervé Besson, Ewout W Steyerberg, Michiel Hemels, Giel Nijpels, Ron MC Herings. (United States)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>8:45am</td>
<td><strong>Comparative Effects of Second Line Antidiabetic Agents Added to Metformin on Patient Centered Outcomes: A Retrospective Cohort Study [798]</strong></td>
<td>James H Flory, Alvin I Mushlin, Ankit Shah, John Cuddeback, Christopher Rowan. (United States)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>9:00am</td>
<td><strong>Changes in Diabetes Therapy One Year Before and After Discharge from a Heart Failure Hospitalization Among Patients with Type II Diabetes [1096]</strong></td>
<td>Ghadeer K Dawwas, Haesuk Park. (United States)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>9:15am</td>
<td><strong>Magnitude of HbA1c Reduction and Attainment of Early Glycemic Control Predict Cardiovascular Outcomes and Mortality: A Population-Based Cohort Study of 24,752 People with Type 2 Diabetes Initiating First Metformin Therapy [800]</strong></td>
<td>Reimar W Thomsen, Lisbeth M Baggesen, Søren P Johnsen, Lars Pedersen, Helene Norrelund, Esben S Buhl, Christiane L Haase, Elisabeth Svensson. (Denmark)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>9:30am</td>
<td><strong>Risk of Acute Myocardial Infarction Associated with Non-Insulin Blood Glucose Lowering Drugs. Results from the SAFEGUARD Project [801]</strong></td>
<td>Ingrid Leal, Gwen Muscle, Lorenza Scotti, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martin, Anita McGregor, Niklas Schmedt, John D Seeger, Gianluca Trifirò, Serena Pecchioi, Cristina Varas-Lorenzo, Mark M Smits, Peter Rijnbeek, Miriam Sturkenboom, Silvana Romio. (Netherlands)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>9:45am</td>
<td><strong>Risk of Congestive Heart Failure (CHF) Associated with Vildagliptin: Pan-European Non-Interventional Safety Study [802]</strong></td>
<td>Rachael Williams, Raymond Schlienger. (United Kingdom)</td>
<td>(The Liffey B)</td>
</tr>
<tr>
<td>8:30am</td>
<td><strong>Keeping Up - A Potpourri</strong> (Wicklow Hall 2)</td>
<td><strong>Moderators:</strong> TBA</td>
<td>(Wicklow Hall 2)</td>
</tr>
<tr>
<td>8:30am</td>
<td><strong>Risk of Erectile Dysfunction Associated with Use of 5-Alpha Reductase Inhibitors for Benign Prostate Hyperplasia or Alopecia [803]</strong></td>
<td>Katrina Wilcox Hagberg, Hozefa A Divan, Rebecca Persson, J Curtis Nickel, Susan S Jick. (United States)</td>
<td>(Wicklow Hall 2)</td>
</tr>
<tr>
<td>8:45am</td>
<td><strong>Risk of Breast Cancer in Risperidone Users: A Nationwide Cohort Study [804]</strong></td>
<td>Johan Reutfors, Louise Wingård, Lena Brandt, Yiting Wang, Hong Qiu, Helle Kieler, Shahram Bahmanyar. (Sweden)</td>
<td>(Wicklow Hall 2)</td>
</tr>
<tr>
<td>9:00am</td>
<td><strong>Prescription Opioid Use and Infection-Related Hospitalization in Hemodialysis Patients [805]</strong></td>
<td>Abhijit V Kshirsagar, Xiaojuan Li, Magdalene Assimon, M Alan Brookhart. (United States)</td>
<td>(Wicklow Hall 2)</td>
</tr>
<tr>
<td>9:15am</td>
<td><strong>Seasonality of Guillain-Barré Syndrome in the United Kingdom from April 2005 to March 2015 [806]</strong></td>
<td>Tom Cattaert, Germano LC Ferreira, Kaatje Bollaerts, Thomas Verstraeten. (Belgium)</td>
<td>(Wicklow Hall 2)</td>
</tr>
<tr>
<td>9:45am</td>
<td><strong>Identifying Incident Uterine Fibroids Using Electronic Medical Record Data [808]</strong></td>
<td>Onchee Yu, Susan Reed, Renate Schulze-Rath, Jane Grafton, Kelly Hansen, Delia Scholes. (United States)</td>
<td>(Wicklow Hall 2)</td>
</tr>
</tbody>
</table>
8:30-10:00am **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Adverse Outcomes and Infectious Diseases** *(Liffey Hall 2)*

**Moderators:** Emily Brouwer & Yared Santa-Ana Tellez

8:30am

- **The Association Between Lansoprazole and Tuberculosis Disease; a Primary Care Based Cohort Study [809]**
  - Ian J Douglas, Laurie Tomlinson, Tom Yates, Krishnan Bhaskaran, Sinead Langan, Sara Thomas, Liam Smeeth. (United Kingdom)

8:45am

- **Do Proton Pump Inhibitors Impact Clinical Outcomes in Staphylococcus Aureus Bacteremia? [810]**
  - Aisling R Caffrey, Tristan T Timbrook, George Sakoulas, Kerry L LaPlante. (United States)

9:00am

- **Opioid Analgesic Use as a Risk Factor for Laboratory-Confirmed Invasive Pneumococcal Diseases: A Nested Case-Control Study [811]**
  - Andrew D Wiese, Marie R Griffin, William Schaffner, C Michael Stein, Edward F Mitchel, Jr., Carlos G Grijalva. (United States)

9:15am

- **Hepatitis C Virus Infection Increases Risk of Developing Chronic Kidney Disease [812]**
  - Chao Chen, Wei Wang, Robert L Cook, Haesuk Park. (United States)

9:30am

- **Risk of Hepatic Decompensation with Cumulative Mitochondrial Toxic Nucleoside Analogue Use in HIV/Hepatitis C Coinfection [813]**
  - Vincent Lo Re III, Bret Zeldow, Michael J Kallan, Janet P Tate, Dena M Carbonari, Jay R Kostman, Robert Gross, Amy C Justice, Jason A Roy. (United States)

9:45am

- **Slow Efavirenz Metabolism Alleles Are Associated with Antiretroviral Failure in Botswana [814]**
  - Robert Gross, Scarlett L Bellamy, Bakgaki Ratshaa, Xiaoyan Han, Marijana Vujkovic, Richard Aplenc, Andrew P Steenhoff, Mosepele Mosepele, Athena Zuppa, Brian L Strom, Gregory P Bisson. (United States)

---

The power of **knowledge.** The value of **understanding.**

Let us help you reduce the uncertainty of risks to patients by investigating disease epidemiology, drug-outcome associations, and product usage in routine clinical practice and by evaluating the effectiveness of your risk minimization strategies.

**Research Triangle Park - Ann Arbor - Barcelona - Ljungskile - Manchester - Waltham**

[LEARN MORE and connect: rtihs.org/ICPE16]
8:30-10:00am **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

### Vaccines: Hit Me with Your Best Shot (Liffey Hall 1)
**Moderator: Catherine Cohet**

- **8:30am**
  - Narcolepsy Incidence Rates in the SOMNIA (Systematic Observational Method for Narcolepsy and Influenza Immunization) Study [815]
    Caitlin N Dodd, Maria de Ridder, Daniel Weibel, Frank DeStefano, Tom Shimabukuro, Bruce Carleton, Silvia Perez-Vilar, Angela Gentile, Norberto Giglio, Maria Giner-Soriano, Lisen Arheim Dalstrom, Wan-Ting Huang, Larry Svenson, Lars Pedersen, Jan Bonhoeffer, Miriam Sturkenboom, Steve Black. (Netherlands)

- **8:45am**
  - Assessing Quadrivalent HPV Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic [816]
    W Katherine Yih, Judith C Maro, Michael D Nguyen, Adamma Mba-Jonas, Meghan A Baker, Carolyn Balsbaugh, David V Cole, Inna Dashevskey, Martin Kulldorff. (United States)

- **9:00am**
  - Human Papillomavirus Vaccination and Risk of Autoimmune Diseases: A Large Cohort Study of Over 2 Million Young Girls in France [817]
    Christophe Chaingot, Sara Miranda, Cedric Collin, Rosemary Dray-Spira, Alain Weill, Mahmoud Zureik. (France)

### Analytic Approaches for Controlling and Exposure Misclassification (The Auditorium)
**Moderators: Suzanne Cadarette & Mollie Wood**

- **8:30am**
  - Multi-State Models – A Complimentary Approach to Group Based Trajectory Models [821]
    Aaron N Winn, Stacie B Dusetzina. (United States)

- **8:45am**
  - Covariate Adjustment of Cumulative Incidence Functions for Competing Risks Data Using Inverse Probability of Treatment Weighting [822]
    Anke Neumann, Cécile Billionnet. (France)

- **9:00am**
  - Propensity Score Methods for Subgroup Analyses: Investigating Covariate Balance [823]
    Phyto T Htoo, Caroline J Mariano, Sharon Peacock-Hinton, Katie Reeder-Hayes, Michele Jonsson Funk, Til Stürmer, Jennifer L Lund. (United States)

- **9:15am**
  - Effectiveness of the Quadrivalent Human Papillomavirus Vaccine (QHPV) Against Anogenital Warts (AGWs) in Manitoba, Canada: A Population-Based Study [818]
    Karla Willows, Songul Bozat-Emre, Erich Kliewer, Salah Mahmud. (Canada)

- **9:30am**
  - Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases [819]
    Huifeng Yun, Fenglong Xie, John W Baddley, Kevin L Winthrop, Kenneth G Saag, Jeffrey R Curtis. (United States)

- **9:45am**
  - New Methods to Estimate Vaccination Coverage from Health Care Databases [820]
    Kaatje Bollaerts, Tom Cattaert, Toon Braeye, Klára Berensci, Marius Gheorge, Vincent Bauchau, Miriam Sturkenboom, Hanne-Dorthe Emborg. (Belgium)

- **9:15am**
  - Adjustment for Unobserved Confounders in Health Administrative Databases [824]
    Bernard Silenou Chawo, Marta Avalos Fernandez, Antoine Pariente, Hélène Jacqmin Gadda. (France)

- **9:30am**
  - The Impact of Censoring on Discontinuation When Modeling the Disease Risk Score [825]
    Justin Bohn, Richard Wyss, Joshua Gagne. (United States)

- **9:45am**
  - Survival Bias in Exposure Crossover Studies [826]
    Thy Do, Emil Scosyrev. (United States)

10:00-10:30am **Break/Posters/Exhibits (The Forum)**
Multiple Database Study Design and Inference (The Auditorium)

Speakers:
- Miriam Sturkenboom, FISPE, Erasmus University Medical Center
- Olaf Klungel, University Medical Centre Utrecht
- Tobias Gerhard, FISPE, Rutgers University
- Andrew Bate (Chair), Pfizer Ltd

Across the globe important experience has been gained with multi-database initiatives such as OMOP, Mini-Sentinel, CNODES, PROTECT, EU-ADR, and ASPEN. These initiatives used different approaches. In this symposium we will discuss the lessons learnt from these initiatives — from the perspectives of data, analysis, and interpretation — aiming to elicit common themes, and examining to what extent discrepancies in findings and lessons learnt can be attributed to differences in approach.

Miriam Sturkenboom: The Data - What Data Sets to Include in a Multiple Country/Site Study?
Several multi-country/site initiatives have been launched over the past decade with the expectation of greater precision and/or validity for drug-effect studies. Debate is still ongoing on whether to use all available databases or to select certain databases. When multiple databases are analyzed together the question remains whether and under what circumstances a common data model (CDM) is preferred. When using CDMs, which models are available and what are their pros and cons (e.g. Jerboa, OMOP CDM, IMEDS, EMIF, etc)?

Olaf Klungel: Analytic Strategy - How to Decide What Methods to Employ and How Many?
When conducting drug-effect hypothesis testing studies multiple choices have to be made on design and analysis. During the past decades these choices have become less based on one specific design and analysis based on the hypothesized mechanism of action of a drug, including exposure-time-event relationship. More and more, sensitivity analyses on various methodological parameters are becoming common practice. Should sensitivity analysis always be conducted on all parameters and should it include the whole range of possible values, or should these be informed by certain plausible ranges, and how to decide on these ranges?

Tobias Gerhard: Output - Interpretation of Studies - The Impact of a Priori Versus Post-Hoc Decisions
When drug-effect studies are conducted in multiple databases it is not straightforward to decide on consistency of results. When should results across multiple databases be considered similar and when not? Is a frequentist approach sufficient to test heterogeneity or should Bayesian approaches be applied?
3:15-4:45pm

**SYMPOSIA AND WORKSHOPS**

**Pattern Discovery in Observational Health Data - What We Did Not Know to Look For [827]** (The Auditorium)
- Meredith Y Smith, Tarek Hammad, Rebecca Noel, Paul Huckle, Francesco Pignatti, Declan Noone. (United States)

**Clinical And Analytic Considerations In The Selection And Evaluation Of Comparators In Observational Database Studies [828]** (The Liffey B)
- Patrick B Ryan, Saad Shakir, David Madigan. (United States)

**Pharmacoepidemiology and Risk Management Planning: Essential Enablers for Development of Innovative Medicines [829]** (The Liffey A)
- Peter R Arlett, June Munro Raine, Almath Spooner, Sebastian Schneeweiss, Eva Flahavan. (United Kingdom)

**Transitioning to ICD-10: International Lessons Learned and Strategies for Moving Forward [830]** (Wicklow Hall 2)
- Joshua J Gagne, Lisa M Lix, Sengwee Toh, David D Dore, Manel Pladevall-Vila. (United States)

**Who to Ask and How? Preference-Based Methods for Benefit-Risk Assessment [831]** (Liffey Hall 2)
- Kevin Marsh, Hans L Hillege, Quazi Ataher, Tommi Tervonen. (United Kingdom)

**The Agony and the Ecstasy: The Creation of the Revised ICH M4E Benefit-Risk Assessment Guideline and Practical Implications for Patients, Industry and Regulators [832]** (Liffey Hall 1)
- Meredith Y Smith, Tarek Hammad, Rebecca Noel, Paul Huckle, Francesco Pignatti, Declan Noone. (United States)

3:15-4:45pm

**CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Practice of Epidemiology in Pregnancy Studies** (The Liffey)
- **Moderator:** Christina Chambers

- **3:15pm**
  - **Validity of a Web-Based Questionnaire to Assess Perinatal Outcome [833]**
    - Marleen MHJ van Gelder, Saskia Vorstenbosch, Lineke Derks, Bernke te Winkel, Eugène P Puijenbroek, Nel Roesleveld. (Netherlands)

- **3:30pm**
  - **Consistency of Measures of Asthma Symptom Control Collected During Pregnancy vs. Retrospectively at 6 Months Post-Partum [834]**
    - Christina D Chambers, Ronghui Xu, Mofei Li, Diana L Johnson, Yunjun Luo. (United States)

- **3:45pm**
  - **Comparison of Electronic Healthcare Data and Prospective Face-to-Face Studies for Evaluating Neurodevelopmental Disorders Following In-Utero Medication Exposures [835]**
    - Rachel Charlton, Anita McGrogan, Julia Snowball, Laura Yates, Amanda Wood, Jill Clayton-Smith, Henry Smithson, Jonathan Richardson, Neil McHugh, Simon Thomas, Gus Baker, Rebecca Bromley. (United Kingdom)

- **4:00pm**
  - **Bias from Restricting to Live Births in a Study of Prescription Drug Use and Pregnancy Complications: A Simulation [836]**
    - Elizabeth A Suarez, Suzanne N Landi, Mitchell M Conover, Michele Jonsson Funk. (United States)

- **4:15pm**
  - **Utilization Patterns of Drugs or Biologics with Pregnancy Exposure Registries in Pregnant and Matched Non-Pregnant Women in the Sentinel Database [837]**
    - Steven T Bird, Lockwood Taylor, Christian Hampp, Leyla Sachin, Darren Toh, Susan Andrade, Katie Haffenreffer, Marsha Reichman, Kate Gelperin. (United States)

- **4:30pm**
  - **Oral Contraceptive Induced Hypertension and Subsequent Pre-Eclampsia: A Retrospective Cohort Study [838]**
    - Brian J Cleary, Maev Eogan, Sharon Sheehan. (Ireland)
### Disease Burden from Clinical Databases (The Liffey B)

**Moderators:** Shahram Bahmanyar & Daniel Mines

#### 3:15pm
- **Time Trends Of Idiopathic Pulmonary Fibrosis (IPF) in the United Kingdom (UK) from 1999 to 2013 Using the Clinical Practice Research Datalink (CPRD)** [839]
  Mellissa Yong, Jenny Chia, David Oliveri, Hubert Chen, Dorothy Cheung, Matt Cohen, Pavel Napalkov. (United States)

#### 3:30pm
- **The Impact and Longevity of Measles-Associated Immune Suppression** [840]
  Caitlin N Dodd, kartini Gadoen, Gwen Masclee, Maria de Ridder, Daniel Weibel, David van de Vijver, Rik de Swart. (Netherlands)

#### 3:45pm
- **Blood Pressure and Risk of Dementia in a Cohort of 2.6 Million People Over Two Decades** [172]
  Nawab Qizilbash, John Gregson, Michelle E Johnson, Neil Pearce, Ian Douglas, Kevin Wing, Stephen JW Evans, Stuart J Pocock. (United Kingdom)

#### 4:00pm
- **Epidemiological Assessment of Real-World Treatment Patterns in Advanced Pancreatic Neuroendocrine Tumors in the Era of Targeted Therapy: Perspectives from an Academic Tertiary Center and Community Oncology Practices** [842]
  Lynn Huynh, Maurice Herring, Mei S Duh, Francis Vekeman, Audrey Tiew, Maureen P Neary, Emily Bergsland. (United States)

#### 4:15pm
- **10-Year Landmark Survival and Characteristics of Advanced Non-Small Cell Lung Cancer (aNSCLC) Long-Term Survivors** [843]
  Ben Lyons, Joe Simpson, Margaret E McCusker, Alan B Sandler. (United States)

#### 4:30pm
- **Reoperation Due to Surgical Bleeding in Breast Cancer Patients and Breast Cancer Recurrence: A Danish Population-Based Cohort Study** [844]
  Rikke N Pedersen, Krishnan Bhaskaran, Uffe Heide-Jørgensen, Mette Nørgaard, Peer M Christiansen, Niels Kromen, Henrik T Sørensen, Deirdre P Cronin-Fenton. (Denmark)

---

**BHE**

Driving Innovation in Healthcare Analytics

BHE combines research expertise, powerful analytic solutions, and a variety of real-world datasets to provide actionable insights to the life science, provider, and payer communities

Visit us at our booth to learn about:

- Instant Health Data (IHD)
  - Generating Actionable Insights in Epidemiologic Studies
  - Analyses in Minutes Rather than Days or Weeks
- Custom Research
  - Observational Studies
  - Statistical, Epidemiologic, and Economic Models

For more information contact Joseph Menzin or Jack Fuller

20 Fox Road / Waltham, MA, 02451 / (781) 290-0808

[www.bhei.com](http://www.bhei.com)
3:15-4:45pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

CV Adverse Events: Affairs of the Heart (Wicklow Hall 2)
Moderator: Nancy Santanello, FISPE & J Bradley Layton

3:15pm
- Opioid Use Prior to Incident Myocardial Infarction and Subsequent Risk of Ischemic Stroke, Venous Thromboembolism, and Death [845]
  Troels Munch, Erzsébet Horváth-Puho, Kasper Adelborg, Lars Pedersen, Morten Schmidt, Henrik T Sørensen. (Denmark)

3:30pm
- Long Acting Bronchodilators and Risk of Myocardial Infarction in Patients with Chronic Obstructive Pulmonary Disease and Who Are at High Risk for Cardiovascular Disease: A Quasi-Cohort Approach [846]
  Sunning Tao, Samy Suissa, Sophie Dell’Aniello, Pierre Ernst. (Canada)

3:45pm
- Association of Proton Pump Inhibitor Use and Acute Myocardial Infarction Among Privately Insured Adults, 2001-2014 [847]
  Suzanne N Landi, Jennifer L Lund, Virginia Pate, Robert S Sandler. (United States)

4:00pm
- Incidence of Cardiovascular Events in New Users of Overactive Bladder Medications in Denmark [848]
  Jesper Hallas, Andrea V Margulis, Anton Pottegård, Nina Kristiansen, Christine L Bui, Whitney Krueger, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Arana. (Denmark)

4:15pm
- Cardiovascular Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers [849]
  Marie Linder, Andrea V Margulis, Ingegärd Anveden-Berglind, Shahram Bahmanyar, Christine L Bui, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Arana. (Sweden)

4:30pm
- Development of a Predictive Model for Drug-Induced QT Prolongation in the Inpatient Setting Using Electronic Health Record Data [850]
  Juan M Hincapie-Castillo, Benjamin Staley, Carl Henriksen, Arwa Saidi, Gigi Lipori, Almut G Winterstein. (United States)

The Clinical Practice Research Datalink (CPRD) provides high quality anonymised health data for observational and interventional public health research.

Visit our stand and talk to our experienced Observational Research team, who can offer expert advice on:

- using Real World Data for research
- international collaborations with academic, industry and government researchers
- how CPRD supports drug safety studies, improving public health.

www.cprd.com
3:15-4:45pm **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

### Adverse Outcomes of Glucocorticoid and Immunomodulator Use (Liffey Hall 2)

**Moderator: Cunlin Wang**

**3:15pm**

- **Trends in Oral Glucocorticoid Utilization Among Older Adults with Respiratory Disease [851]**
  M Amine Amiche, Linda E Lévesque, Tara Gomes, Jonathan D Adachi, Suzanne M Cadarette. (Canada)

**3:30pm**

- **Use of Glucocorticoids and Risk of Community-Acquired Staphylococcus aureus Bacteraemia: A Population-Based Case-Control Study [852]**
  Jesper Smit, Achim Kaasch, Mette Segaard, Reimar W Thomsen, Henrik Nielsen, Trine Froslev, Henrik C Schonheyder. (Denmark)

**3:45pm**

- **Use of Glucocorticoids and the Risk of Osteoporotic Fracture in Patients with Sarcoidosis [853]**
  Olorunfemi Oshagbagbemi, Johanna Driessen, Peter Vestergaard, Joop van den Bergh, Frank deVries. (Netherlands)

**4:00pm**

- **Risk of Lymphoma in Users of Topical Tacrolimus, Pimecrolimus and Corticosteroids (JOELLE Study) [854]**

**4:15pm**

- **Pharmacological Treatments Preceding Diagnosis Of Progressive Multifocal Leukencephalopathy [855]**
  Sarah Burkill, Ellen Iacobaeus, Shahram Bahmanyar, Lou Brundin, Michael Fored, Tomas Olsson, Scott Montgomery. (Sweden)

**4:30pm**

- **Association Between Breast Cancer Recurrence With Immunosuppression In Rheumatoid Arthritis And Inflammatory Bowel Disease: A Cohort Study [856]**
  Ronac Mamtani, Amy S Clark, Frank I Scott, Colleen M Brensinger, Ben Boursi, Lang Chen, Fenglong Xie, Huifeng Yun, Mark T Osterman, Jeffrey R Curtis, James D Lewis. (United States)

---

**MEET OUR DECISION SUPPORT AND SAFETY EXPERTS AT BOOTHs 35/40**

- **DRUG UTILIZATION STUDIES, PASS AND SAFETY REGISTRIES**
- **GLOBAL NETWORK OF PATIENT-LEVEL DATASETS**
- **WORLD-CLASS EPIDEMIOLOGICAL DATA**
- **NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)**

- **EPI DATABASE®**
- **CANCERMPACT® PATIENT METRICS**
- **40+ YEARS’ EXPERTISE IN PHYSICIAN-AND PATIENT-CENTERED STUDY DESIGNS WITH DATA COLLECTED THROUGH OUR PROPRIETARY, VALIDATED EDC SYSTEM**

info.kantarhealth.com/icpe2016
### Thin Blood: Anticoagulants (Liffey Hall 1)
**Moderator:** John Acquavella, FISPE

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15pm</td>
<td>Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Clinical Practice—Interim Results of a Long-Term Study Program [857]</td>
<td>Krista F Huybrechts, Dorothee B Bartels, Chandrasekar Gopalakrishnan, John D Seeger, Kristina Zint, Katsiaryna Bykov, Sebastian Schneeweiss. (United States)</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Comparative Effectiveness and Safety of New Oral Anticoagulants (NOACs) and Warfarin in Patients with Atrial Fibrillation: A Multi-Database Study in the US and UK [858]</td>
<td>M Sanni Ali, Rianne van den Ham, Rolf HH Groenwold, Mikkel Z Ankarfeldt, Erpur Adalsteinsson, Cynthia Girman, Olaf H Klungel. (Netherlands)</td>
</tr>
<tr>
<td>3:45pm</td>
<td>Clinical Events Preceding Changes During Treatment With Non-VKA Oral Anticoagulants In Patients With Atrial Fibrillation [859]</td>
<td>Maja Hellfritzsch, Erik L Grove, Steen E Husted, Lotte Rasmussen, Birgitte K Poulsen, Søren P Johnsen, Jesper Hallas, Anton Pottegård. (Denmark)</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Use of New Oral Anticoagulants in the Secondary Care Setting vs Primary Care in the UK: Interim Results from Two Post-Authorisation Studies [504]</td>
<td>Deborah Layton, Alison Evans, Miranda Davies, Sandeep Dhanda, Saad AW Shakir. (United Kingdom)</td>
</tr>
<tr>
<td>4:15pm</td>
<td>The Safety and Effectiveness of New Oral Anticoagulants versus Vitamin K Antagonists - Pilot Implementation of a Real-Time Monitoring Program in Italy [861]</td>
<td>Flavia Mayer, Ursula Kirchmayer, Nera Agabiti, Valeria Belleudi, Giovanna Cappai, Mirko Di Martino, Danilo Fusco, Sebastian Schneeweiss, Marina Davoli, Elisabetta Patorno. (Italy)</td>
</tr>
<tr>
<td>4:30pm</td>
<td>Stroke, Bleeding, and Mortality Risks in Older Patients Treated with Dabigatran or Rivaroxaban for Nonvalvar Atrial Fibrillation [862]</td>
<td>David J Graham, Marsha E Reichman, Michael Wernecke, Ya-Hui Hsueh, Riina Izern, Mary Ross Southworth, Yuqin Wei, Jiemin Liao, Margie R Goulding, Katrina Mott, Yoganand Chillarige, Thomas E MaCurdy, Chris Worrall, Jeffrey A Kelman. (United States)</td>
</tr>
</tbody>
</table>

### Is it Safe Enough? (The Auditorium)
**Moderators:** Stella Blackburn, FISPE & Ola Caster

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30pm</td>
<td>Analysis of Patient Narratives in Disease Blogs: Enhancing Pharmacovigilance Using Real-World Health Data on the Internet [864]</td>
<td>Shinichii Matsuda, Kotonari Aoki, Shihoo Tomizawa, Masayoshi Sone, Sawako Satomi, Terumi Nakayama, Riwa Tanaka, Hiroshi Kuriki, Yoichiro Takahashi. (Japan)</td>
</tr>
<tr>
<td>3:45pm</td>
<td>Prediction Model Based Algorithm for a Computer-Assisted Database Screening Tool [865]</td>
<td>Joep Scholl, Florence van Hunsel. (Netherlands)</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Assessment of the US Food and Drug Administration’s Sentinel Analysis Tools: Angiotensin-Converting Enzyme Inhibitors And Angioedema [866]</td>
<td>Joshua J Gagne, Xu Han, Sean Hennessy, Charles E Leonard, Elizabeth A Chriseilles, Ryan M Carnahan, Shirley V Wang, Candace Fuller, Aarthi Iyer, Hannah Katcoff, Tiffany S Woodworth, Patrick Archdeacon, Tamra E Meyer, Sebastian Schneeweiss, Sengwee Toh. (United States)</td>
</tr>
<tr>
<td>4:15pm</td>
<td>An Automatized Model for Sequential Monitoring of Effectiveness of New Drugs Using Dronedarone as Example [867]</td>
<td>Thomas Cars, Martin Neovius, Lars Lindhagen, Rickard E Malmström, Jonas Schwieler, Björn Wettermark, Johan Sundström. (Sweden)</td>
</tr>
<tr>
<td>4:30pm</td>
<td>Monitoring All Drugs for Specific Outcome in the Sentinel System [88]</td>
<td>Judith C Maro, Gerald J Dal Pan, Inna Dashevsyky, Jeffrey S Brown, Martin Kulldorff. (United States)</td>
</tr>
</tbody>
</table>
Powerful Data.
High-Quality Research.
Think Truven Health Analytics.

When you need ‘big’ data for pharmacoepidemiological research, you also need leading experts in prospective and retrospective analytics and data linkages working with you. We have both — data and experienced epidemiologists ... plus specialty data found nowhere else.

- Drug Treatment Pattern Analysis and Visualization Tool
- Retrospective and Prospective Research
- MarketScan® Research Databases
- Linked Data
- DRUG-REAX® Data

We are unveiling Treatment Pathways’ advanced drug treatment pattern analysis capabilities at the conference, so visit our booth at the ICPE 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Dublin.

©2016 Truven Health Analytics, an IBM Company. All rights reserved. All other product names used herein are trademarks of their respective owners. LS_16938_0616

Consulting in Clinical Drug Safety, Pharmacovigilance, and Medical Product Epidemiology since 1988!

The Degge Group, Ltd.
9302 Lee Highway, Suite 700, Fairfax, VA 22031 USA
+1 571.490.8020 info@deggegroup.com www.deggegroup.com

Visit Booth #15 to learn more

Identify databases by subscribing to our online compendium of ~275 population database profiles from 36 countries

Search, review, and compare database profiles
[Profiles are reviewed by respective database managers and frequently updated.]
Access specialized glossary and interactive maps of databases

+1 571.490.8400 info@bridgetodata.org www.bridgetodata.org

B.R.I.D.G.E. TO DATA® is an online service provided by DGI, LLC, a non-profit organization

Your connection to healthcare databases worldwide®
4:45-5:30pm  **THE FINAL WORD**

**Spotlight Poster Awards** (The Auditorium)
- Lisa Gai Pont, FISPE, Co-Chair, Spotlight Sessions
- J Bradley Layton, Co-Chair, Spotlight Sessions

**2017 ISPE Meetings**
- **Mid-Year** - London
  - Alison Bourke, FISPE, Co-Chair, Program Planning Committee

- **ICPE - Halifax**
  - Adrian Levy, Chair, 2017 Scientific Program Committee
  - Ingrid Sketris, Chair, 2017 Local Host Committee

**Adjournment of ICPE 2016**
- Mary E Ritchey, Chair, ICPE 2016 Scientific Program Committee

**ICPE 2017 Drawing for complimentary registrations**

5:45-6:30pm  **2017 ICPE Scientific Program Committee Meeting** (EcoCem)

---

See you next year in Halifax!
Your Partner of Choice for Building an RWE Ecosystem

IMS Health brings together the real-world data (RWD), technology, analytics, and scientific and commercial expertise you need to support product value, safety, access and price.

- **500+ million** anonymous longitudinal patient data records including EMR, claims data, hospital data and lab tests in **25+ markets**
- Data sourcing and enriched RWD capabilities, supported by an expanding **RWD Catalogue of 2,200+ sources** globally
- **Leading edge technology and analytics**
- **Experts in 20+ markets** with deep specialism in RWE, pharmacoepidemiology, drug safety, HTA, and payer requirements to translate insights into actions
- **3,500+ publications** building healthcare knowledge

IMS Health Real-World Evidence Solutions

Uncovering insights from real-world data to improve decision making and patient outcomes
Overview

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, and to promote conversations and networking among conference participants.

POSTER SESSION

Spotlight Session posters will be displayed in the Third Floor Foyer while all other posters will be displayed in The Forum of the Convention Centre Dublin, August 26-28. Each day will have a separate poster session and Spotlight Sessions. All posters for a specific day's session must be removed at the end of that day.

1. Set Up:
7:00am-8:00am; all posters must be in place by 8:00am. The poster areas (including floor) must remain clear and clean of tubes.

2. Hours:
Posters will be displayed from 8:00am to 6:00pm on Friday and Saturday, and from 8:00am to 1:45pm on Sunday.

3. Discussion Time:
General Poster Sessions: Presenters should be at their posters between 12:15-1:15pm on Friday (A) and Sunday (C); and between 11:45-12:45pm on Saturday (B) [The Forum]

Spotlight Poster Sessions: Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters between 12:15-1:15pm on Friday (A) and Sunday (C); and between 11:45-12:45pm on Saturday (B). [Third Floor Foyer]

The spotlight sessions offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the spotlight chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

Friday
- Adherence
- Databases
- Devices
- Pediatrics

Saturday
- AsPEN
- BRACE
- Drug Utilization Research
- Medications in Pregnancy

Sunday
- Vaccines
- CER
- Biologics & Biosimilars.

4. Take Down:
All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

Spotlight Session Prizes
A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced during The Final Word at 4:45pm, Sunday, August 28.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster on that day as listed in the Final Program, which will be available at the ISPE Registration Desk, as well as included online in Abstracts2view. The POSTER BOARD NUMBER is the first number (or letter) listed. The ABSTRACT NUMBER, for use in locating abstracts in the Final Program or in Abstracts2view, is listed after the abstract title.

Example
97 Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]
Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

Key
97 POSTER BOARD NUMBER
176 PUBLICATION Number

1. Poster Specifications
Posters must be designed to fit a freestanding poster board approximately 4 feet WIDE x 8 feet HIGH (1.2 meter WIDE x 2.4 meters HIGH). Only VERTICAL/PORTRAIT posters will be allowed.

2. Disclosure Statement
A disclosure statement must accompany each abstract. This statement should follow the title page and should be a positive disclosure of all funding sources for the current project as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.

3. Call4Posters
Posters ordered through Call4Posters can be picked up in the exhibit hall (The Forum) at the times below.

Poster Pick Up Schedule:
Thursday, August 25:  1:00pm-5:00pm
Friday, August 26:   7:00am-1:00pm
Saturday, August 27: 7:00am-1:00pm
Sunday, August 28:  7:00am-Noon
Spotlight Session-Adherence

A. Polypharmacy and Adherence to TNF-alpha Inhibitors: Variation by Specific Concurrent Medications [80]
   Sruthi Adimadhayam, Wan-Ju Lee, Gregory S Calip. (United States)

B. Predicting Adherence to Chronic Disease Medications in Patients with Long-Term Initial Medication Fills [81]
   Julie C Lauffenburger, Jessica M Franklin, Alexis A Krumme, William H Shrank, Troyen A Brennan, Olga S Mattlin, Claire M Spettell, Gregory Brill, Niteesh K Choudhry. (United States)

C. Association Between Trajectories of Diabetes Medication Adherence and Hospitalization Risk in a Large Medicaid Program [82]
   Wei-Hsuan Lo-Ciganic, Julie M Donohue, Bobby L Jones, Joshua M Thorpe, Subashan Perera, Zachary A Marcum, Walid F Gella. (United States)

D. Association Between Patient-Centered Medical Homes and Adherence to Chronic Medications [83]

E. Influence of Antidepressant Treatment on Use of and Adherence to COPD Maintenance Medications [94]
   Yu-Jung Jenny Wei, Linda Simon-Wastila, Jennifer S Albrecht, Ting-Ying Huang, Patience Moyo, Bilal Khokha, Ilene Harris, Patricia Langenberg, Giora Netzer, Susan Lehmann. (United States)

F. Impact of Treatment Satisfaction and Adverse Drug Events on Antihypertensive Medication Adherence in Ambulatory Patients in Ethiopia [95]
   Derbew Fikadu Berhe, Katja Taxis, Flora M Haaijer-Ruskamp, Afewerk Mulugeta, Yewondwossen Tadesse Mengistu, Peter GM Mol. (Netherlands)

G. Impact of High Deductible Health Plans on Adherence to Essential Medications for Patients with Chronic Conditions [86]
   Jennifer Lewey, Joshua J Gagne, Jessica Franklin, Julie Lauffenburger, Samantha Dougherty, Gregory Brill, Niteesh K Choudhry. (United States)

H. An Example of Exposure Heterogeneity When Pooling Epidemiologic Studies for Meta-Analysis of Antiretroviral Medication Adherence [87]
   Mary-Ellen Mackesy-Amiti, Lauren Strand, Robin Nance, Redonna Chandler, William Cunningham, Elise Riley, Shruti Mehta, Frederick Altice, Wendee Wechsberg, Chinazo Cunningham, Charles Cleland, Lisa Metsch, Daniel Feaster, Carlos del Rio, Curt Beckwith, Ann Kurth, Irene Kuo, Bridget Kruksza, Sandra Springer. (United States)

Spotlight Session-Databases

I. Pilot Test of the Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Severe Hypoglycemia [89]

J. Quality of Diabetes Recording: How Does Coding Impact Incidence Estimates? [90]
   A Rosemary Tate, Sheena Dungay, Simon Glew, Natalia Beloff, Rachael Williams, Tim Williams.

K. Evaluation of Free-Text Comments to Validate Common Cancer Diagnoses in the UK CPRD [91]
   Joan Fortuy, James A Kaye, Christine L Bui, Alicia W Gilsenan, Jennifer Bartsch, Estel Plana, Lisa J McQuay, Brian Calingaert, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milbhor D'Silva, Susana Perez-Gutthann, Alejando Arana, Andrea Y Margulis. (Spain)

L. Abstract Withdrawn [92]

M. An Algorithm to Identify Duplicate Patients When Pooling Aggregate Data from Two Primary Care Databases in the United Kingdom [93]

N. Methods to Estimate Days’ Supply within Pharmacy Data of the Health Improvement Network (THIN) [94]
   Kirsten J Lum, Craig W Newcomb, Jason A Roy, Dena M Carbonari, M Elle Saine, Serena Cardillo, Harshvinder Bhuilar, Arlene M Gallagher, Vincent Lo Re Ill. (United States)

O. Evaluating the Utility of the CPRD GOLD-HTI Linkage: Anticoagulant Prescribing at the GP Practice Compared to Hospital Dispensed Medication at Discharge Date [95]
   Arlene M Gallagher, Rachel Tham, Hassy Dattani, Adam Collier, Frank de Vries, Tim Williams. (United Kingdom)

Spotlight Session-Devices

P. Estimated Effects of Treatment Changes on Hemoglobin A1c in a Cohort with Incident Type 1 Diabetes [96]
   Richard S Swain, Janet T Holbrook, Dana Y Teltsch, MAJ Christina L Cristaldi, Jodi B Segal, G Caleb Alexander. (United States)

Q. Cement Leakage and New Vertebral Fractures after Kyphoplasty and Vertebroplasty: A Meta-Analysis [97]
   Hong Cheng, Yuzhi Hu, Nishant Mishra, Colin Anderson-Smits. (United States)

R. Assessing Real-World Use and Outcomes of Newly Marketed Bioprosthetic Aortic Valves Using Japanese Nationwide Cardiovascular Surgical Registry [98]
   Hiraku Kumanarou, Hiroaki Miyata, Noboru Momotora, Nobuhiro Handa, Kan Nawata, Minoru Ono, Shinichi Takamoto. (Japan)

S. Comparison of New Vertebral Fractures After Kyphoplasty and Vertebroplasty Using Medicare Data [99]
   Hong Cheng, Yuzhi Hu, Jie Zhou, Colin Anderson-Smits. (United States)

T. Treatment Patterns in a Cohort of Patients with Incident Type 1 Diabetes [100]
   Richard S Swain, Jodi B Segal, Dana Y Teltsch, MAJ Christina L Cristaldi, G Caleb Alexander, Janet T Holbrook. (United States)

U. Risk Factors for Persistent and New Chronic Opioid Use in Patients Undergoing Total Hip Arthroplasty [101]
   Maria CS Inacio, Craig Hansen, Elizabeth E Roughhead, Nicole L Pratt, Stephen E Graves. (Australia)

V. A Comparative Analysis of Secondary Surgeries of Six Total Cervical Disc Arthroplasty Devices to Cervical Arthrodhesis at 5-Years [102]
   Colin Anderson-Smits, Davic Sing, Anton Dmitriev, Hong Cheng. (United States)

W. Hospital Variation And Patient Characteristics Associated With Vena Cava Filter Use For Venous Thromboembolism [103]
   Joshua D Brown, Jeffery C Talbert. (United States)
Spotlight Session-Pediatrics

X. Use of Contraindicated Drugs in Pediatric Outpatients in the Nordic Countries [104]
Tuire Prami, Disa Långström, Ilona Iso-Mustajärvi, Niklas Sandler. (Finland)

Y. Recent U.S. Drug Utilization For Pediatric Inflammatory Bowel Disease, 2009-2015 [105]
Susan A Hall, Emma W Viscidi, Jeff K Allen, Maneesh Junega, Susan Eaton, Suzanne F Cook, Anne B Dilley. (United States)

Z. Psychiatric Diagnoses and Medication Patterns in a Medicaid-Insured Birth Cohort [106]
Dinci Pennap, Julie M Zito, Mehmet Burcu, Daniel J Safer. (United States)

AA. Poor Guideline Adherence In The Initiation Of Antidepressant Treatment In Children And Adolescents In The Netherlands: Choice Of Antidepressant And Dose [107]
Ynkje Anna de Vries, Peter de Jonge, Luuk Kalverdijk, Jens HJ Bos, Catharina CM Schuilling-Veninga, Eelko Hakt. (Netherlands)

BB. The Association Between Fluorquinolone and Musculoskeletal Adverse Events in Pediatrics [108]
Ching-Lan Cheng, Yea-Huei Kao Yang, Yi-Fen Hsu. (Taiwan)

CC. First Time Signal Detection of Global Paediatric Data – Putting Theory into Practice [109]
Kristina Star, Lovisa Sandberg, Imti Choona, Pia Caduff, I Ralph Edwards. (Sweden)

DD. The Impact of Birth Season on Time to First Antibiotic Use Among Infants Born in Denmark 2004-2012 [110]
Alan C Kinlaw, Henrik T Sørensen, Jennifer L Lund, Christina D Mack, Pedersen Lars, Julie L Daniels, Michael D Kappelman, Til Stürmer. (United States)

EE. Prevalence and Risk Factors for Opioid Misuse in Youth: Results from a National Study in the US [111]
Vicki Osborne, Mirsada Srdarevic, Hannah Crooke, Catherine Striley, Linda B Cottrell. (United States)

Burdens of Disease - Alimentary & Metabolic

1. Urosepsis and Urinary and Genital Infections Among Diabetes Patients and Matched Controls [112]
Gregory A Nichols, Kimberly G Brodovicz, Dorothee B Bartels. (United States)

2. Gastrointestinal Cancer Incidence in Type 2 Diabetes Mellitus; Results from a Large Retrospective Population-Based Cohort Study in the UK [113]
Ronaldus GPJ de Jong, Paul JHL Peeters, Andrea M Burden, Marie L de Bruin, Harm R Haak, Ad AM Mascele, Frank de Vries, Maryska LG Janssen-Heijnen. (Netherlands)

3. Association Between Insulin Treatment and Breast Cancer Characteristics [114]
Jetty A Overbeek, Pauline AJ Vissers, Amber AWA van der Heijden, Heleen K Bronsveld, Myrthe PP van Herk-Sukel, Ron MC Herings, Giel Nijpels, Marjanka K Schmidt. (Netherlands)

4. A Population Based Study of Metformin and the Association with Survival in Pancreatic Cancer Patients [115]

5. Prevalence of Type 1 and Type 2 Diabetes Among U.S. Pediatric Population in the MarketScan Multi-State Medicaid Database, 2002-2013 [116]
Yong Chen, Tongtong Wang, Ravi Shankar. (United States)

6. Renal Function Measurements in Diabetes Patients; A Population Based Study in the Netherlands [117]
Elisabeth Smits, Eline Houben, Jetty A Overbeek, Peter AGM de Smet, Myrthe PP van Herk-Sukel, Martina M De Leede, Elske Anna de Vries, Maryska LG Janssen-Heijnen. (Netherlands)

7. Prevalence of Combinations of Diabetes Complications Across NHANES and NHWS [118]
Carey Strader, Amir Goren, Marco DiBonaventura. (United States)

8. Estimating the Prevalence and Incidence of Type 2 Diabetes Mellitus Using Population Level Pharmacy Claims Data [119]
Sarah-Jo Sinnott, Sheena McHugh, Helen Whelton, Richard Layte, Steve Barron, Patricia M Kearney. (United Kingdom)

Carey Strader, Nikoletta Sternbach, Kathy Annunziata.

10. An Algorithm To Identify And Classify Individuals With Type 1 And Type 2 Diabetes Mellitus In A Primary Care Database [121]
Sonia J Coton, Irene Petersen, Irwin Nazareth, Manuj Sharma. (United Kingdom)

11. Trends in Incidence and Prevalence of Type 2 Diabetes in the United Kingdom (2004 - 2014) Using the Clinical Practice Research Datalink (CPRD) [122]
Salwa S Zghibbi, Douglas T Staninek, Matthew J Carr, Darren M Ashcroft. (United Kingdom)

Rohini Mathur, Krishnan Bhaskaran, Emma Edwards, Helen Lee, Liam Smeeth, Ian Douglas. (United Kingdom)

13. Intensification of Basal Insulin Treatment Among Patients with Type 2 Diabetes Mellitus in the Netherlands [124]
Jetty A Overbeek, Eline Houben, Sofia I Kring, Jonathan Briers, Fernie JA Penning-van Beest, Amber AWA van der Heijden, Giel Nijpels, Ron MC Herings. (Netherlands)

14. Validation and Incidence of Pneumonia in Patients with Diabetes in BIFAP Database [125]
Javier Gorricho Mendivil, Luis Carlos Saiz Fernandez, Javier Garçon Parra, Juan Erviti López, Miguel Gil García, Elisa Martín Merino. (Spain)

Burdens of Disease - Infection

15. A Validation Study of Algorithms to Identify Clostridium difficile Infection Using a Japanese Hospital-Based Administrative Database [126]
Tomomi Kimura. (Japan)

16. Disease and Treatment Epidemiology of Initial Clostridium Difficile Infection (CDI) in a National Cohort [127]
Tristan Timbrook, Aisling Caffrey, Yan Wang, Kerry LaPlante, Haley Morrill. (United States)

17. Impact of Macrolides Use on Hepatotoxicity in 4 European Countries [128]
Pili Ferrer, Elena Ballarin, Mónica Sabaté, Xavier Vidal, Marietta Rottenkolber, Sven Schmiedl, Luisa Ibáñez.

Megan K Luther, Kerry L LaPlante, Aisling R Caffrey, David Dosa, Thomas P Lodise, Haley J Morrill. (United States)
19. Predictors of Mortality among Unvaccinated Veterans with Serious Streptococcus Pneumoniae Infections [130] Jacob B Morton, Haley J Morrill, Kerry L LaPlante, Aisling R Caffrey. (United States)


22. Quantification Of Risk Factors For Postherpetic Neuralgia In Herpes Zoster Patients: A Cohort Study [133] Hamlet Forbes, Krishnan Bhaskaran, Sara Thomas, Liam Smeeth, Tim Clayton, Kathrynn Mansfield, Caroline Minassian, Sinéad Langan. (United Kingdom)

Burden of Disease - Cancer

23. Exploring The Treatment Pathways Of Breast Cancer Survivors In Primary Care In England [134] Lydia Tutt, Li-Chia Chen, Claire Anderson, Tracey Thomley. (United Kingdom)

24. Validity of Cutaneous Squamous Cell Carcinoma Diagnosis in the Health Improvement Network [135] Zelma C Chiesa Fuxench, Andrea B Troxel, Joel M Gelfand. (United States)


26. Incidence of Second Primary Malignancies In Patients With Primary Myelofibrosis [137] Alejandro Allepuz, Aleksandra Sarnecka, Katarzyna Sablinska. (Switzerland)


29. Incidence of Myeloid Neoplasms in Patients with Primary Myelofibrosis [140] Alejandro Allepuz, Aleksandra Sarnecka, Katarzyna Sablinska. (Switzerland)

30. Incidence of Cardiovascular Disease Among Early Stage Breast Cancer Patients in Denmark [141] Deidre Cronin-Fenton, Anders Kjaersgaard, Mette Norgaard, Justyna Amelio, Alex Liede, Rohini K Hernandez, Henrik T Sørensen. (Denmark)

31. Characteristics And Outcome Of Newly Diagnosed Immune Thrombocytopenia In Adults: Results From The PGRx Information System [142] Clementine Nordon, Lamiae Grimaldi, Marc Michel, Lucien Abenhaim, Bertrand Godeau.

32. Infection and Anti-Infective Treatment Preceding a Diagnosis of Primary Persisting Immune Thrombocytopenia [143] Donia Sohrabian, Marie Linder, Charlotta Ekstrand, Honar Cherif, Helle Kieler, Shahram Bahmanyar.

33. Comorbidities in the Young and Aging Populations with Haemophilia A [144] Ceri Hirst, James Black. (Switzerland)


35. Risk Score for Major Hemorrhage Among Chronic Lymphocytic Leukemia Patients in the US Veterans Administration Healthcare System [146] Peter Georgantopoulos, Huiying Yang, Monica Cai, LeAnn Norris, Charles L Bennett. (United States)

36. Diabetes and New-Onset Atrial Fibrillation in a Hypertensive Population [147] Lia Alves-Cabratosa, Maria García-Gil, Marc Comas-Cufí, Ruth Martí, Anna Ponjoan, Didac Parramon, Jordi Blanch, Rafel Ramos. (Spain)

37. Risk of Hypertension (HTN) and Malignant Hypertension (mHTN) in Patients Treated for Multiple Myeloma (MM) [148] Ajai Char, Sanjay Aggarwal, Khalid Mezzi, Shao Zhu, Winifred Werther, Diana Felici, Alexander R Lyon. (United States)

38. Pharmacological Treatments Preceding Diagnosis of Idiopathic Intracranial Hypertension [149] Sarah Burkhill, Anna Sudholm, Olafur Sveinsson, Shahram Bahmanyar, Ingela Nilsson. (Sweden)

39. Risk of Thrombotic and Hemorrhagic Event Associated with Oral Anticoagulants: A Retrospective Analysis in a Local Health Authority in Northern Italy [150] Salvatore Mannino, Alfredo Cocci, Silvia Lucchi. (Italy)

40. Treatment Practices for Acute Ischemic Stroke (AIS) in Quebec (Canada) [151] Mareva Faure, Anne-Marie Castilloux, Yola Moride, Agnès Lillo-Le-Louët. (Canada)

41. Stroke Risk in Individuals with versus without Atrial Fibrillation at VaryingCHA2DS2-VASc Score Levels: Implications for Anti-Coagulant Treatment [152] Michelle Z Leisner, Anne Ording, Dora Körmendiné Farkas, Erzsébet Horváth-Puhó, Morten Schmidt, Henrik Toft Sørensen, Paolo Prandoni, Morten Olsen. (Denmark)

42. Incidence and Risk Factors for Atrial Fibrillation in Patients with Newly Diagnosed Heart Failure in UK General Practice [153] Mar Martín-Pérez, Ana Ruígómez, Alexander Michel, Luis A García Rodríguez. (Spain)

43. One-Year Survival After Acute Myocardial Infarction (AMI): The Effect of Care Pathway in Italy [154] Valeria Belleudi, Martina Ventura, Paolo Scialtiella, Nera Agabiti, Mirko Di Martino, Riccardo Di Domenicantonio, Marina Davoli, Danilo Fusco. (Italy)

44. Epidemiology of Pulmonary Arterial Hypertension in a Large US Commercially Insured Pediatric Population, 2010-2013 [155] Lin Li, Susan Jick, Stefanie Breitenstein, Gemzel Hernandez, Alexander Michel, David Vizcaya. (United States)

45. Doubling of Serum Creatinine and the Risk of Cardiovascular Outcomes in Patients with Chronic Kidney Disease and with Diabetes Mellitus Type 2: A Cohort Study [156] Cornelia Schneider, Blai Coll, Susan S Jick, Christoph R Meier.

POSTER SESSION A: Friday, August 26 | 8:00am - 6:00pm
Burden of Disease - Neurological

46. Use of Antidepressants Before and After Start of Treatment for Psoriasis. A Nation-Wide Cohort Crossover Study [157] Ingegärd Anveden-Berglind, Anders Sundström. (Sweden)

47. Association Between Atopic Diseases and Attention-Deficit/Hyperactivity Disorder: Systematic Review and Meta-Analyses [158] Jurjen van der Schans, Rukiye Cicek, Tjalling W de Vries, Elkelo Hak, Pieter J Hoekstra. (Netherlands)


49. Correlates of Osteoporotic Fractures Among Type 2 Diabetic Patients [160] Inbal Goldshtein, Julie Chandler, Ann DePapp, Sophia Ish-Shalom, Gabriel Chodick, Allison Martin Nguyen. (Israel)

50. Osteonecrosis Of The Jaw And Cancer Survival: A Danish Population-Based Cohort Study [161] Priscila Corraini, Uffe Heide-Jørgensen, Morten Schiedt, Sven Erik Narholt, Henrik Toft Sørensen, Vera Ehrenstein. (Denmark)

51. Comorbid Diseases Preceding Diagnosis of Progressive Multifocal Leukencephalopathy [162] Ellen Iacobaeus, Sarah Burkhill, Shahram Bahmanyar, Lou Brund, Mikael Fored, Tomas Olsson, Scott Montgomery. (Sweden)

52. Comorbid Diseases Preceding Diagnosis of Idiopathic Intracranial Hypertension [163] Anna S Sundholm, Sarah Burkhill, Olafur Sveinsson, Shahram Bahmanyar, Ingela Nilsson Remahl. (Sweden)

53. Psoriasis and Suicide [164] Wendy J Carman, J Michael Woolley, Xiangmei Gu, Bruce R Turnbull, Cheryl Enger. (United States)

54. Cluster Headache Diagnosis and Treatment in the Clinical Practice Research Datalink (CPRD) [165] Evelyn M Flahavan, Meghan E Jones, Lucy Mitchell, Jonathan L Swain, James M Martinez, Andrew H Ahn. (United Kingdom)

55. Difference in the Rate of Multiple Sclerosis-Related Hospitalizations in Portugal Between 2008 and 2013 [166] Marta Pereira, Dimitra Lambrelli, Radek Wasiak, Sreeram V Ramagopalan. (United Kingdom)

56. Comparing the Incident Rates of Multiple Outcomes in Multiple Sclerosis Population by Marketscan and Clinfomatics Data Mart [167] Ling Zhang, Susan Coillia, Chuntao Wu, Jasmanda Wu, Jane Thammakhoune, Meera Kumar, Stephanie Tcherny-Lessenot, Marie-Laure Kurzinger, Susan Welsh, Juharei Juharei. (United States)

57. Multiple Sclerosis and VTE [168] Wendy J Carman, Julia LaGuette, David Dore, Andrew T McAfee. (United States)

58. Epidemiology of Treatment Resistant Depression in Taiwan: Estimates and Limitations [169] Daniel Fife, Yu Feng, Michael Yao-Hsien Wang, Bruce Wang, C J Chang. (United States)


60. Irritable Bowel Syndrome, Depression and Antidepressant Dispensing: A Study of Administrative Claims [171] Robert Perry, Chong Kim, Masaum Patidar, David Tabano, Heather Anderson. (United States)

61. Body Mass Index and Risk of Parkinson’s Disease in a Cohort of Two Million People Over Two Decades [173] Navab Quilbash, John Gregson, Michelle E Johnson, Neil Pearce, Ian Douglas, Kevin Wing, Stephen JW Evans, Stuart J Pocock. (United Kingdom)


63. Increasing Mental Health Diagnosing and Treatment Among U.S. Medicaid Youth, 2001-2010 [175] Stephen Crystal, Scott Bilder, Cassandra Simmel. (United States)

64. Benzodiazepine Use and Risk of Developing Alzheimer’s Disease - A Case-Control Study Based on Swiss Claims Data [176] Fabienne Bliéry, Alena Pfeil, Oliver Reich, Matthias Schwenkglenks, Christoph R Meier. (Switzerland)

65. Association Between Prescription Opioid Use and Insomnia Among Community Members in Northeast Florida [177] Mirsada Serdarevic, Vicki L Osborne, Linda B Cottler. (United States)


Burden of Disease - Respiratory


68. Validation of Claims Approach to Identify Asthma and COPD Overlap Syndrome Patients in the US [180] Bo Ding, Michael DePietro, Bingcao Wu, Ozgur Tunceli, Ralph Turner. (Sweden)

69. Chronic Oral Corticosteroid Use in Adults with Persistent Asthma [181] Trung N Tran, Michael Schatz, Qiaowu Li, Wansu Chen, Deepak Kathry, Robert S Zeliger.


71. Stability of the Frequent Exacerbator - A Danish Nationwide Register-Based Study [183] Mette MK Reilie, Jesper Lykkegaard, Anders Halling, Jørgen Vestbo, Jens Søndergaard, Anton Pottegård. (Denmark)

72. Multimorbidity Clusters Differ by Exacerbation Frequency in Chronic Obstructive Pulmonary Disease [184] Emin Hoxha Ekström, Maria Andersson, Maria Gerhardsson de Verdier, Jan Hedner, Ann Ekborg Jansson, Max Petzold, Kjell Torén, Mikael Svensson. (Sweden)

73. Review Of The Epidemiology Of Chronic Obstructive Pulmonary Disease In The Asia-Pacific Region [185] See-Hwee Yeo, Marie-Jo Horner, Sumitra Shantakumar.

Burden of Disease - Other

75. Influence of Age and BMI on Risk of Venous Thromboembolism: A Meta-Analysis of 246,513 Women Using Combined Oral Contraceptives Based on 521,516 Women-Years [187]
Claire Barnett, Anja Bauerfeind, Do Minh Thai, Klaas Heinemann. (Germany)

76. Body Mass Index and Cause-Specific Mortality: Population-Based Study Among 2 Million UK Adults Using Electronic Health Records Linked to National Mortality Data [188]
Krishnan Bhaskaran, Ian Douglas, Liam Smeeth. (United Kingdom)

77. Natural History Of Primary Sclerosing Cholangitis – A Study Using The UK Clinical Practice Research Datalink (CPRD GOLD) [189]
Hufilang Liang, Sudhakar Manne, Jesse Shick, Punam Bharania, Paul Dolin. (United States)

78. Statin Use and Risk of Gallstone Disease in Switzerland - A Case-Control Study Based on Swiss Claims Data [190]
Fabienne Bélyry, Olivier Reich, Matthias Schwenkglenks, Christoph R Meier. (Switzerland)

79. Use of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin-Receptor Blockers and the Risk of Acute Kidney Injury After Colorectal Cancer Surgery: A Population-Based Cohort Study [191]
Charlotte Slagelse, Henrik Gammelager, Lene Hjerrild Iversen, Sinna Piilgaard Ulrichsen, Henrik Toft Sørensen, Charlotte Slagelse, Henrik Gammelager, Christian Fynbo Christiansen. (Denmark)

80. Prevalence of Cigrilier-Najjar in the Turkish Population [192]
Alexander Cole, Sulena Shrestha, Erdem Baser. (United States)

81. The Association Between Chronic Urticaria and Autoimmune Thyroid Disease: A Nationwide Population-Based Study in Taiwan [193]
Jin-Bon Hong, Chi-Chuan Wang. (Taiwan)

82. Disease Severity and Characteristics of Patients with Atopic Dermatitis (AD) Investigated Using Administrative Claims Data [194]
Fredrik Nyberg, Ralph Turner, Ozgur Tunceli, Michael J Aitkenhead, Angela E Williams. (Sweden)

83. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Long-Term Sequelae Based on a 5-Year Follow-Up Analysis [195]
Maren Paulmahn, Carmen Kremmler, Peggy Sekula, Laurence Valeyre-Allanore, Luigi Naldi, Sylvia Kardaun, Maja Mockenhaupt. (Germany)

84. Atopic Diseases and the Risk of Developing Ulcerative Colitis [196]
Samman Azim, Eelko Hak, Jens HJ Bos, Catharina CM Schuiling-Veninga. (Netherlands)

85. Can Rheumatoid Arthritis Associated With Interstitial Lung Disease (RA-ILD) Be Classified As An Orphan Disease In The U.S.? [197]
Edgar P Simard, Fee Ruehmkorf, Jennifer CL Hayes, Patrice Verpillat. (Germany)

86. Claims-Based Prediction Models Are Unable to Accurately Predict Disease Activity for Rheumatoid Arthritis [198]
Brian C Sauer, Chai-Chen Teng, Neil Accord, Mona M Trivedi, David H Collier, Grant W Cannon. (United States)

Rhonda Bohn, Maureen Cooney, Atul Dodhia, Jeffrey R Curtis, Amanda Golembesky. (United States)

88. Pigmented Villonodular Synovitis (PVNS): Incidence, Patient Characteristics, Treatment and Recurrence: a Cohort Study in Denmark [200]
Soren L Andersen, Ibrahim Gazi, Robert Sikorski, Neil Sankar, John F Acquavella, Vera Ehrenstein. (Denmark)

89. The Association Between Prior Appendicectomy and/or Tonsillectomy in Females and Subsequent Pregnancy Rate: A Cohort Study [201]
Li Wei, Thomas M MacDonald, Sami Shah Othman, Niels Pfeiffer, Zeynep Çakır Orhan. (United States)

90. Longitudinal Changes in Prevalence of Rare Diseases and Related Costs in Taiwan (2003-2014) [202]
Jason C Hsu, Christine Y Lu. (Taiwan)

91. Time Trends And Patterns Of Prescriptions For Drug Pairs With A Serious Drug-Drug Interaction In UK Primary Care [203]
Adrian Root, Liam Smeeth, Ian Douglas. (United Kingdom)

92. A Systematic Review and Methodological Framework for Estimating Prevalence of Rare Diseases [204]
Kerstin Müller, Sheena Kayaniyil, Sarah M Goring. (Canada)

93. Mortality Rates in People with Intellectual Disabilities [205]
Rachael Williams, Jessie Oyiniola, Pauline Heslop, Gyles Glover.

Medical Devices

94. Use of FDA Approved Stents Intended for Adults for the Treatment of Pulmonary Artery Stenosis in Children [206]
Dale Tavris, Frank Ing, Anna Ghambaryan, Donald Hagler, Richard E Ringel, Lauren Deegan, Thomas Forbes, Jamie Magdi, Benjamin C Eloff. (United States)

95. Magnetic Resonance Imaging Examination in People with Cardiac Implantable Electronic Devices [207]
Marianne H Gillam, Maria CS Inacio, Nicole L Pratt, Elizabeth E Roughead. (Australia)

96. Spinal Degenerative Disc Disease Procedure Trends in the United States Using the National Inpatient Sample (2008-2012) [208]
Colin Anderson-Smits, Ariella Apfel, Yuzhi Hu, Hong Cheng, and Nilsa Loyo-Berrieros (United States)

97. The Impact of Channelling Bias in Device Epidemiology: Assessing Metal-on-Metal Total Hip Arthroplasty Implants [209]
Daniel Prieto Alhambra, Andrew Jonathan Carr, Anne Lübbecke. (United Kingdom)

98. Abstract Withdrawn [210]

Sandrine Colas, Bob-Valery Occean, Annie Rudnichi, Rosemary Dray-Spira, Mahmoud Zureik. (France)

100. Multiple Circular Stapler Use During Left-Sided Colon Resections as a Surrogate Measure of Procedural Complexity [212]
Katherine Eter, Sanjoy Roy, Iftekhar Kalsekar, Andrew Yoo. (United States)

101. Analyses of Surgical Adverse Events – The Importance of Procedure Modifiers [213]
Chantal E Holy, Howard L Levine. (United States)

102. Research Using Claims Databases to Evaluate Adherence to Medical Guidelines: The Case of Tympanostomy Tube Insertion in the United States [214]
Chantal E Holy, Howard L Levine. (United States)

Analytical Methods

103. Combining Observational Data from Multiple Databases: Comparison of Individual Patient Data and Aggregate Data Meta-Analysis in the CARING Study [215]
Nils Ekström, Marloes T Bazelier, Vidar Hjellvik, Frank de Vries, Jari Haukka, Peter Vestergaard, Marie L de Bruin, Morten Andersen. (Sweden)

133. Methods to Detect Misspecification in Propensity Score Models [245] Mark Lunt. (United Kingdom)

134. Reporting of the Trimmed Population in Propensity Score Analyses [246] Ryan Ziemiecki, Dawn Odom, Xiaolei Zhou, Steven M Thomas. (United States)


137. Better Alternatives to Existing Methods to Take into Account Prognostic Scores in Observational Studies [249] David Hajage, Yann De Rycke, Guillaume Chauvet, Florence Tubach. (France)

138. Predicting Chronic Medication Count in Veterans with and without HIV Infection [250] Janet P Tate, Kirsha M Gordon, Amy C Justice. (United States)


Data Linkage

140. Predictability of Electronic Medical Record (EMR)-Based Patient Characteristics Using Health Care Utilization Data in Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Glucose-Lowering Agents [252] Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica Franklin, Kimberly Brodovicz, John Seeger, Dorothee Bartels, Jun Liu, Sebastian Schneeweiss.

141. Combining Different Health Care and Health System Registries to Identify Diseases for Research and Health Policy Purposes: The Danish Registry of Selected Chronic Diseases [253] Ulrik Hesse, Katrine Fascius, Pia Christiansen, Anna S Engelbrecht, Ulla Nielsen, Marie-Louise Marthendal Olsen, Katarina M Gesser. (Denmark)

142. Complementary Observational Studies Assessing the Incidence of a Rare Cancer Outcome by Linking State Cancer Registry Data to Large Pharmacy Claims Databases in the United States [254] Nicole Kellier-Steele, Alicia Gilsenan, Kirk Midkiff, David Harris, Elizabeth Andrews. (United States)

143. Identification of Associations Between Prescribed Medications and Cancer: A Nationwide Screening Study [255] Anton Pottegård, Søren Friis, René D Christensen, Lauret A Habel, Joshua J Gagne, Jesper Hallas. (Denmark)

144. Semi-Automatic Coding of Case Definitions [256] Benedikt Becker, Erik van Mulligen, Daniel Weibel, Miriam Sturkenboom, Jan Kors. (Netherlands)

145. Identifying the Prescribing Physician in US Healthcare Claims Data [257] Jane S Der, Fei Yue, M Alan Brookhart. (United States)

Measurement & Validation Methods


147. Agreement Between ICD-9 Codes and Laboratory Results Indicative of Myelosuppression (MS) in Patients with Longer-Term Exposure to Linezolid in a Claims Database [259] Thomas Rhodes, Vinay Mehta, Mike Senderak, Carisa S de Anda, Thomas C Mast. (United States)


149. Validity of Claims-Based Definitions for Hospitalized Volume Overload Among Hemodialysis Patients [261] Magdalene M Assimon, Jennifer E Flythe. (United States)

150. Do Hemoglobin Lab Test Results Increase Detection of Upper Gastrointestinal Bleeding (UGIB)? [262] Elisabetta Patorno, Josh Gagne, Kevin Haynes, Christine Lu, Jason Roy, Andrew Sterrett, Ximeng Wang, Marsha Raebel.

151. Cancer Recording in Patients With Type 2 Diabetes In Primary Care And Hospital Admission Data [263] Rachael Williams, Arlene M Gallagher, Tjeerd van Staa, Tarek Hammad, Bert Leufkens, Frank de Vries.

152. Authenticity Validation of Lung Cancer Records from a Standardized Inpatient EMR Database in China and Comparison of Different Methods [264] Meng Shu, Wenhua Liang, Yongjing Zhang, Jianxing He. (China)

153. Ascertainning Pulmonary Hypertension and Other Conditions in Claims Databases [265] David Vizcaya, Alexander Michel, Lin Li, Stefanie Breitenstein, Gemzel Hernandez, Montse Soriano-Gaborro, Susan Jick. (Germany)


155. Development and Validation of an Algorithm to Identify Endometrial Adenocarcinoma in US Administrative Claims Data [267] Daina B Esposito, Ruihui Yin, Leo J Russo, Marcela G del Carmen, Steven R Goldstein, Bruce Patens, Stephan F Lanes. (United States)

156. Development and Validation of an Algorithm to Identify Endometrial Hyperplasia in US Administrative Claims Data [268] Daina B Esposito, Ruihui Yin, Leo J Russo, Gregory Ridgeway, William J Finkle, Steven R Goldstein, Khushbakht Mittal, Brian W Walsh, Stephan F Lanes. (United States)

157. Can Population-Based Incidences Help Define Bladder Cancer Outcomes in a Medicare Cohort? [269] Elizabeth M Garry, John B Buse, Virginia Pate, Til Stürmer. (United States)

158. Agreement Between Hospital Diagnosis Codes and Medical Records to Identify Metastatic Colorectal Cancer and Comorbidities in Elderly Patients [270] Amandaine Gourrène, Diana Dolatkhan, Magali Rouyer, Angelina Grelaud-Boussinot, Florence Francis, Véronique Gilleron, Annie Fourrier-Réglat, Pernelle Noize. (France)
159. Adding of CPT Codes Improves Classification of Type of Bowel Resection Based Only on ICD-9-CM Procedure Codes [271] 
Tongtong Wang, Zhiwen Liu, Daniel Mines. (United States)

160. Validation of Stevens-Johnson Syndrome and Toxic Epidermal Nekrolysis Diagnoses in the Clinical Practice Research Datalink [272] 
Noel C Frey, Andreas Bircher, Michael Bodmer, Susan S Jick, Christoph R Meier, Julia Spoendlin. (Switzerland)

161. Comparing Instant Health Data and SAS for Evaluation of Incidence Rates in Multiple Sclerosis Using MarketScan [273]

162. Medications Prescription at Hospital Discharge in Patients with Validated Diagnosis of Dementia [274]
Francesca Palese, Federico Romanese, Fabio Barbone, Federica E Pisa. (Italy)

163. Comparing Methods Generating Drug Exposure Time From Prescription Register Data [275]
Antti Tanskanen, Heidi Taipale, Marjaana Koponen, Anna-Maja Tolpanen, Sirpa Hartikainen, Riitta Ahonen, Jari Tiihonen. (Sweden)

164. A Summary of Clinical Coding Systems by Different Clinical Settings in Healthcare Databases in the US and UK [276]
Yong Chen, Tongtong Wang, Edward A Bortnichak. (United States)

165. Standardizing Diversity of Event Definitions in Federated Networks of Heterogeneous Health Data Sources: The “Component Algorithm Strategy” [277]
Giuseppe Roberto, Ingrid Leal, Naveed Sattar, Robert Steward, Maria Garcia-Gil, Paul Aviliach, Peter Egger, Rients van Wijngaarden, David Ansell, Suilev Reisberg, Alessandro Pasqua, Lare Pedersen, Lara Tramontan, Miguel A Mayer, Tallia Duarte, Ron Herings, Preciosa Coloma, Francesco Lapi, Miriam Sturkenboom, Johan van der Lei, Martijn Schuermie, Peter Rijnbeek, Rosa Gini. (Italy)

166. Designing Medical Record Abstraction Forms for Retrospective Chart Review Studies: Considerations and Recommendations [278]
Ellen E Korol, Sheena Kayaniyil, Katherine M Osenenko. (Canada)

167. Validity of the Prescriber Information in the Danish National Prescription Registry [279] 
Lotte Rasmussen, Julie Valentin, Katarina M Gesser, Jesper Hallas, Anton Pottegård. (Denmark)

168. Validation of the Recording of Key Medical Conditions in General Practice Data [280] 
Jenny JL Wong, Suzie Seabroke, Katherine Donegan. (United Kingdom)

169. Claims-Based Algorithms Greatly Impact the Estimated Incidence of Serious Angioedema Among Heart Failure (HF) Patients in the United States (US) [281] 
Thy P Do, Arpanas Seetasith, Rosella Bellili, Raymond Schlienger, Chakkarin Burudpakdee, Hendrik J Streefkerk, Sigrid Behr. (Switzerland)

170. Patterns and Predictors of Having a Colonoscopy Following Drug Initiation in Older US Adults with Diabetes [282]
Phyo T Htoo, M A Marquis, Mugdha Gokhale, Virginia Pate, John Buse, Til Stürmer. (United States)

171. Feasibility of Using Procedural Code Combinations for Identifying Conversion from Video Assisted Thoracic Surgery (VATS) to Thoracotomy [283]
Katherine Etter, Sanjoy Roy, Andrew Yoo, Iftekhar Kalsekar. (United States)

Study Design

172. Influenza Vaccine Effectiveness Estimates in the Dutch Population from 2003 to 2014: The Test-Negative Design Case-Control Study with Different Control Groups [284]
Eva van Doorn, Maryam Darvishian, Frederika Dijkstra, Ge Donker, Pieter Overduin, Adam Meijer, Eelko Hak. (Netherlands)

173. Study Design and Analytic Approach for Research on the Effectiveness of Childhood Vaccine Schedules [285] 
Anne M Butler, J Bradley Layton, B Diane Reams, Catherine A Panozzo, M Alan Brookhart. (United States)

174. Investigating the Assumptions of the Self-Controlled Case Series Method [286] 
Heather Whitaker, Yonas Ghebremichael-Weldeselassie, Paddy Farrington, Ian Douglas, Liam Smeth. (United Kingdom)

175. Abstract Withdrawn [287]

176. Effect-Modifiers of Antipsychotic Drugs Effect, in Schizophrenia Treatment [288]
Clementine Nordon, Witold Wieczek, Helene Chevrou-Severac, Javier Jimenez, Helene Karcher, Lucien Abenhaim. (France)

177. A Systematic Literature Review on the Efficacy-Effectiveness Gap: Comparison of Randomized Controlled Trials and Observational Studies of Glucose-Lowering Drugs [289] 
Mikkel Zölner Ankarfeldt, Erpur Adalsteinsson, Rolf Groenwold, Sanni Ali, Olaf Klungel. (Denmark)

178. Interim Analyses in Prospective Observational Studies of Medical Product Safety [290] 
Jie Li, Rima Izem. (United States)

179. Incorporating Clinical Factors That Are Inconsistently Recorded in Electronic Health Records to Improve Confounding Adjustment in Claim-Based Comparative Effectiveness Research [291] 
Peter M Wahl, Jessica M Franklin, Jeremy A Rassen, Marc B Rosenman, Nandini Selvam, Robert J Glynn, Murray A Mittleman, Sebastian Schneeweiss. (United States)

180. Abstract Withdrawn [292]

181. Abstract Withdrawn [293]

Pediatrics

182. Early Life Antibiotic Exposure Is Associated with an Increased Risk of Atopic Eczema and Hay Fever [294] 
Fariba Ahmadizar, Susanne Viljerberg, Hubertus Arets, Anthonius de Boer, Johan Garssen, Aletta Kraneweld, Anke-Hilse Maitland-van der Zee.

183. Abstract Withdrawn [295]

184. Analysis of Splitting Sustained-Release, Enteric-Coated Drugs in Pediatric Patients: HIRA-PPS [296]
Kiyou Rhew. (Republic of Korea)

185. Differences Between Genders in Antipsychotic Medication Among Children and Adolescents – Patterns in Use and Underlying Mental Disorders [297] 
Ragnar Nesvåg, Ingeborg Hartz, Jørgen Branness, Vidar Hjelvik, Marta Handal, Svetlana Kurcutveit. (Norway)

186. Psychiatric Medication Use Before and After the Onset of Type 1 Diabetes in Children and Adolescents: A Population-Based Cohort Study [298] 
Soulmaz Fazeli Farsani, Heshu Abdullah-Koolmees, Patrick C Souverein, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)

187. Abstract Withdrawn [299]
189. Antidepressant Drug use Among Adolescents in Norway from 2004 to 2013- A Population-Based Register Study [300]
   Ingeborg Hartz, Svetlana Skurtveit, Vidar Hjelvik, Kari Furu, Ragnar Nesvåg, Marte Handal. (Norway)

190. Proceedings of a Workshop from the USFDA: Evaluation of Long-Term Neurocognitive Development in Pediatrics [301]
   Ann W McMahon, Philip H Sheridan, Lynne Yao. (United States)

191. Drug Utilization Among Norwegian Children Diagnosed with Chronic Fatigue Syndrome / Myalgic Encephalomyelitis [302]
   Inger J Bakken, Simon Collin, Kari Tveito, Kari Furu, Siri E Häberg. (Norway)

192. Out of Hospital Cardiovascular Medication Use in Children with Congenital Heart Defects [304]
   Morten Olsen, Nicolas Madsen. (Denmark)

193. Obesity Predicts Shorter Time to First Exacerbation in Pediatric Patients with Uncontrolled Mild to Moderate Asthma [305]
   Cristina Longo, Gillian Bartlett, Brenda MacGibbon, Francine M Ducharme, Tracie Barnett. (Canada)

194. Childhood Obesity in Relation to Poor Asthma Control and Exacerbations [306]
   Fariba Ahmadizar, Susanne Vijverberg, Hubertus Arets, Anthonius de Boer, Jason Lang, Meyer Kattan, Colin Palmer, Somnath Mukhopadhyay, Steve Turner, Anke-Hilse Maitland van der Zee. (United Kingdom)

195. State Register of Medicinal Products Published from 1979 to 2013 [307]
   Alexander V Matveev, Nail S Yagya, Natalia N Yarkova, Alexander Y Eminitskiy.

196. Quality of Pediatric Pharmacoepidemiological Safety Studies Published from 1979 to 2013 [308]
   Osameke U Osokogu, Julijana Dukanovic, Carmen Ferrajolo, Wichor M Bramer, Daniel Weibel, Geert t’ Jong, Katia Verhamme, Florentia Kagueldiou, Miriam Sturkenboom. (Netherlands)

197. Use of Copay as an Instrumental Variable for Adherence in Comparative Effectiveness and Safety Research [309]
   Sapna Rao, Xiaojuan Li, Alan Brookhart. (United States)

198. Positive Predictive Value of Antidiabetic Agent Exposure from EHR Prescribing Data Relative to Pharmacy Dispensing Data in the OptumLabs™ Data Warehouse [310]
   Christopher G Rowan, Nikita Stempiewicz, James Flory, Tobii Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)

199. Primary Non-Adherence Associated with Antidiabetic Agents (ADAs) from Electronic Health Record Prescribing Data (EHRx) in the OptumLabs™ Data Warehouse [311]
   Christopher G Rowan, Nikita Stempiewicz, James Flory, Tobias Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)

200. Medication Possession Ratio Associated with Antidiabetic Agents from Electronic Health Record Prescribing Data (EHRx) in the OptumLabs™ Data Warehouse [312]
   Christopher G Rowan, Nikita Stempiewicz, James Flory, Tobii Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)

201. Abstract Withdrawn [313]

202. Patient Adherence to Treatment After Discharge for Acute Coronary Syndrome in Vietnam: A Prospective Observational Study [314]
   Thang Nguyen, Thao Huong Nguyen, Hoang Thai-Kim Cao, Khanh Kim Le, Suol Hoang Thi-Kim Cao, Khanh Kim Le, Suol Hoang Thi-Kim Cao, Khanh Kim Le, Suol Hoang Thi-Kim Cao, Khanh Kim Le, Suol (Viet Nam)

203. Impact of Hospitalization Periods on the Calculation of Adherence Measures [315]
   Yaa-Hui Dong, Niteesh K Choudhry, Alexis Krumme, Moa Lee, Li-Chu Wu, Mei-Shu Lai, Joshua J Gagne. (United States)

204. Prior Medication Adherence As A Strong Predictor Of Future Adherence [316]
   Hiraku Kumamaru, Moa P Lee, Yaa-Hui Dong, Alexis A Krumme, Nazleen Khan, Gregory Brill, Shun Kohsaka, Hiroaki Miyata, Niteesh K Choudhry, Sebastian Schneeweiss, Joshua J Gagne. (United States)

205. Reliably Estimating Adherence to Therapy in Chronic Patients from Italian Administrative Databases [317]
   Rosa Gini, Martijn J Schuemie, Alessandro Pasqua, Patrizio Dazzi, Emanuele Carlini, Iacopo Cricelli, Valentina Barletta, Paolo Francesconi, Francesco Profili, Francesco Lapi, Andrea Donatini, Dal Co Giulia, Cricelli Claudio, Mariadonata Bellantini, Miriam Sturkenboom, Niek Klazinga. (Italy)

206. The Use of New Oral Anticoagulants in Patients with Atrial Fibrillation in Scotland – A Population-Based Drug Utilisation Study [318]
   Tanja Mueller, Samantha Alvarez-Madrazo, Chris Robertson, Marion Bennie. (United Kingdom)

207. Non-Adherence to Methotrexate in Rheumatoid Arthritis; a Prospective Cohort Study (RAMS) [319]
   Holly F Hope, James Anderson, Anne Barton, Lis Cordingley, Kimme L Hyrich, Jamie Sergeant, Suzan MM Verstappen. (United Kingdom)

208. Persistence to Anti-Osteoporosis Treatments in Primary Care Patients Recorded in the Spanish Electronic Database BIFAP [320]
   Elisa Martín Merino, Arturo Álvarez-Gutierrez, Consuelo Huerta Álvarez, Daniel Prieto-Alhambra, Dolores Montero Corominas. (Spain)

209. Associations Between Personality Traits and Adherence to Antidepressants Assessed Through Alternative Data Sources: Claims, Self-Report, Electronic Monitoring, and Pharmacy Dispensing Data [321]
   H Wouters, D F Amin, K Taxis, E R Heerdink, A CG Egberts, H Gardarsdottir. (Netherlands)

210. Impact of Pharmaceutical Care on Medication Adherence, Hemoglobin Levels and Interdialytic Weight Gain Among Hemodialysis Patients – A Multicentric Trial [322]
   Udai Venkat Mateti, Anantha Naik Nagappa, Ravindra Prabhu Atturu, Shankar N Prasad. (India)

211. Male Breast Cancer and Adherence to Adjuvant Endocrine Therapy [323]
   Inyoung Lee, Wan-Ju Lee, Gregory S Calip. (United States)

212. Alternative Data Processing in the Culig Adherence Scale [324]
   Aleksandar Momirovic, Marcel Leppee, Dario Naletilic, Josip Culig. (Croatia)

213. Predicting Refill Adherence from Alternative Data Sources: Claims, Structured Electronic Health Record Data, and Physician Notes [325]
   Jessica M Franklin, Alexis A Krumme, Chandrasekar Gopalakrishnan, Karandeep Singh, James R Rogers, Joe Kimura, Caroline McKay, Newell McElwee, Niteesh K Choudhry. (United States)
214. Pharmacy Inducement Programs Associated with Better Medication Adherence: A Cohort Study [326]  
Scot H Simpson, Mu Lin, Dean T Eurch. (Canada)

215. New Self-Questionnaire Way To Measuring Adherence To Medication [327]  
Martina Bago, Ivana Prga, Marcel Leppée, Josip Cullig, Ivana Radman. (Croatia)

Use of Medicines - Alimentary & Metabolic

216. The Quality of Prescribing in Type 2 Diabetes Mellitus After Intervention of Evidence-Based Drug Formulary in a Private Hospital in Indonesia [328]  
Erna Kristin, Alfi Yasmina, Iwan Dwipaynastho. (Indonesia)

217. New Glucose Lowering Drugs (Gld) Usage in Portugal: Results of an Intensive Monitoring Study in Real-Life Conditions [329]  
Carla Torre, Jose Guerreiro, Patricia Longo, Hubert Leufkens, Ana Paula Martins.

218. Utilisation of Once Weekly Exenatide (Bydureon®) for Type 2 Diabetes Mellitus (T2DM): Interim Results from an Observational Cohort Study in England [330]  
Abigail Coughtrie, Deborah Layton, Qing Qiao, Saad Shakir.

219. How To Use Pharmacy Dispensing Data To Measure Adherence And Identify Nonadherence With Oral Hypoglycaemic Drugs [331]  
Fong Sodihardjo-Yuen, Liset van Dijk, Michel Wensing, Peter de Smet, Martina Teichert. (Netherlands)

220. Factors Associated with T2DM Treatment Choice Across Europe [332]  
Jetty A Overbeek, Edith M Heintjes, Gillian C Hall, Daniel Prieto-Alhambra, Fransesco Lapi, Katherine Tsai, Niklas Hammar, Irene D Bezemer. (Netherlands)

221. Comparison of Glucose Lowering Drugs Usage Between Portugal and 6 European Countries, in 2014 [333]  
Carla Torre, Jose Guerreiro, Patricia Longo, Suzete Costa. (Portugal)

Gillian E Caughhey, John D Barratt, Sepehr Shakhib, Anna Kemp-Casey, Elizabeth E Roughhead. (Australia)

Use of Medicines - Hematological and Cardiovascular

223. The Application of the HAS-BLED Criteria within Post Authorisation Safety Studies to Characterise Anticoagulant New User Patients with Non-Valvular Atrial Fibrillation (AF): Interim Results from a Specialist Cohort Event Monitoring (SCEM) Study [335]  
Deborah Layton, Alison Evans, Miranda Davies, Vicki Osborne, Saad AW Shakir. (United Kingdom)

224. Characteristics of Patients at Initiation of Treatment for Primary Chronic Immune Thrombocytopenia [336]  
Charlotte Ekstrand, Marie Linder, Honar Cherif, Helle Kieler, Shahram Bahmanyar. (Sweden)

225. Factors Associated with Rivaroxaban Prescribing in Specialist Care Setting: Interim Results from the Rivaroxaban Observational Safety Evaluation (ROSE) Study [337]  
Deborah Layton, Alison Evans, Miranda Davies, Vicki Osborne, Saad AW Shakir. (United Kingdom)

226. Cohort Characteristics and Determinants of Prescribing Rivaroxaban in Primary Care in England: Interim Results from a Post Authorisation Safety Study (PASS) [338]  
Sandee Dhanda, Miranda Davies, Deborah Layton, Vicki Osborne, Saad AW Shakir. (United Kingdom)

227. Characterisation of Baseline Risk Factors for Bleeding Outcomes in Patients with Non-Valvular Atrial Fibrillation (AF) Prescribed Rivaroxaban in Primary Care in England: Interim Results from a Post Authorisation Safety Study (PASS) [339]  
Sandee Dhanda, Miranda Davies, Deborah Layton, Vicki Osborne, Saad AW Shakir. (United Kingdom)

228. A Retrospective Analysis in a Local Health Authority in Northern Italy to Evaluate the Utilization of Oral Anticoagulants [340]  
Alfredo Cocci, Silvia Lucchi, Salvatore Mannino. (Italy)

229. How Complete Are Primary Care and Cardiologist Data in Germany for Research of Oral Anticoagulants in Non-Valvular Atrial Fibrillation? [341]  
Shuk-Li Collings, Michelle Johnson, Sebastian Kloss, David Evans, Andrew Maguire, Cinira LeFèvre. (United Kingdom)

230. Compliance and Persistence to Anticoagulation Therapy: A Retrospective Analysis in a Local Health Authority in Northern Italy [342]  
Silvia Lucchi, Alfredo Cocci, Salvatore Mannino. (Italy)

Derbew Fikadu Berhe, Katja Taxis, Flora M Haaijer-Ruskamp, Afework Mulugeta, Yewondwosen Tadesse Mengistu, Peter GM Mol. (Netherlands)

232. Adherence to Lipid-Lowering Therapy in Elderly – A Pharmacy Database Study in Bulgaria [344]  
Hristina Lebanova, Evgeni Grigorov. (Bulgaria)

233. The Association Between Statin Therapy and Neovascular Age-Related Macular Degeneration [345]  
Wan-Ju Annabelle Lee, Chien-Hsun Li, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

234. Association Between Exposure to Evidence-Based Heart Failure Drug Treatment and All-Cause Hospitalization and All-Cause Mortality [346]  
Jocelyne Moisan, Catherine Girouard, Norma Pérez, Éric Demers, Jean-Pierre Grégoire. (Canada)

235. Classification of Drugs Implicated in Cases of Proarrhythmia: Results from the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study in England [347]  
Abigail Coughtrie, Elijah Behr, Deborah Layton, Saad Shakir.

236. Characterization of New Users of Cilostazol in the United Kingdom, Spain, Sweden, and Germany [348]  
Jord Castellsague, Brian Calingaert, Beatriz Poblador-Plou, Maria Giner-Soriano, Marie Linder, Oliver Scholle, Cristina Varas-Lorenzo, Alejandro Arana, Christine Bui, Alexandra Prados-Torres, Francisca Gonzalez-Rubio, Albert Roso-Llorach, Anna Citarella, Edeltraut Garbe, Tilo Blenk, Susana Perez-Guthmann.

237. Physician Adherence to Acute Coronary Syndrome Prescribing Guidelines in Vietnam: A Prospective Observational Study [349]  
Thang Nguyen, Huong Thao Nguyen, Hoang Thi-Kim Cao, Khanh Kim Le, Suol Thanh Pham, Hoa Thi-Kim Pham, Phong Thanh Pham, Linh My Ho, Trang Ngoc-Diem Thai, Tam Thi Pham, Katja Taxis. (Viet Nam)

238. Lipid Profile and Patient Characteristics Prior to Initiation of Niaspan (Extended Release Niacin) Therapy: Analysis of a Large Electronic Medical Record Database [350]  
Syed S Islam, Ran Gao, Michael F Jarvis, Ramon Espaillat, Hans P Bacher. (United States)
241. Continuity of Prescribing and Use of Medicines - Other
242. Time-to-Treatment In The Management Of Relapsing/Remitting Multiple Sclerosis
243. Potentially Inappropriate Prescriptions for Stimulant Medication for Treatment of Attention Deficit Hyperactivity Disorder Among Canadian Adults
244. Psychotropic Medication Use in Patients with Eight Major Cancers in Australia: A Retrospective Descriptive Study Using a Health Insurance Claims Database
245. Use of Benzodiazepines in Circumstances at Increased Risk of Adverse Effects in the French Population
247. Use of Medicines - Neurological
248. Drug-Drug Interactions at Increased Risk of Adverse Effects for Antipsychotic Users in France from 2007 to 2012: A Population-Based Study
249. Antipsychotic Medication Treatment of New Depressive Episodes in the US Medicaid Population
250. Potentially Inappropriate Medications in Elderly Patients: Prevalence and Changes During Hospital Stay
251. Initiation Of Strong Prescription Opioids in Australia: Cohort Characteristics And Factors Associated With The Type Of Opioid Initiated
252. Alcohol and Illicit Drug Use and Their Association with Prescription Opioid Misuse Among Undergraduate and Postgraduate Medical Students in Greece
253. Drug Utilization Study for Lisdexamfetamine Dimesilate in Australia
254. Use of Medicines - Other
256. Characteristics of Opioid Maintenance Therapy (OMT) Prescribers and Their Distribution Among OMT Patients in Ontario
257. Detection of aberrant opioid use in prescription claims data: comparison and validation of five algorithms
258. Prescription Opioid Access Patterns in Australia: A National Observational Cohort Study
259. Abstract Withdrawn
260. Association Between High Risk Opioid Prescribers and Patients
261. The Influence of Concomitant Opioids on Opioid Utilisation for Tramadol Users – A Retrospective Cohort Study in the UK Primary Care Setting
262. The Difference in Baseline Characteristics Between Persistent Tramadol Users Defined by Different Criteria
263. Monitoring of Medication Uptake in Difficult Asthma
264. Oral Corticosteroids in Asthma Exacerbations: Differences Between Patient-Reported Data and Proxies from Claims Data
265. Excess Dosing and Knowledge About Currently Used Acetaminophen-Containing Products
266. Abstract Withdrawn
267. Antibiotics Resistance Pattern and Prevalence of Urinary Tract Pathogens in Malaysia [379]
Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari. (Malaysia)

268. Antibiotic Use Practices By Pharmacy Staff: A Cross-Sectional Study in Saint-Petersburg, Russia [380]
Tatiana Belkina, Natalia Duvanova, Arina Korolkova, Jurjen Duintjer Tebbens, Jiri Vlcek. (Czech Republic)

269. Abstract Withdrawn [381]

270. Prevalence and Predictors of Post-Discharge Antibiotic Use Following Mastectomy [382]
Margaret A Olsen, Katelin B Nickel, Victoria J Fraser, Anna E Wallace, David K Warren. (United States)

Yizhou Ye, Aisling R Caffrey. (United States)

272. The Practice Pattern of Initial DMARDs Treatment and Hepatitis Screening in Rheumatoid Arthritis Patients: A Cross-National Comparison Between USA And Taiwan [384]
Tzu-Chieh Lin, Daniel H Solomon, Seoyoung C Kim, Yea-Huei Kao Yang, Rishi Desai. (United States)

273. Perceptions of Oncology Practitioners Towards Off-Label Use of Anti-Cancer Medicines [385]
Mohd Masnoon Saiyed, Pei Shi Ong, Lita Chew.

274. The Relationship Between Patient Safety Culture and Medication Errors Among Healthcare Professionals in Nigeria [386]
Beatrice O Odugbemi, Katja Taxis, Eugene Van Puijenbroek, Onoja M Akpa. (Netherlands)

275. Drug Utilization Study: Evaluation of the Relationship Between Patient Perceptions of Oncology Practitioners And Dispensing Patterns of Drug Utilization Study: Evaluation of the Relationship Between Patient Perceptions of Oncology Practitioners And Dispensing Patterns of

Yizhou Ye, Aisling R Caffrey. (United States)

277. Cyproterone/Ethinylestradiol Use and Indications in the Netherlands [390]
Irene D Bezemer, Lisa Smits, Fernie JA Penning-van Beest, Alex Asimwe, Ron MC Herings. (Netherlands)

278. Cyproterone/Ethinylestradiol Use and Indications in the Netherlands [390]
Irene D Bezemer, Lisa Smits, Fernie JA Penning-van Beest, Alex Asimwe, Ron MC Herings. (Netherlands)

279. Incidence of and Factors Associated with Anticholinergic Drugs Among Women with Urinary Incontinence: A Population-Based Cohort Study [391]
Sri Mauseth, Svetlana Skurtvet, Arnulf Langhammer, Olav Spigset. (Norway)

280. Retention in Methadone Maintenance Treatment (MMT) in Primary Care: National Cohort Study Using Proportional Hazards Frailty Model for Recurrent MMT Episodes [392]
Gräinne Cousins, Fiona Boland, Joseph Barry, Suzi Lyons, Kathleen Bennett, Tom Fahey. (Ireland)

281. Quality Use of Medicines Among Makkah Community [393]
Abdul Haseeb, Rozan Mohammad Radwan, Hani Saleh Falah, Rehah Adnan Baghdadi, Mahmoud Mohamed Ahmed Mohamed, Mahmoud E Elragagl, Fahad Saleem, Azmi Hassali. (Saudi Arabia)

Johann Castaheda-Sanabria, David Hajage, Mélisande Le-Jouan, Anne Perozziello, Florence Tubach. (France)

283. Assessment of Vaccine Cold Chain Management Status at Service Delivery Health Facilities in Dawro Zone, South West Ethiopia [395]
Abbe Bekebede, Michael Mesfin, Seid M Ahmed. (Ethiopia)

Ilse Truter, Brian Godman, Amaan Baker, Anna Bucsics, Joseph Fadare, Ulrik Hesse, Andrew Martin, Hye Young Kwon, Corinne Zara, Marion Bennie. (Sweden)

285. Use of Nepafenac in the Netherlands [387]
Eugene Van Puijenbroek, Onoja M Akpa. (Netherlands)

286. Limitation of Use of Nepafenac in the Netherlands [387]
Eugene Van Puijenbroek, Onoja M Akpa. (Netherlands)

287. Defining Prescription Quality Indicators at Primary Care Level in Portugal [399]
Mila Fernandes, Ana Costa, Manuela Cruz, Cristina Ribeiro, Luis Rebelo, Vasco Al Maria. (Portugal)

288. An European Repository for Electronic Selection of Explicit Criteria of Potentially Inappropriate Prescriptions (PIPs) in Old Age [400]
Ivana Ivanova, Maarten Wauters, Robert Vander Stichele, Thierry Christiaens, Jonas De Wolf, Tine Dilles, Monique Elseviers. (Belgium)

289. Evolution of the Medication Use in a Cohort of Newly Admitted Nursing Homeresidents (Ageing@NH); Report of the First Follow-Up Observations [401]
Ivana Ivanova, Maarten Wauters, Robert Vander Stichele, Thierry Christiaens, Jonas De Wolf, Tine Dilles, Monique Elseviers. (Belgium)

290. Comparing Spontaneous Report Disproportionality Measures to Estimates of Adverse Events from Cochrane Systematic Reviews [690]
Raphaelle Beau Lejdstrom, Sarah Crook, Tsung Yu, Milo Puhu. (Switzerland)
Spotlight Session-AsPEN

A. Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation: A Population-Wide Cohort Study in Chinese Patients [482]
Wallis CY Lau, Esther W Chan, Ian CK Wong.

Rhanye Mac Guad, Wan Ahmad Hafiz Wan Md Adnan, Raja Elina Raja Azidin, Zahurin Mohamed, Nur Lisa Zaharan. (Malaysia)

C. Association of Aspirin Use and Age-Related Macular Degeneration in Taiwan [484]
Wan-ju Annabelle Lee, Ching-ian Cheng, Yea-Huei Kao Yang. (Taiwan)

D. Risk Factors of Trastuzumab Related Cardiotoxicity in Taiwanese Breast Cancer Women [485]
Hsu-Chih Chien, Yea-Huei Kao Yang, Jane PF Bai. (Taiwan)

E. Antipsychotic Polypharmacy of Schizophrenia Treatment – a Database Approach in China [486]
Hong Qiu, Yong He, Yongjing Zhang, Minfu He, Jin Liu, Rui Chi, Tianmei Si, Wentian Hong Qiu, Yong He, Yongjing Zhang, Minfu He, Jin Liu, Rui Chi, Tianmei Si, Wentian Dong. (United States)

F. Statin Induced Diabetes Mellitus in Cardiovascular Patients: A Multicentric Observational Study of Hospital Databases in South Indian Tertiary Healthcare Facilities [487]
Jessie Margaret Saldanha, K Shetty Ranjan, M Sekhar Sonal. (India)

G. Incidence and Medical Resource Utilization for Cardiovascular Events in Asia [488]

H. Epidemiology in Asian Pharmacoepidemiology Network (AsPEN): Study in Surveillance of Health Care in Asian Network (SCAN) [489]

Spotlight Session-BRACE

I. European Healthcare Professionals’ Familiarity with and Perceived Usefulness of Safety Communications on Medicines [490]
Maartje van der Sar, Sieta de Vries, Peter Mol, On Behalf of SCOPE Workpackage 6. (Netherlands)

J. A Number Needed to Treat Test [491]
Colin R Dormuth. (Canada)

Madalena Arregas, Annalisa Rubino. (Portugal)

L. Evaluating Physician Knowledge of Risks and Safe Use of Xarelto (Rivaroxaban) [493]
Laurie J Zografos, Kiliana Suzart, Andrea Horvat-Broeker, Montse Soriano-Gabarró, Dan L Wolin, Brian Calingaert, Eric K Davenport, Kelly A Hollis, Elizabeth Andrews. (United States)

M. Semi-Quantitative Benefit-Risk Assessment for Dengvaxia [494]
Lydie F Marcelon, Carine H Cohen, Alena Khromava, Leon R Ochiai, Anh T Wartel, Sophia Gaillardou. (France)

N. Traditional vs. HIV-Specific Cardiovascular Disease Risk Scores in Persons Living with HIV [495]

O. Quantitative and Qualitative Methods to Support Therapeutic Risk Minimization Efforts [496]
Noelia Alfaro, Nawab Qizilbash, Annalisa Rubino. (United Kingdom)

P. Additional Risk Minimisation Measures to Prevent Medication Error in the EU [497]
Esther Artime, Nawab Qizilbash, Annalisa Rubino. (United Kingdom)

T. Patient Characteristics Associated with Persistent Tramadol Use for Patients with Chronic Non-Cancer Pain in U.K. General Practices [501]
Teng-Chou Chen, Li-Chia Chen, Roger Knaggs. (United Kingdom)

U. Patterns of Tiotropium Dispensing in the United States and Impact of FDA Drug Safety Communications [502]
Elizabeth Kang, Simone Pinheiro, Esther Zhou, Yulan Ding, Sally Seymour, Jacqueline M Major.

V. In-Hospital Antipsychotic Use Among Elderly Patients Discharged to Nursing Homes [503]
Kate L Lapane, Bill M Jesdale, Christine M Ulbricht, Anne L Hume, Jacob Hunnicutt, Jon DeShazo, Jennifer Tija, Carmel M Hughes. (United States)

X. Poor Adherence With Non-Vitamin K Oral Anticoagulant (Dabigatran, Rivaroxaban) Among Patients With Nonvalvular Atrial Fibrillation Initiating Anticoagulant Therapy In 2013 In France. A Cohort Study On The French Healthcare Databases [505]
Géric Maura, Antoine Pariente, Alain Weill, François Alla, Cécile Billionnet. (France)

Spotlight Session-Medications in Pregnancy

Y. Neurodevelopmental Problems At 18 Months Among Children Exposed To Paracetamol In Utero – A Propensity Score Matched Cohort Study [506]
Richelle Vlenterie, Mollie E Wood, Ragnhild Eek Brandlstuen, Nel Roeleveld, Marleen MJ van Gelder, Hedvig Nordeng. (Netherlands)

Z. Mood Stabilizer Use and Risk of Ischemic Placental Disease [507]
Jacqueline M Cohen, Elisabetta Patorno, Krista F Huybrechts, Yoonyoung Park, Brian T Bateman, Sonia Hernández-Díaz, . (United States)

AA. Maternal and Infant Characteristics – Differences and Similarities Between the Nordic Countries and the United States [508]
Lukas Löfling, Gabriella Bröms, Shahram Bahmanyar, Helle Kieler. (Sweden)

BB. Preconception Use of Pain Relieving Medication and Time to Pregnancy: A Prospective Study [509]
Kathryn A McInerney, Elizabeth E Hatch, Amelia K Wesselinik, Kenneth J Rothman, Ellen M Mikkelsen, Lauren A Wise. (United States)
A Qualitative Study to Identify Interventions to Reduce Pain or Syncpe Related to Adolescent Vaccination [518]
Jennifer L. Kunz, Michelle L. Henninger, Jennifer Schneider, Alison Firemark, Karin Bok, Jennifer Gordon, Allison L. Naleway. (United States)

Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care Hospital: Administration of Interacting Comedication and QT-Prolongation [519]
David F. Niedrig, Sarah Mächler, Lisa Hoppe, Natascia Corti, Helen Kovari, Stefan Russmann. (Switzerland)

Methodologies To Assess the Benefit and Risk Balances in Examples in Vaccines [521]
Julie Mouchet, Bernard Begaud. (France)

Digoxin Use After Diagnosis of Prostate Cancer and Survival: A Population-Based Cohort Study [522]
Reema Karasneh, Liam Murray, Carmel Hughes, Chris Cardwell. (United Kingdom)

A Framework for the Evaluation of the Effectiveness of Risk Minimisation Measures Applied to Retrospective Danish Real-World Dabigatran Etxelate Data [523]
Martin Erik Nyelund, Flemming Skjøth, Peter Bronnum Nielsen, Jette Kjældgaard, Torben Bjerggaard Larsen, Mona Vestergaard Laursen, Torbjørn Calniri. (Denmark)

The Association Between Statin Use And Kidney Stones In Adult Men: A Systematic Review To Evaluate The Available Evidence And Provide Benefit/Risk Assessment [524]
Emre Yucel, Aylin Yucel, Latif Ozbay. (United States)

Assessment of Effectiveness of Dronedarone Risk Minimization Measures Through a Drug Utilization Study in Two European Countries [525]
Stephanie Tcherny-Lessenot, Birgit Ehiken, Chuntau Wu, Hayet Kechemir, Pierre D’Arbigny, Peggy Sarah, Laurence Pedrazzini, Juhaeri Juhaeri, Susan Welsh. (France)

Cardiovascular Disease, Medications, and Heat: What Precautionary Advice Is Available? [526]
Nanthanan Jayakumar, Genevieve Gabb, Debra Rowett, Tadros Rami. (Australia)

Improving a Drug Information Leaflet of Antihypertensives for Senior Citizens; Employing Performance-Based User-Testing [527]
Lyn-Hyang Lee, Haeri Shim. (Republic of Korea)

Evaluation of Physician Awareness of Risks Described in the SIMPONI (Golimumab, GLM) EU-RMP Educational Program [528]
Manjoo Otero-Lobato, Wim Noël, Anja Geldhof, Mallik Ghotra, Lauren Felo. (Netherlands)

Evaluation of Risk Minimisation Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 μg [529]
Kimberly H. Davis, Alex Asimwe, Laurie J. Zogafos, David J. McSorley, Elizabeth Andrews. (United States)

Assessment Of Pharmacist Mediated Education On Health Related Quality Of Life In Type 2 Diabetes Mellitus Patients In Rural India [530]
Sai Pawan Ramesh Adepu, KV Ramanathan, Shashikantha Bhat, Steny Sam, Cuckoo Omanakuttan. (India)

Pharmaceutical Risk Management Program: Outcomes from Diabetes Screening of Adults Receiving Antipsychotics [531]
Elaine H. Morroto, Elizabeth J. Campagna, Sarah E. Brewer. (United States)

Compliance with Renal Testing Recommendations for Fampridine Use in a German Population with Multiple Sclerosis [532]
Nicholas J. Everage, Andrew Maguire, Lalitha Mahadavan, Madé Wenten. (United States)

Usage Of Vapraote In Women In The UK [533]
Dervia Quinn, Katherine Donegan. (United Kingdom)

Impact of an Opioid Risk Reduction Initiative on Motor Vehicle Crash Risk Among Chronic Opioid Therapy Patients [534]
Ryan N. Hansen, Rod L. Walker, Susan M. Shortreed, Sascha Dublin, Kathleen Saunders, Evelette J. Ludman, Michael Von Korff. (United States)

Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States [535]
Kevin M. Fair, Carlos Castillo-Salgado, David D. Dore, G Caleb Alexander. (United States)
23. Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid REMS [536]
Diana B Esposito, Paul M Coplan, M Soledad Cepeda, Crystal N Holick, Vibha Desai, Caitlin Knox, Niania Liu, Shiva-Krishna Vojala, Jean-Yves Mazerie, Gregory P Medin, Stephan Lanes. (United States)

24. Experience from the Zyprexa Relprevv Patient Care Program: 2010-2015 [537]
Kristin J Meyers, Meghan E Jones, Balasubramamya S Rao, Deborah Falk, Debra Gash, Himanshu Upadhyaya. (United States)

25. Presentation of Stigma Associated with Mental Disorders in the News Media [538]
Gerard N Lim, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

Joseph Facade, Kazeem Oshikoya, Olayinka Ogunleye, Olufemi Desalu, Okezie Enwere, Taofiki Sumonu. (Nigeria)

27. Regulatory Considerations for Knowledge, Attitude, and Belief Surveys: A Systematic Review of Physician Survey Response [546]
Sarah E Brewer, Elaine H Morrato. (United States)

28. Applying The Number Needed To Harm (NNH) to Benefit-Risk Assessment (B-RA): Is There a Room for Improvement Through Good Pharmacoepidemiology Practices (GPP)? [539]
Christine A Radavski, Kenneth Hornbuckle, Rebecca A Noel, Meghan E Jones, Debashish Dey.

29. Review of the Pharmacoepidemiological Studies Using the Medical Information Databases in Japanese Hospitals [540]
Katsuhiro Horii, Michio Kimura, Kazuhiro Ohe, Naoki Nakajima, Hitoko Yokoi, Masahiro Tohkin, Kimie Sai, Takuya Imatoh, Tsugumichi Sato, Syunya Ikeda, Yoshiro Saito, Junichi Kawakami. (Japan)

30. A Cross-Sectional Study on the Adequacy of Product Information in Medical Advertisements Published in Print Media [548]
Ronald Kah Heng Toh, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

31. Use of Cognitive Testing to Optimize Questionnaire Wording and Mode of Administration in the Evaluation of Risk Minimization Activities [547]
Laurie J Zografos, Elizabeth Andrews, Diane Whalley, Paul Petraro, Zdravko Vassilev. (United States)

Sachiko Masuda. (Japan)

33. Drug Promotion In Nigeria: Does It Influence Prescribing Practice? [549]
Paul Lin, Beatrice L. Njoku, Adekunle O. Odekun, Olusade K. Ogunniyi, Adebayo O. Adeniyi. (Nigeria)

34. A Study of Preexisting Diabetes in Pregnancy and Associated Prescribing Patterns [551]
Sonia J Coton, Irwin Nazereth, Irene Petersen. (United Kingdom)

35. Safety Of Antidiabetic Drugs In A Databases in Japanese Hospitals [542]
Nicolaas D Vlieland, Bart JF van den Bemt, Marcel L Bouvy, Toine CG Egberts, Helga Gardarsdottir, Sophia Van Der Stokker, Paul T.J. van der Giet. (Netherlands)

36. Applying The Number Needed To Harm (NNH) to Benefit-Risk Assessment (B-RA): Is There a Room for Improvement Through Good Pharmacoepidemiology Practices (GPP)? [539]
Christine A Radavski, Kenneth Hornbuckle, Rebecca A Noel, Meghan E Jones, Debashish Dey.

37. Review of the Pharmacoepidemiological Studies Using the Medical Information Databases in Japanese Hospitals [540]
Katsuhiro Horii, Michio Kimura, Kazuhiro Ohe, Naoki Nakajima, Hitoko Yokoi, Masahiro Tohkin, Kimie Sai, Takuya Imatoh, Tsugumichi Sato, Syunya Ikeda, Yoshiro Saito, Junichi Kawakami. (Japan)

38. Review of the Pharmacoepidemiological Studies Using the Medical Information Databases in Japanese Hospitals [540]
Katsuhiro Horii, Michio Kimura, Kazuhiro Ohe, Naoki Nakajima, Hitoko Yokoi, Masahiro Tohkin, Kimie Sai, Takuya Imatoh, Tsugumichi Sato, Syunya Ikeda, Yoshiro Saito, Junichi Kawakami. (Japan)

39. Drug Promotion In Nigeria: Does It Influence Prescribing Practice? [549]
Paul Lin, Beatrice L. Njoku, Adekunle O. Odekun, Olusade K. Ogunniyi, Adebayo O. Adeniyi. (Nigeria)

40. A Study of Preexisting Diabetes in Pregnancy and Associated Prescribing Patterns [551]
Sonia J Coton, Irwin Nazereth, Irene Petersen. (United Kingdom)

41. A Cross-Sectional Study on the Adequacy of Product Information in Medical Advertisements Published in Print Media [548]
Ronald Kah Heng Toh, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

42. Use of Antihypertensive Drugs During Pregnancy in the Netherlands [555]
Josta de Jong, Jens HJ Bos, Catharina CM Schuling-Veninga, Lokkie TW de Jong-van den Berg. (Netherlands)

43. Exposure To Thiocolchicoside During Pregnancy: First Clinical Data in EFEMERIS [556]
Caroline Hurault-Delarue, Isabelle Lacroix, Jean-Louis Montastrauc, Anna-belle Beau, Christine DAMase-Michel. (France)

44. Venlafaxine Exposure in Pregnancy, A Multicenter ENTS Study [557]
Jennifer Campbell, Tarita Murray-Thomas. (United Kingdom)

45. Psychopharmacological Drug Utilization Patterns in Pregnant Women with Bipolar Disorder – A Nationwide Register-Based Study [559]
Sophie C Broeks, Katja Giejsstedt Ingrup, Henriette Thisted Horsdal, Christiane Gasse. (Netherlands)

46. Impact of Evolution and Intensity of Prenatal Exposure to Anxiolytics and Hypnotics on Neonatal Health: A Study in EFEMERIS Using a Trajectory Method [560]
Caroline Hurault-Delarue, Cecile Chouquet, Isabelle Lacroix, Anna-belle Beau, Jean-Louis Montastrauc, Nicolas Savy, Christine Damase-Michel. (France)

47. First Trimester Antidepressant Use in the National Birth Defects Prevention Study [561]
Jennifer N Lind, Jennida Reethfuis, Jan M Friedman, Allen A Mitchell, Tiffany Riehle-Colarusso, Kara N Polen, Margaret A Honein. (United States)

48. Abstract Withdrawn [562]

49. Should We Treat Or Not Mildly To Moderately Depressed Pregnant Women During Pregnancy? [563]
Maëlle Dandjinou, Odile Sheehy, Anick Berard. (Canada)

50. Maternal Depression and Use of Antidepressants During Pregnancy Increase the Risk of Adverse Pregnancy Outcomes: An IPD Meta-Analysis [564]
Richelle Vlenterie, Marleen van Gelder, Monica Pop-Purceleanu, Nel Roeleveld. (Netherlands)

51. Posterior Session B: Saturday, August 27 | 8:00am - 6:00pm
52. The Risk Of Specific Congenital Anomalies In Relation To Newer Antiepileptic Drugs: A Literature Review [565]
   Josta de Jong, Ester Garne, Lokej TW de Jong - van den Berg, Hao Wang. (Netherlands)

53. Prenatal Exposure to Non-Steroidal Anti-Inflammatory Drugs and Child Behavior at 36 Months: Birth Weight and Gestational Age as Mediators [566]
   Mollie E Wood, Hedvig Nordeng. (Norway)

54. Opioid Use Following Discharge After Cesarean Delivery [567]
   Brian T Bateman, Krista F Huybrechts, Jessica Booth, Holly Briggs, Pamela Froid, Melissa Bauer, Ruth Landau. (United States)

55. Opioid Use During Pregnancy: A Population-Based Cohort Study [568]
   Jamie Falk, Matt Dahl, Colette Raymond, Dan Chateau, Alan Katz, Christine Leong, Elaine Burland, Shawn C Bugden. (Canada)

56. Increase in Aberrant Prescription Opioid Use by Pregnant Women in a Nationwide Cohort of Medicaid Beneficiaries [569]
   Kathryn Rough, Sonia Hernández-Diaz, Krista F Huybrechts, Rishi J Desai, Elisabeta Patorno, Brian T Bateman. (United States)

57. Risk Of Preterm Birth Following Late Pregnancy Exposure To Medications Used In The Treatment Of Autoimmune Diseases (AD) [570]
   Anick Béard, Odile Sheehy, Sylvie Girard, Jin-Ping Zhao. (Canada)

58. Feasibility of Using the Medicaid Statistical Information System (MSIS) to Assess Safety and Effectiveness of 3rd Trimester Vaccination: A Case Study with Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis (Tdap) [571]
   Yandong Qiang, Yoganand Chillarige, Maria Said, Tina Liu, Carmen Dekmezian, Scott Winiecki, Michael D Nguyen, Chris M Worrall, Jeffrey A Kelman, Michael Wernske, Wei Hua. (United States)

59. Prevalence of Maternal and Child Adverse Pregnancy Outcomes Recorded in Primary Care in the United Kingdom [572]
   Sonia J Coton, Irwin Nazerath, Irene Petersen. (United Kingdom)

60. Pregnancy Studies Assessing Drug Exposure in Populations with Multiple Sclerosis [573]
   Whitney S Krueger, Mary S Anthony, Brigitta Monz, Catherine W Saltus, Ceri Hirst, Andrea V Margulis, Elizabeth B Andrews. (United States)

61. Assisted Reproductive Technologies and the Risk of Cryptoorchidism and Hypospadias: Population-Based Study [574]
   Gabriel Chodick, Britton Trabert, Varda Shalev, Katherine A McGlynn. (Israel)

   Cormac J Sammon, Irene Petersen.

63. Drug Utilization Among Pregnant Women: Real-World Findings from a US EMR Database [576]
   Caitlin A Knox, Elise Kaufman, William K Mountford. (United States)

64. Safety Profile of Medication Used in Pregnancy: Results of a Multinational European Study [577]
   Johanne N Tronnes, Angela Lupattelli, Hedvig Nordeng. (Norway)

65. Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists [578]
   Molly M Lynch, Jacqueline Amoozegar, Emily M McClure, Linda B Squiers, Cheryl S Brousard, Jennifer N Lind, Kara N Polen, Meghan T Frey, Suzanne M Gilboa, Janis Biermann. (United States)

66. Unique Approaches for Conducting Lactation and Placental Transfer Studies [579]
   Deborah L Covington, Nicole Hurst, Anne Tronel-Peyroz. (United States)

67. Utilization of Laboratory Results Data to Enhance Pregnancy Cohort Identification [580]
   Kevin Haynes, Andrew Sterrett, Susan Shetterly, Mano Selvan, Josh Gange, Christine Lu, Azadeh Shoab, Marsha A Raebel. (United States)

68. Spontaneous Preterm Labor (SPTL) in the Netherlands: Creation Of Linked Mother-Child Cohorts For Epidemiological Studies [581]
   Libby K Black, Eline Houben, Jeanne M Pimenta, Irene D Bezemer, Elisabeth Smits, Loes van der Leeuw-Harmsen, Fernie JA Penning-van Beest. (United Kingdom)

69. What Factors Contribute to Pregnancy Registry Success? [582]
   Kristin Veley, Ann Mallard, Deborah L Covington. (United States)

70. Validity Of Electronic Health Data For Pregnancy Outcomes [583]
   Sascha Dublin, Darios T Getahun, Rod L Walker, Victoria L Holt, Jennifer Bobb, Blair Darney, Dmitry Dukhovny, Jasmine Lai, Gaia Pocobelli, Deborah A Wing, Aaron B Caughey. (United States)

71. Using Web-Based Questionnaires to Assess Medication Use During Pregnancy: A Validation Study in Two Prospective Cohort Studies [584]
   Marleen MHJ van Gelder, Saskia Vorstenbosch, Bernike te Winkel, Eugène P Puijenbroek, Nel Roeleveld. (Netherlands)

72. Development of a Mother-Baby Linkage Using Integrated Claims and Electronic Health Records (EHR) [585]
   Nancy D Lin, Cheryl Enger, Wendy Carman, Michael Doherty, John D Seeger.

73. Validation of Multiple Births in Medicaid Analytic eXtract (MAX) Data [586]
   Yammin Zhu, Carl Henriksson, Almut G Winterstein. (United States)

**Changing Drug Utilization**

74. Changes in Prescription Drug Use After Gastric Bypass Surgery: A Nationwide Cohort Study [587]
   Sigrid B Gribsholt, Reimar W Thomsen, Dorå K Farkas, Henrik T Sørensen, Bjørn Richelsen, Elisabeth Svensson. (Denmark)

75. Impacts of Reimbursement Policy for Targeted Therapies Utilization for Lung Cancer Treatment in Taiwan [588]
   Jason C Hsu, Chen-Fang Wei, Christine Y Lu. (Taiwan)

   Sharon L Larson, H K Kirchner, Haiyun Wang. (United States)

77. Prescription Behaviour for Gastroprotective Drugs in New Users as a Result of Communications Regarding Clopidogrel – Proton Pump Inhibitor Interaction [590]
   W J Kruijk-Kollöffel, J van der Palen, H J Kruijk, M P van Herk-Sukel, K L Morig. (Netherlands)

78. Changes in Antihypertensive Drug Use After the Implementation of Evidence-Based Drug Formulary in a Private Hospital in South Sumatra, Indonesia [591]
   Erna Kristin, Alfi Yasmina, Iwan Dwiprahasto. (Indonesia)


   Bo Ram Yang, Joongyu Lee, Ju-Young Shin, Xue-Mei Jin, Byung-Joo Park.
Drug Utilization and Policy

90. Integration of Medicines Budget Impact with Market Uptake Models in Horizon Scanning Through Use of the C-Tobia Model – A Collaboration Across Europe [603]
Roberta Joppi, Renato Guseo, Claudio Jonnyni, Cinzia Mortarino, Marion Bennie, Björn Wettermark, Gisbert Selke, Irene Langner, Thomas Cars, Neil Hawkins, Reinhard Schuster, Brian Godman. (United Kingdom)

91. Varying Patterns of Penetration of New Antidiabetic Medications in Asia and US: A Cross-National Comparison Study [604]

92. Does Free Medication Impact Drug and Health Services Use by Low-Income Diabetic Patients? [605]
Régis Blais, Michal Abrahomowicz, Jean Lachaine, Eric Latimer, Robyn Tamblyn. (Canada)

93. The Use of Nitrofurantoin in France: Assessment of Compliance with Therapeutic Indication and Guidelines [606]
Pierre Nguyen, Fanny Raguindeau, Caroline Semaille, Mahmoud Zureik, Rosemary Dray-Speria. (France)

94. Detection of Trastuzumab Related Cardiotoxicity in Taiwanese Breast Cancer Women [607]

95. Compliance to Multiple Sclerosis Disease-Modifying Therapies: A Population-Based Cohort Study In The Lazio Region, Italy [608]
Anna Maria Bargagli, Nera Agabiti, Flavia Mayer, Silvia Cascini, Paola Colais, Marina Davoli, Multiple Sclerosis Study Group Lazio Region. (Italy)

96. Effect of a “Pill Mill” Law on Opioid Prescribing and Utilization: The Case of Texas [609]
Tatyana Lyapustina, Linie Rutkow, Hsien-Yen Chang, Matthew Daubresse, Alim F Ramji, Mark Faut, Elizabeth A Stuart, G Caleb Alexander. (United States)

97. Comparison Of Generic- to-Brand Switchback Patterns For Authorized Generic Vs. Independent Generic Drugs [610]
Richard A Hansen, Jingjing Qian, Richard Berg, James Lenniman, Enrique Seoane- Vazquez, Sarah Dutcher, Saeed Raof, Peggy Peissig. (United States)

98. The Recently Introduced System of Generic Substitution and Reference Pricing in Ireland: Generic Dispensing, Savings and Costs to the Health Service, and the Burden of Co-Payment [611]
Susan Spilliane, Cara Usher, Michael Barry. (Ireland)

Jodi B Segal, Matthew Daubresse, Oluwadamilola Onasanya, Sarah Dutcher, Wenlei Jiang, Robert Romanelli. (United States)

100. Disposal of Unused or Expired Medications Among a Mexican Sample [613]
Arel Vergara Castañeda, Laura Martino Roaro. (Mexico)

Geriatric Pharmacoeconomics

101. Pharmacoeconomic Evaluation of Geriatric Diabetics in a Tertiary Care Hospital: A Prospective Study [614]
Ramanath Kattavenkatesh, MM Prabhu, K Nandakumar, K Sreedhara R Pai. (India)

102. Selection of Sulfonylureas Over Metformin in Elderly Nursing Home Residents with Diabetes Mellitus [615]
Andrew R Zullo, David D Dore, Roei Gutman, Vincent Mor, Robert J Smith. (United States)

103. Polypharmacy: Prevalence and Associated Factors in Elderly with Diabetes Mellitus in Minas Gerais, Brazil [616]
Michael Ruberson Ribeiro da Silva, Leonardo Mauricio Diniz, Jéssica Barreto Ribeiro dos Santos, Edna Alfonso Reis, Adriana Rodrigues da Mata, Vania Eloisa de Araújo, Juliana Alvares, Francisco de Assis Acuciro. (Brazil)

104. Real-World Risk of Diabetes with Second-Generation Antipsychotics in Older People [617]
Prasad S Nishthala, Te-yuan Chyou. (New Zealand)

105. Increasing Prevalence Of Anticholinergic Medication Use Over 20 Years In The UK Older Population: Cognitive Function And Ageing Study I and II [618]
Carlota M Grossi, Ian Maidment, Kathryn Richardson, Chris Fox, Carol Brayne, Fiona Matthews, Louise Robinson, George M Savva. (United Kingdom)
107. Antipsychotic Use And The Risk Of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease [620]
Marjaana Koponen, Heidi Taipale, Piia Lavikainen, Antti Tanskanen, Jari Tiitohon, Anna-Maija Tolppanen, Riitta Ahonen, Sirpa Hartikainen. (Finland)

108. Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: A Replication Study [621]
Darmendra Ramcharran, Hong Qiu, Martijn Schuemie, Patrick Ryan.

109. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease [622]
Marjaana Koponen, Heidi Taipale, Piia Lavikainen, Antti Tanskanen, Jari Tiitohon, Anna-Maija Tolppanen, Riitta Ahonen, Sirpa Hartikainen. (Finland)

110. Abstract Withdrawn [623]

111. Co-Prescription of Antipsychotic and Antiparkinson Medication Regimens Containing Levodopa: Adherence to Guidelines and the STOPP (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions) Criteria in Beneficiaries of the Nova Scotia [624]
Sara Rehan, Ingrid Skeptris, Hili-Taylor Barbara, Rigby Heather. (Canada)

112. Frequent Use Of Psychotropic Drugs Among Persons with Alzheimer’s Disease Aged 90 Years Or More In Finland [625]
Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Anna-Maija Tolppanen, Jari Tiitohon, Sirpa Hartikainen. (Finland)

113. Benzodiazepine and z-Substance Use and Risk of Dementia – A German Claims Data Analysis [626]
Willy Gomm, Klaus von Holt, Friederike Thomé, Karl Broich, Wolfgang Maier, Klaus Weckbecker, Anne Fink, Gabriele Doblhammer, Britta Haenisch. (Germany)

114. Trends in Prescribing of Antipsychotics in Dementia: A Population-Based Study [627]
Vicky Sandy, Zeenat Gul, Mary Teeling, MaryJo MacAvin, Kathleen Bennett. (Ireland)

115. Psychotropic Medication Use and Alzheimer’s Disease: A Story of Sex Differences in Two Countries [628]
Daniela C. Moga, Heidi Taipale, Anna-Maija Tolppanen, Antti Tanskanen, Jari Tiitohon, Sirpa Hartikainen, Qishan Wu, Gregory A Jicha, Danijela Gnjidic. (United States)

116. Risk of Pneumonia Associated with Incident Benzodiazepine Use Among Community-Dwelling Persons with Alzheimer’s Disease [629]
Heidi Taipale, Anna-Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Piia Lavikainen, Reijo Sund, Jari Tiitohon, Sirpa Hartikainen. (Finland)

117. Risk Of Stroke Associated With Benzodiazepine And Related Drug Use Among Persons With And Without Alzheimer’s Disease [630]
Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Piia Lavikainen, Anna-Maija Tolppanen, Reijo Sund, Jari Tiitohon, Sirpa Hartikainen. (Finland)

118. Comparative Risk Of All-Cause Mortality In Older Patients Prescribed Codeine Or Tramadol For Non-Malignant Pain: Retrospective Cohort Study [631]
Craig Allen, Wilhelmine Meeraus, Katherine Donegan. (United Kingdom)

119. Long-Term Use of Opioids Among Community-Dwelling Persons with and without Alzheimer’s Disease [632]
Aleksi Hamina, Heidi Taipale, Antti Tanskanen, Anna-Maija Tolppanen, Jari Tiitohon, Sirpa Hartikainen. (Finland)

120. Hospice Use and Pain Management in Nursing Home Residents with Cancer [633]
Jacob N Hunnicutt, Jennifer Tija, Kate L Lapane. (United States)

121. Antidepressant Use And Associated Risk Of Head And Brain Injuries Among Persons With And Without Alzheimer’s Disease [634]
Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Piia Lavikainen, Reijo Sund, Jari Tiitohon, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)

122. Antidepressant Use And Associated Risk Of Hip Fractures Among Community-Dwelling Older Persons With And Without Alzheimer’s Disease In Finland [635]
Sanna Torvinen-Kiiskinen, Anna-Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Jari Tiitohon, Sirpa Hartikainen, Heidi Taipale. (Finland)

123. Factors Influencing the Quality of Antidepressant Prescribing for Older, Community-Dwelling Adults, and the Risk of Emergency Outcomes [636]
Rian Marie Eustavour, Matthew Perri. (Trinidad and Tobago)

124. Incidence Of Antidepressant Use In Community-Dwelling Persons With And Without Alzheimer’s Disease – 13-Year Follow-Up [637]
Arto Puranen, Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Anna-Maija Tolppanen, Jari Tiitohon, Sirpa Hartikainen. (Finland)

Ruby Castiglia, Miguel Habeych. (United States)

126. Outcomes After Induction Agent Use In Older Kidney Transplant Recipients [639]
Mara McAdams-DeMarco, Qiong Huang, Dorny Segev.

127. Time Trends of Vitamin B12 Deficiency in Older Adults: A Population-Based Cohort Study [640]
Nancy Presse, Marie-Jeanne Kergoat, Marc Dorais, Sylvie Perreault. (Canada)

128. Patterns and Predictors of Potentially Inappropriate Medication Use in Older Colon Cancer Patients [641]
Jennifer L Lund, Sharon Peacock Hinton, Virginia Pate, Hanna K Sanoff, Marcela Jiron, Jena Ivey Burkhart, Hyman B Muss, Til Stürmer. (United States)

129. Prevalence and Predictors of Inappropriate Medications According to START/STOPP Criteria Version-2 in Indian Elderly [642]
Pradeep Gunda, Stylo Sharmeen, Anusha Lokalobaiona, Vishwas Hunsur Nagendra, Satyanaryan Pattnaik. (India)

130. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions/Screening Tool To Alert Doctors To The Right Treatment) Criteria: Systematic Review And Meta-Analysis Of Randomized Controlled Studies [643]
Kieran A Walsh, Barbara Hill-Taylor, Samuel A Stewart, Jill Hayden, Stephen Byrne, Ingrid Sketris. (Ireland)

131. Potentially Inappropriate Prescribing Measured by STOPP and START and Functional Decline and Quality of Life in Older People: A Cohort Study [644]
Frank Moriarty, Kathleen Bennett, Caitriona Cahir, Rose Anne Kenny, Tom Fahey. (Ireland)
132. STOIP 2 versus EU(7)-PIM: Comparing Prevalence and Impact of Inappropriate Prescribing on Mortality and Hospitalisation [645]
Maarten Wauters, Monique Elseviers, Bert Vaes, Jan Degryse, Robert Vander Stichele, Thierry Christaens, Majda Azermai. (Belgium)

133. Drug Burden in Aging Adults with Intellectual Disabilities Living in Residential Facilities: A Cross-Sectional Study [646]
Maire O’Dwyer, Clare Donegan, Philip McCallion, Mary McCarron, Martin Henman. (Ireland)

134. The Effect of Pharmacist-Led Interventions in Optimising Prescribing in Older Adults in Primary Care: A Systematic Review [647]
David J O Riordan, Kieran A Walsh, Rose Galvin, Carol Sinnott, Patricia M Kearney, Stephen Byrne. (Ireland)

135. Medication Regimen Complexity and Clinical Outcomes in Older People: A Systematic Review [648]
Barbara C Wimmer, Amanda J Cross, Natali Jokanovic, Michael D Wiese, Johnson George, Kristina Johnell, Basia Diug, J Simon Bell. (Australia)

136. An Educational Intervention to Reduce Acute Health Care Consumption in Elderly Patients with Inappropriate Drugs - A Cluster Randomised Trial in Primary Care [649]
Katharina Schmidt-Mende, Morten Andersen, Björn Wettermark, Jan Hasselström. (Sweden)

137. Risk Factors For Unplanned Readmissions In French Older People Discharged From Acute Geriatric Units [650]
Dominique Bonnet-Zamponi, Florence Tubach, Marie Line Gaubert-Dahan, Blandine Pasquet, Sophie Lacaillle, Sylvie Legrain. (France)

138. Pro Re Nata (as Needed) Medication in Nursing Homes: The Longer You Stay, the More You Get? [651]
Michael Dörks, Guido Schmiemann, Falk Hoffmann. (Germany)

139. Assessment of Frequency and Effects of Potentially Inappropriate Medications in Elderly Persons: An Italian Population-Based Study [652]
Francesco Giorgianni, Ylenia Ingrasciotta, Ilaria Marcianò, Michele Tari, Achille P Caputi, Gianluca Trifrò. (Italy)

140. Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs. 2011 [653]
Dima Qato, Jocelyn Wilder, Philip Schumm, Victoria Gillet, Caleb Alexander. (United States)

141. Feasibility of Using Real-World Databases to Assist Discovery of Unknown Associations Between Genetic Diseases and Other Health Conditions – A Testing Case of Gaucher’s Disease and Parkinson’s Disease [654]
Zhiwen Liu, A Lawrence Gould, David J Stone, Heiko Runz, Jennifer K Pai, Edward A Bortnichak. (United States)

142. Meta-Analysis of the Genome Wide Association Studies (GWAS) on the Intolerance of Angiotensin Converting Enzyme Inhibitors (ACEIs) [655]
Seyed Hamidreza Mahmoudpour, Moneez K Siddiqui, Abirami Veluchamy, Folkert W Asselbergs, Patrick C Souverein, Catherine E de Keyser, Albert Hofman, Bruno H Stricker, Anthonius de Boer, Anke-Hilse Maaitland-van der Zee, Collin NA Palmer. (Netherlands)

143. Long-Term Survival After Myocardial Infarction: Impact of Patient Non-Compliance to the EOLE Study Protocol [656]
Cécile Droz-Perroteau, Daniel Thomas, Nicolas Danchin, Caroline Dureau-Pournin, Marie-Agnès Bernard, Regis Lassalle, Patrick Bli, Nicholas Moore. (France)

144. In Silico Integration of Epidemiologic and Genetic Evidence on Sex/Race-Related Modifying Effects on Hip Arthroplasty Outcomes [657]
Yelizaveta Torosyan, Nilisa Loyo-Berrios, Tigran Karapetyan, Terrie Kitchner, Murray Brilliant, Danica Marinac-Dabic. (United States)

145. Multi-Variant Genetic Panel for Genetic Risk of Opioid Addiction [658]
Keri Donaldson, Joe Lopez, Sherman Chang. (United States)

146. KRAS Testing Status in Patients with Metastatic Colorectal Cancer – A Danish Population-Based Study [659]
Anne G Ording, Trine Frosliev, Margaret McCusker, Elaine Cheng, Lisa Wang, Julie Ta, Vera Ehrenstein, Henrik T Sørensen. (Denmark)

147. Comorbidity Among Patients with Metastatic Colorectal Cancer According to KRAS-Mutation Testing Status – A Danish Nationwide Prevalence Study [660]
Anne G Ording, Trine Frosliev, Margaret McCusker, Elaine Cheng, Julie Ta, Vera Ehrenstein, Henrik T Sørensen. (Denmark)

148. The Prevalence RAS and BRAF Mutations Among Patients in the Middle East and Northern Africa with Metastatic Colorectal Cancer [661]
Tamer Garawin, Kimberly Lowe, George Kafatos, Samuel Murray. (United Kingdom)

149. An Estimation of RAS Mutation Prevalence Amongst Patients With mCRC Using A Meta-Analytical Approach [662]
George Kafatos, Kimberley Lowe, Daniela Niewel, Sophie Jenkins-Anderson, Hal Westhead, Tamer Garawin, Zuzana Traugottova, Antonios Bilalis, Edit Molnar, Jozielf Timar, Erika Toth, Nikolaos Gouvas, George Papaxoinis, Samuel Murray, Nadia Mokhtar, Hana Vosmikova, Pavel Fabian, Alena Skalova, Piotr Wójcik, Andrezj Tysarowski, Jeannette Rodger, Mario Barigel, J Han van Krieken, Jörg Trojan. (United Kingdom)

150. A Comparative Effectiveness Review of Benefits and Harms of PCSK9 Inhibitors [663]
Marian McDonagh, Kim Peterson, Sergio Fazio. (United States)

151. Systematic Evaluation of Interventions to Reduce Overprescribing of Antibiotics for Acute Respiratory Tract Infections [664]
Marian S McDonagh, Kim Peterson, Kevin Winthrop, Amy Cantor, Brittany Holzhammer, David Buckley. (United States)

152. The Association Between Diabetic Complications and Androgen Deprivation Therapy Used for Clinically Localized Prostate Cancer [665]
Marie C Bradley, Grace Zhou, Andrew N Freedman, Reina Haque, Marianne Ullickas Yood, Stephen K Van Den Eeden, Arnold L Potosky. (United States)

153. Temperature, Real-Time, On-Site, Potency Monitoring Studies of Three Brands of Amoxicillin Dispersible Tablets Stored in Hospital and Community Pharmacies in Different Part of Kerala [666]
SS Kiron, M Saritha. (India)

154. Cohort Study Examining the Contribution of Antiepileptic Drugs to Poisoning Deaths in Epilepsy [667]
Hayley C Gorton, Roger T Webb, Matthew J Carr, Darren M Ashcroft. (United Kingdom)

155. Level of Evidence for Labeled Dosing and Overprescribing of Antibiotics - A Meta-Analysis of the Genome Wide Association Studies (GWAS) on the Intolerance of Angiotensin Converting Enzyme Inhibitors (ACEIs) [655]
Seyed Hamidreza Mahmoudpour, Moneez K Siddiqui, Abirami Veluchamy, Folkert W Asselbergs, Patrick C Souverein, Catherine E de Keyser, Albert Hofman, Bruno H Stricker, Anthonius de Boer, Anke-Hilse Maaitland-van der Zee, Collin NA Palmer. (Netherlands)

156. The DIFFuse Algorithm: A Practical Method for Data Source Identification, Method for Data Source Identification, and Genetic Evidence on Sex/Race-Related Modifying Effects on Hip Arthroplasty Outcomes [657]
Yelizaveta Torosyan, Nilisa Loyo-Berrios, Tigran Karapetyan, Terrie Kitchner, Murray Brilliant, Danica Marinac-Dabic. (United States)
Xuan Wang, Raquel Lahoz, Lisa Burdulkova, Kristijan Kahler, Maria Nassim, Shiva Kumar Venkata, Shantanu Jawla, Amit Khandhare, Anikumar Jalapu, Nahlia Justo. (United States)

158. Dynamic Real World Data Platform Integrating Automated Claims and Registry Data for Pharmacoepidemiologic Studies [671]
Syd Phillips, Andre Araujo, Charissa Proctor, William Malatestinic, Cynthia Larmore, Leslie R Harrold, George W Reed, Deb Casso, Karin Johnson, Jeremy Stamer, Susan A Oliveria. (United States)

159. Time Trends Of Studies Accounting For Immortal-Time Bias – A Review [672]
Paren Vora, Gunnar Brobert, Alex Asimwe. (Germany)

160. Quality of Cancer Records in the Information System for the Development of Primary Care Research (SIDIAP) [673]
Tallia Duarte-Salles, Leonardo Méndez-Boo, Francesco Macià, Marta Banqué, Ricardo Riel-Cabrera, Cristian Llacer-Pinós, María del Mar García-Gil. (Spain)

161. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Study Cohort: Presentation of 5,870 Patients with New Type 2 Diabetes Enrolled from 2010 Through 2014 [674]
Diana H Christensen, Sia K Nicolaisen, Klára Berencsi, Henning Beck-Nielsen, Jørgen Rungby, Sören Friiborg, Ivan Brandslund, Jens S Christiansen, Allan Vaag, Henrik T Sørensen, Jens S Nielsen, Reimar W Thomsen. (Denmark)

162. The Surveillance of HealthCare in Asian Network (SCAN): Infrastructure Development for Multinational Pharmacoepidemiologic Studies (MPES) [675]
Edward Chia-Cheng Lai, Martijn Schuermie, Patrick Ryan, Paul Stang, Yukari Kamijima, Shinya Kimura, Kiyoshi Kubota, Kenneth KC Man, Rae Woong Park, Chien-Chou Su, Ian CK Wong, Yea-Huei Kao Yang, Yinghong Zhang, Soko Setoguch-Iwata. (United States)

163. A Study to Assess the Capture of Sublingual Immunotherapy Within an Electronic Health Record (EHR) System [676]
Florence T Wang, Edward Green, Daniel Mines, Vinay Mehta, Nancy D Lin. (United States)

164. Pitfalls and Value of Clinical and Laboratory Values in Electronic Health Record Data [677]
Anita M Loughlin, Stephen M Ezzy, Anthony P Nunes, Cheryl L Enger, David D Dore, John D Seeger. (United States)

165. The Role of Poison Data in Regulatory Decision-Making [678]
Syed Rizwanuddin Ahmad. (United States)

166. Determining the Citation Impact of the Canadian Network for Observational Drug Effect Studies (CNODES) Publications: Methods and Outcomes [679]
Ingrid Sketris, Melissa Rothfus, Robyn Traynor, Melissa Helwig, Samuel Stewart. (Canada)

Irene Pan. (Canada)

168. Weighted Multiple Imputation of Ethnicity Data That Are Mising Not at Random in Primary Care Databases [681]
Tra My Pham, Irene Petersen, James Carpenter, Tim Morris.

169. The Joint Action Of Patient, Physician And Pharmacist In Order To Improve Adherence To Medication [682]
Ivana Prga, Martina Bago, Marcel Leppé, Josip Culig, Ivana Radman. (Croatia)

170. Counselling In Community Pharmacies In The Nelson Mandela Metropole, South Africa: Codeine-Containing Analgesics [683]
Brent C Knoesen, Ilse Truter. (South Africa)

171. The Epichron Cohort Proven Useful for Pharmacoepidemiological Studies [684]
Alexandra Prados-Torres, Beatriz Poblador-Piñol, Francisca Gonzalez-Rubio, Jordi Castellsague, Susana Perez-Guthmann, Alejandro Arana. (Spain)

172. Training Pharmacy Students and Disseminating Information on Appropriate Use of Medicines: The Weblog as a Tool [685]
Joyce CM Faria, Daniela RG Junqueira, Raissa CF Cândido, Alba VSM Moraes, Alessandra ACM Frade, Daniela F Silva, Erika PS Santos, Louise CO Santos, Mariana FL Nascimento, Weverton T Silva, Alessandra R Mesquita, Cristiana A Menezes de Pádua, Edson Perini. (Brazil)

Mary E Ritchey. (United States)

174. Lost in Translation: No Effect of a Language Translated Website to Improve Appropriation Use of Medicines: The Weblog as a Tool [687]
Ivana Prga, Martina Bago, Marcel Leppé, Josip Culig, Ivana Radman. (Croatia)

175. Development, Applications, and Methodological Challenges to the Use of Propensity Score Matching Approaches in FDA’s Sentinel Program [688]
John G Connolly, Judy C Maro, Shirley V Wang, Sengwee Toh, Candace C Fuller, Cathy A Panuzzo, Joshua J Gagne. (United States)

176. Effect of Lawyer-Submitted Reports on Safety Signals in the FDA Adverse Event Reporting System (FAERS) [689]
James R Rogers, Ameet Sarpatwari, Riashi J Desai, Justin M Bohn, Nazleen F Khan, Aaron S Kesselheim, Michael A Fischer, Joshua J Gagne, John G Connolly. (United States)

177. An Educational Intervention to Improve Nurses Reporting of Adverse Drug Reactions [690]
Susana T Marquez, Maria T Herdeiro, Inês R Vaz. (Portugal)

178. One Size Does Not Fit All - Right-Sized Signal Detection Systems That Are Appropriate for Your Portfolio Benefit-Risk Management Strategy [692]
Deirdre M McCarthy. (United States)

179. Abstract Withdrawn [693]

180. PRR Computations Over Time Continue to Reveal Serious Safety Signals Aoon After Drug Approval [694]
Keith L Altman. (United States)

181. Utilising Electronic Healthcare Data To Support Early Phases Of Safety Signal Assessment [695]
Katherine Donegan, Helena Bird, Brian Burch, Alex Smith, Otuloyin Agbaje, Temitope Ibitoye, Jenny Wong, Rebecca Owen, Phil Tregunno. (United Kingdom)

182. Identification of Generic Drugs in the FDA Adverse Event Reporting System [696]
Geetha S Iyer, Sathiyah Priya Marimuthu, Jodi B Segal, Sonal Singh. (United States)

183. The Landscape of Active Surveillance Systems for Postmarketing Drug Safety Monitoring [697]
Ayad K Ali, Kristin J Meyers, Yu-Jing Huang, Claudia A Salinas, Hu Li. (United States)

184. Web-Based Query Log Reaction Score Methods to Detect Safety Signals for Pharmaceutical Drugs [698]
Susan Coillita, Elad Yom Tov, Ying Zhang, Marie-Laure Kurzinger, Stephanie Chernen-Lessenot, Susan Welsh, Juhaeri Juhaeri. (United States)
POSTER SESSION B: Saturday, August 27 | 8:00am - 6:00pm

Nabarun Dasgupta, Carrie E Pierce, Khaled Bouri, Carol Pamer, Scott Proestel, Harold W Rodriguez, Hoa Van Le, Clark C Freifeld, John S Brownstein, Mark Walderhaug, I Ralph Edwards. (United States)

186. Risk Management and Specialist Cohort-Event Monitoring – Responding to Change [700]
Deborah Layton, Saad AW Shakir. (United Kingdom)

187. Knowledge and Attitude Towards Adverse Drug Reactions Among Healthcare Professionals [701]
Young-Hee Nam, Hyun Jung Jin, Soo-Keol Lee. (Republic of Korea)

188. Implementation of Pharmacovigilance Practices by Clinical Pharmacists in an Oncology Hospital--A Step to Improve Patient Safety Monitoring During Cancer Care [702]
Himanshu Patel, Parthasarathi Gunumurthy, Ramesh Madhan. (India)

189. Assessing Studies of Patients Spontaneously Reported Adverse Drug Reactions (ADR’s): A Review Study [703]
Sondus I Ata, Tariq M Alhawawi, Nasser M Bin Dhim, Lisa G Pont, Hisham S Aljadhey. (Saudi Arabia)

190. Performance of Disproportionality Analysis for Statistical Signal Detection in Social Media Data [704]
Ola Caster, Magnus Larch, Bernt Vroman, John van Stekelenborg. (Sweden)

191. Assessment of Reported Medication Errors in General Medicine Wards in a Tertiary Care Hospital [705]
Sri Harsha Chalasani, Madhan Ramesh. (India)

192. Barriers and Facilitators to Using a Mobile App for Two-Way Risk Communication: A Qualitative Study [706]
Sieta T de Vries, Lisa Wong, Carmen Lasneras Ruiz, Francois Houyze, Sandra Fernandes, Raphael van Eemeren, Alastair Sutcliffe, Peter GM Mol, IMI WEB/RADR Work Package 3b.

193. Improving the Yield of Relevant Data for Pharmacovigilance Analysis by Reducing Search Term Complexity – A Study on Reddit Data [707]
Sara Hedfors, Tomas Bergvall, Michael Gilbert, Carrie Pierce, Nabarun Dasgupta, Johan Ellenius. (Sweden)

194. What are Patients Asking Social Media About Drug Products and Treatments? [708]
Soraya Shaikh, Heidi G Bell, Laurie S Anderson, Gregory E Powell. (United Kingdom)

Marie-Laure Kürzinger, Nathalie Texier, Stéphane Schuck, Carole Faviez, Thierry Deliens, Ling Zhang, Stéphanie Tcherny-Lessenot, Juhaeri Juhaeri, Susan Welsh. (France)

Johan Ellenius, Tomas Bergvall, Nabarun Dasgupta, Sara Hedfors, Carrie Pierce, G Niklas Norén. (Sweden)

197. Impact of the 2012 European Pharmacovigilance Legislation on Required Additional Risk Minimisation Measures [711]
RDC Francisca, IM Zomerdijk, MCJM Sturkenboom, SMJM Straus. (Netherlands)

198. An Analysis of Characteristics of Post-Approval Safety Studies Registered on ENECPP [712]
Sreeram Ramagopalan, Radek Wasiak, Dimitra Lambrelli. (United Kingdom)

199. Studies Evaluating Effectiveness of Risk Minimisation Measures [713]
RDC Francisca, IM Zomerdijk, MCJM Sturkenboom, SMJM Straus. (Netherlands)

Cristiano Matos, Florence van Hunsel, Linda Härmäk. (Spain)

201. Assessment of Impact of Structured Educational Intervention on Adverse Drug Reaction Reporting Behaviour of Community Pharmacists in South India [715]
MS Srikanth, Ramesh Adep. (India)

Ingrid Oosterhuis, Leán Rolles, Corine Ekhart, Annemarie Müller-Harmsma, Linda Härmäk. (Netherlands)

203. Evaluation of a Newly Developed Intelligent Drug Alert System for Enforcing Medication Safety [717]
Ibrahim Oregaag, Sunday Eyuar, Olufunsho Awodele, Sunday Olayemi. (Nigeria)

204. The Documentation of Clinical Information of Adverse Drug Reaction Reports: A Paired Comparison of ‘Duplicate’ Reports of Patients and Healthcare Professionals [718]
Leán Rolles, Laura van der Linden, Florence van Hunsel, Katja Taxis, Eugène van Puijenbroek. (Netherlands)

Pharmacovigilance by Geography

Kevin W McConeghy, Haley Morrill, Aisling R Caffrey, Amal Trivedi, Kerry L LaPlante. (United States)

206. Prevalence and Predictors of Adverse Drug Reactions in Hospitalized Elderly Patients of India [720]
Shyla Sharmeen, Pradeep Gunda, Anusha Lokalaboina, Vishwas Hunsur Nagendra, Satyanaryan Pattnaik. (India)

207. [NEWCOMER TRACK] A Hospital-Based Prospective Cohort for Adverse Herbal Drug Reactions [721]
Mikyung Kim, Chang-ho Han. (Republic of Korea)

208. Rate of Off-Label Prescriptions in Adverse Drug Reactions in Crimian Children [722]
Alexander V Matveev, Alexander Y Ezerntskiy, Elena I Konyaeva, Natalya V Matveeva.

209. Patient Relevant Outcomes Associated with Generic Drugs in FDA’s Adverse Event Reporting System [723]
Sathiya Priya Marimuthu, Geetha S Iyer, Jodi B Segal, Sonal Singh. (United States)

Danya M Qato.

211. Prescribing Errors Incidence in Four Hospitals in Saudi Arabia [725]
Hisham Aljadhey, Mansour Adam Mahmoud, Mohamed Azmi Hassali. (Saudi Arabia)

212. Knowledge, Attitude and Concept of Pharmacovigilance Among Community Health-Care Professionals in Saudi Arabia [726]
Thamir M Alshammarri, Arshad Hussain, Mukhtar Ansari. (Saudi Arabia)

213. First Characterization Of Adverse Drug Reactions in the Dominican Republic [727]
Nicolas Thurin, Adrian Puello, Marianne Moully, Carla Garrido, Françoise Haramburu. (France)
214. Development of a New Trigger Tool for Adverse Drug Reaction Detection at a Large Teaching Hospital, Thailand [728] Nicharee Inprasit, Promote Tragupilankit, Ticha Rerkpattanapipat. (Thailand)

215. Testing of ADR Thai Trigger in Surgical Patients at a Large Teaching Hospital, Thailand [729] Nicharee Inprasit, Promote Tragupilankit, Ticha Rerkpattanapipat. (Thailand)

216. Adverse Drug Reactions in Medicine Wards at a Large Teaching Hospital, Thailand [730] Nicharee Inprasit, Promote Tragupilankit, Ticha Rerkpattanapipat. (Thailand)


221. Attitudes of Community Pharmacy Professionals Towards Consumers Reporting in Portugal [735] Cristiano Matos, Liliana Rodrigues, Joao Joaquim, Maria Clara Rocha. (Portugal)

222. Abstract Withdrawn [736]

Pharmacovigilance - Alimentary and Metabolic


224. Development of a Detection Algorithm for Prednisolone-Induced Diabetes Mellitus Using a Medical Information Database [738] Imatoh Takuya, Sai Kimie, Hori Katsuhito, Segawa Katsunori, Kimura Michio, Kawakami Junichi, Saito Yoshio. (Japan)

225. FDA AERS Data Shows a Strong Signal for SGLT2 Inhibitors and Diabetic Ketoacidosis [739] Keith L Altman. (United States)


227. A Population-Based Cohort Study Suggests No Elevated Risk of Severe Joint Pain in Association with Dipeptidyl Peptidase-4 Inhibitors Use in Patients with Type 2 Diabetes [741] Wen-Hsuan Hou, Kai-Cheng Chang, Chung-Yi Li, Huang-Tz Ou. (Taiwan)

228. Changes in Health Parameters Over 12 Months in Users of Once Weekly Exenatide (Bydureon®) [742] Abigail Coughtrie, Deborah Layton, Qing Qiao, Saad Shakir.


Pharmacovigilance - Anti-infectives


234. A Prospective Observational Pharmacovigilance Study to Evaluate Incidence, Onset and Severity of Adverse Effects During Anti-Tubercular Therapy [748] Akhil Bharat Agrawal. (India)


Pharmacovigilance - Cancer


238. Study Update for a Postmarketing Case Series Study of Adult Osteosarcoma and Teriparadate in the US [752] Kirk D Midkiff, David H Harris, Alicia W Gilsenan, David J McCorley, Nicole A Kellner-Steele, Daniel N Masica, Elizabeth B Andrews. (United States)

239. Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre [753] Kayleigh J Mason, Mark Lunt, Nick J Reynolds, Darren M Ashcroft, A David Burden, Anthony D Ormerod, Jonathan NWN Barker, Catherine H Smith, Adele Green, Hassan Ali, Ian Evans, Shamilla Irshad, Kathleen McElhone, Victoria Wilde, Christopher EM Griffiths. (United Kingdom)

Pharmacovigilance - Cardiovascular

243. Evaluation of New Oral Anticoagulants (NOACs) Bleeding Adverse Reaction Reports in the FDA Adverse Events Reporting System (FAERS) [757]
Ahmed Fahmy, Mohamed Mekkawy, Adel Abou-Ali. (Egypt)

Thamir M Alshammarhi, Taqir M Alhawassi, Hisham S Aljadhey. (Saudi Arabia)

245. The Effect of Race, Age, and Sex on the Risk of Angioedema Among Heart Failure (HF) Patients Initiating Angiotensin Converting Enzyme Inhibitors (ACEIs) [759]
Thy P Do, Arpamas Seetasith, Raymond Schlienger, Rossella Belleli, Sigrid Behr. (Switzerland)

246. Abstract Withdrawn [760]

247. Signal Detection Using Temporal Pattern Discovery (TPD) in Electronic Health Records (EHRs) - Lessons from Statistics and Rhabdomyolysis [761]
Manfred Hauben, Qing Liu, Eric Hung, William Blackwell, David Fram, Andrew Bate. (United States)

248. The Impact of Age and Gender on Reporting of Cough and Angioedema with RAS Inhibitors: A Case/Non-Case in VigiBase [762]
Fawaz F Alharbi, Anzhelika AV Khodol, Patrick C Souverein, Ronald H Meyboom, Mark CH Groot, Anthonius de Boer, Olaf H Klungel. (Netherlands)

Pharmacovigilance - Pain and Neurological

250. Cardiovascular and Gastrointestinal Safety of Paracetamol in French Population: A Self-Controlled Cohort Study [764]
Mai Duong, Régis Lassalle, Cécile Droz, Nicholas Moore. (France)

251. Cardiovascular and Gastrointestinal Safety of OTC and Prescription-Only Ibuprofen versus Paracetamol in French Population [765]
Mai Duong, Régis Lassalle, Cécile Droz, Nicholas Moore. (France)

252. Cardiovascular and Gastrointestinal Safety of Non-Prescription NSAIDs versus Paracetamol in French Population [766]
Mai Duong, Régis Lassalle, Cécile Droz, Nicholas Moore. (France)

253. Gastrointestinal Toxicity Among Patients Taking Selective Cox-2 Inhibitors or Conventional NSAIDs Alone or Combined with Proton Pump Inhibitors: A Case Control Study [767]
Mohammad Bakhriransyah, Patrick C Souverein, Anthonius de Boer, Olaf H Klungel. (Netherlands)

254. Safety Of Non-Prescription NSAIDs [768]
Elina Pradhan, Lisa G Pont. (Australia)

255. Codeine Use in Children with Common Cold in Taiwan: Data from National Health Insurance Research Database (NHIRD) and National Adverse Drug Reaction (ADR) Reporting System [769]
Ching-Huan Wang, Chih-Wen Lin, Fei-Yuan Hsiao, Wei-I Huang, Wei-Ming Ke, Pi-Hui Chao, Wen-Wen Chen. (Taiwan)

256. Automating Opioid Overdose Surveillance Using Natural Language Processing [770]
Brian L Hazlehurst, Yannick Fortin, Harlen D Hays, Douglas S McNair, Lise M Bjørre, Dafna E Kohen, Santiago Perez-Lloret, Donald R Mattison, David Krewski. (Canada)

257. Associations Between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease [777]
James AG Crispo, Allison W Willis, Dylan P Thibault, Yannick Fortin, Harlen D Hays, Pauline Zeller, Angela DeVeaugh-Geiss, James AG Crispo, Allison W Willis, Dylan P Thibault. (France)

258. Social Media Mining to Investigate Multiple Sclerosis Treatment Patterns and Adverse Effects [772]
Selin Cooper, Radek Wasiak, Sreeram V Ramagopalan.

259. Lymphopenia in Multiple Sclerosis Patients Treated with Delayed-Release Dimethyl Fumarate: Analysis of 2 Electronic Health Record Databases in the US [773]
Made Wienten, Nicholas Everage, Teesta Somani, Cathy Lally, Maneesh Juneja, Susan Eaton, Claudia Prada, Anne Dilley. (United States)

260. Rapidly Increasing Atypical Antipsychotic Use in Middle Age Australians [774]
Debra S Rowett, Alicia Segrave, Maxine Robinson, Frances Wilson. (Australia)

261. Metabolic Syndrome Among Clients On Atypical Antipsychotics In Jos, Plateau State [775]
Rachel U Odesanya, Moses D Audo, Cioma D Nwazor. (Nigeria)

262. Safety of Brotizolam in Hospitalized Patients in Internal Medicine Departments [776]
Ophir Lavon, Shmuel Bejell. (Israel)

263. Associations Between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease [777]
James AG Crispo, Allison W Willis, Dylan P Thibault, Yannick Fortin, Harlen D Hays, Douglas S McNair, Lise M Bjørre, Dafna E Kohen, Santiago Perez-Lloret, Donald R Mattison, David Krewski. (Canada)

Pharmacovigilance - Other Therapeutic

264. Eosinophilic Pneumonia and NSAIDs: Contribution of Spontaneous Reports Database [778]
Aurelien Provost, Francois Krabansky, Pauline Zeller, Aurore Morel, Malak Abou Taam, Thierry Tremue. (France)

265. Abstract Withdrawn [779]

266. Varenicline and Risk of Self-Harm: A Nested Case-Control Study [780]
Mina Tadrous, Diana Martins, Zhan Yao, Muhammad M Mambani, David N Jurelink, Tara Gomes, Tony Antoniou, Debra S Rowett, Alicia Segrave, Maxine Robinson, Frances Wilson. (Australia)

267. Adverse Drug Reaction Monitoring at a Regional Pharmacovigilance Centre (B.P.K.I.H.S.) [781]
Gajendra Prasad Rauniar. (Nepal)

268. Daily Limit of Acetaminophen More Likely to Be Exceeded in Cold/Flu Season [782]
Saul Shiffman, Deena R Battista, Judith P Kelly, Mary K Malone, Rachel Weinstein, David W Kaufman. (United States)
<table>
<thead>
<tr>
<th>Poster Session B: Saturday, August 27</th>
<th>8:00am - 6:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>272. Abstract Withdrawn [786]</td>
<td></td>
</tr>
<tr>
<td>274. Use of Sildenafil or Other Phosphodiesterase Inhibitors and Risk of Melanoma [788] Anton Pottegård, Sigrun AJ Schmidt, Anne B Olesen, Ninah Achacoso, Stephen K Van Den Eeden, Jesper Hallas, Henrik T Sørensen, Søren Friis, Laurel A Habel. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>275. Androgen-Deprivation Therapy and Cardiovascular Risk (ADTCR): A Nationwide Population-Based Cohort Study [789] Lucie-Marie Scailteux, Sébastien Vincendeau, Emmanuel Nowak, André Happe, Frédéric Balusson, Christophe Leclerc, Elisabeth Polard, Emmanuel Oger. (France)</td>
<td></td>
</tr>
<tr>
<td>276. Liver Enzyme Elevations Associated With Two-Month Rifampicin, Isoniazid, Pyrazinamide, And Ethambutol Anti-Tubercular Therapy In Indonesia [790] Waqqas Hanafi, Ully A Mulyani, Dyah Perwitasari, Jarir Atthobari. (Indonesia)</td>
<td></td>
</tr>
<tr>
<td>Other Safety &amp; Effectiveness</td>
<td></td>
</tr>
<tr>
<td>279. Proton-Pump Inhibitor Induced Risk of Liver Cancer: A Nested Case-Control Study [1029] Yu-Hsuan Joni Shao, Kitaw Demissie, Szu-Yuan Wu. (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>End Session B</td>
<td></td>
</tr>
</tbody>
</table>
Spotlight Session-Vaccines

A. Autoimmune Disorders Following HPV Vaccination in Young Women: Is the Risk Real? [869]
   Lamiae Grimaldi-Bensouda, Michel Rossignol, Fatihah Karam, Thomas Popo, Patrick Vermersh, Isabelle Bourgault, Roger Dachez, Gerard Breal, Lucien Abenhaim. (United Kingdom)

B. Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review [870]
   Joao F Gruber, Lucinda M Gruber, Rachel Palmiери Weber, Sylvia Becker-Dreps, Michele Jonsson Funk. (United States)

C. Cluster Analysis of HPV Vaccine Reports in a Global Database of Suspected Adverse Events [871]
   Rebecca E Chandler, Jonas Fransson, Kristina Juhlin, Ola Caster, I Ralph Edwards, G Niklas Norén. (Sweden)

D. Safety of TDaP Vaccination in Pregnancy [872]
   J Bradley Layton, Anne M Butler, Dongmei Li, Kim A Boggess, Sylvia Becker-Dreps. (United States)

E. Methodological Approaches to Enhanced Safety Surveillance for Seasonal Flu Vaccines: Early Experience in the UK [873]
   Lorna Hazell, Saad AW Shaker, Andrew Finlay, Hannah Coulter, Robert S Brody, Robert P Wise. (United Kingdom)

F. Passive Enhanced Safety Surveillance In Children Receiving Fluvar® Tetra Vaccination In England During The Early 2015/2016 Influenza Season [874]
   Lorna Hazell, Saad AW Shaker, Andrew Finlay, Hannah Coulter, Robert S Brody, Robert P Wise. (United Kingdom)

Spotlight Session-Biologics

M. Inclusion of Elderly Patients in Randomized Controlled Trials on Targeted Agents in the Treatment of Metastatic Colorectal Cancer: A Systematic Review [881]
   Amandine Gouverneur, Francesco Salvo, Driss Berdai, Annie Fourrier-Réglat, Perline Nozé. (France)

N. The Long-Term Use of Biologics in Hong Kong [882]
   Kenneth KC Man, Shirley X Li, Esther W Chan, Ian KC Wong. (China)

O. Assessment of Biosimilar Somatropin Use in Italian Routine Care: A 6-Year, Multicenter, Retrospective Study Using a Database Network [883]

P. Determining the Optimal Position For Vedolizumab In Telia Current Treatment Paradigm For Ulcerative Colitis: A Markov Model [888]
   Frank I Scott, Yash Shah, Karen Lasch, Michelle Luo, James D Lewis. (United States)

Q. Real-World Comparative Risks of Omalizumab for the Treatment of Severe Asthma [887]
   Mina Tadrous, Kimberly Fernandes, Wayne Khuu, Gerald Lebovic, Matthew Stanbrook, Diana Martins, J Michael Paterson, Muhammad M Mamdani, David N Juurlink, Tara Gomes. (Canada)

Biologics

1. Risk of Serious Infections During Use of Biologic Therapies for Psoriasis: A Systematic Review [889]
   Zenas ZN Yiu, Lesley S Exton, Zarif Jabbar-Lopez, M Firouz Mohd Mustapa, Eleanor Samarasekera, David Burden, Ruth Murphy, Caroline M Owen, Richard Parslew, Vanessa Venning, Darren M Ashcroft, Christopher EM Griffiths, Catherine H Smith, Richard B Warren. (United Kingdom)

2. Quality of Life Outcomes of a 12-Month Follow-Up Brazilian Cohort of Patients with Rheumatic Diseases Using Biological Agents [890]
   Haltion Alves de Oliveira Junior, Jéssica Barreto dos Santos, Bruna Assis Viana, Francisco Assis Accurio, Alessandra Maciel Almeida, Juliana Alves, Mariangela Leal Cherchiglia. (Brazil)

3. Identifying Anti-TNF Use for Crohn’s Disease and Ulcerative Colitis in Primary Care [891]
   Andrew Maguire, Jorge Puellés. (United Kingdom)

4. Incidence of Bowel Surgery in a Cohort of Crohn’s Disease Patients Treated with Infliximab or Adalimumab in Lazio, Italy [892]
   Riccardo Di Domeniconi, Nera Agabiti, Silvia Cascini, Francesco Trotta, Antonio Addis, Anna Kohn, Marina Davoli. (Italy)

5. Top-Down versus Step-Up Strategy of Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease [893]
   Wan-Ju Lee, Leslie Briars, Todd A Lee, Gregory S Calip, Katie J Suda, Glen T Schumock. (United States)

6. Effectiveness and Safety of Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer According to Frailty in the EREBUS Study [894]
   Amandine Gouverneur, Juliette Coutureau, Magali Rouyer, Denis Smith, Eric Francois, Alain Monneresse, Aurélie Balestra, Jérémie Jové, Régis Lassalle, Nicholas Moore, Annie Fourrier-Réglat, Perline Nozé. (France)

7. Tracking Trastuzumab (H) Therapy in Early Through Late Stage HER2-Positive Breast Cancer (HER2BC) in Australia: A National, Retrospective Cohort Study [895]
   Benjamin Daniels, Sallie-Anne Pearson. (Australia)
8. Risk of Type 1 Diabetes Mellitus Associated with Vaccination During Childhood and Adolescence [896]

   Anu Jain, Albert Jan van Hoek, Sara L Thomas. (United Kingdom)

10. Is Mortality Associated with Combination DTPa Vaccines? A Linkage Study Among Australian Children Using 12 Years of Data [898]
    Katherine M Duszynski, Nicole M Pratt, John W Lynch, Michael S Gold. (Australia)


12. Measles, Mumps, and Rubella (MMR) Vaccines Differ Considerably with Regards to Immediate Injection Pain: A Systematic Literature Review [900]
    Corinne Willame, Ouzama Henry, Laurence Barili. (Belgium)

13. Increased Incidence of Narcolepsy After the 2009 H1N1 Pandemic and Vaccination Campaign in Taiwan [901]
    Wan-Ting Huang, Hsin-Chun Lee, Hui-Chen Lin, Chin-Hui Yang. (Taiwan)

14. Comparison Of Different Collection Methods For Reported Adverse Events Following Pandemic And Seasonal Influenza Vaccination [902]
    Jeanet Kemmeren, Maaike Hansbeek, Frederika Dijkstra, Marit de Lange, Nicole van der Maas, Ronald Smallenburg, Carl Koppenschaar, Wim van der Koek, Ingegärd A Berglind, Daniel Dedman, James A Kaye, Carolina Pardo, Kenneth J Rothman, Susana Perez-Gutthann. (Sweden)

15. Comparison Of The Tolerability Of Newly Introduced Childhood Vaccines In The Netherlands [903]
    Jeanet Kemmeren, Nicole van der Maas, Hester de Melker. (Netherlands)

16. Disease and Exposure Misclassification in Studies of Vaccine Effectiveness: A Simulation Tool [904]
    Elizabeth Merrill, Denis Macina, Silvia Perez-Vilar, Silvia Perez-Vilar, Kaat Bollaerts. (Netherlands)

17. Systematic Review and Quantitative Synthesis of Evidence to Support Regulatory Review of Oncaspar for Treatment of Acute Lymphoblastic Leukemia (ALL) [905]
    Ryan D Kilpatrick, Michael D Hale, Cristina Ivanescu, Montserrat Casamanyor, Claudia Lebedinsky. (United States)

18. Treatment Regimens and Duration of Lines of Therapy in Medicare-Enrolled Patients with Multiple Myeloma [906]
    Akeem A Yusuf, Tanya Natwick, Diana Felici, Winifred Werther. (United States)

19. Transitions Across Different Lines of Therapy in Medicare-Enrolled Patient Populations with Multiple Myeloma [907]
    Akeem A Yusuf, Tanya Natwick, Diana Felici, Winifred Werther. (United States)

20. Risk of Skin Cancer in Users of Topical Tacrolimus, Pimecrolimus and Corticosteroids. JOint European Longitudinal and Skin Cancer Evaluation (JOELLE) Study [908]

21. Phosphodiesterase Type 5 Inhibitors And Risk Of Malignant Melanoma: Matched Cohort Study Using Primary Care Data From The UK Clinical Practice Research Datalink [909]
    Anthony Matthews, Sinead M Langan, Ian Douglas, Liam Smeeth, Krishnan Bhaskaran. (United Kingdom)

22. ‘Real World’ Ipilimumab Survival Data in Ireland [910]
    Laura McCullagh, Susanne Schmitz, Roisin Adams, Michael Barry, Cathal Walsh. (Ireland)

23. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis [911]
    Geetha Iyer, G Caleb Alexander, Eleanor Lucas, Dora Lin, Sonal Singh. (United States)

    Oluwadamilola Onasanya, Geetha Iyer, Eleanor Lucas, Sonal Singh, G Caleb Alexander. (United States)

25. Risk of Gynecomastia with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia [913]
    Katrina Wilcox Hagberg, Hozefa A Divan, J Curtis Nickel, Shona Fang, Susan S Jick. (United States)

26. Population-Based Comparison of the Risks of Serious Adverse Events from Intermittent versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer Patients [914]
    Huei-Ting Tsai, Ruth Pfeiffer, George Philips, Ana Barac, Alex Z Fu, Grace Y Zhou, Arnold Potosky.

27. Oral Contraceptives and VTE Across the Sentinel Data Network – An IMEDS Evaluation Pilot Assessment [915]
    Andrew Bate, Rachel E Sobel, Jim Marshall, Greg Daniel, Troy McCall, Robert F Meadows, Jeff Brown. (United States)

28. Testosterone Replacement Therapy (TRT) and Risk of Acute Myocardial Infarction (AMI): An Administrative Healthcare Claims Study [916]
    Hu Li, Xiang Zhang, Lucy Mitchell, Darel Heiselman, Stephen Motsko.

29. Effects of Supplemental Intravenous Agents to Mitigate Peri-Operative Complications Arising from Inhaled Anesthetics [917]
    Kyle P Paredes, Aaron WC Kamauu, Rebekah K Paredes, Andrew Wilson. (United States)

30. Elevated Bladder and Prostate Cancer Rates Following Initiation of OAB Medication: Findings from a Danish Registry [918]
    Jesper Hallas, Andrea Margulis, Anton Pottegård, James A Kaye, Nina Kristiansen, Christine L Bui, Willem Jan Atsma, Kware Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Arana. (Denmark)

31. Cancer Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers [919]
    Marie Linder, Andrea V Margulis, Ingegärd Arveden-Berglind, Shahram Bahmanyar, Christine L Bui, Willem Jan Atsma, Kware Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Susana Perez-Gutthann, Alejandro Arana. (Sweden)
32. Do Individual Antimuscarinic Drugs to Treat Overactive Bladder Have Different Cardiovascular Risks? A UK CPRD Cohort Study [920]
Alejandro Arana, Cristina Varas-Lorenzo, Lisa J McQuay, Ryan Ziemiecki, Christine L Bui, Alicia W Gilsenan, Kenneth J Rothman, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milbhor D’Silva, Andrea V Margulis, Susana Perez-Guthmann. (Spain)

33. Abstract Withdrawn [921]

34. Risk of Major Adverse Cardiovascular Events Associated with Biologic Therapies in Patients with Plaque Psoriasis: Systematic Review and Meta-Analysis of Randomised Controlled Trials [922]
Watcharee Rungapiriyom, Richard B Warren, Zenas NZ Yu, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)

35. Development of a Prospective, Non-Interventional, Longitudinal, Multicenter Registry Study of Patients Initiating a N [923]
Rita Kristy, Kevin V Carlson, Anna S Deal, Kavita V Nair, Eric S Rovner, Eric Gemmen, Eva E Oakkar, Julie Park, Priscilla Velentgas, Pamela Bradt, Katherine Gooch, Carol Schermer. (United States)

36. Risk of Urinary Adverse Events Associated with Inhaled Anticholinergics in Adult Men [924]
Scott M Vouri, Seth A Strope, Jiajing Chen, Margaret A Olsen. (United States)

37. Survival In Kidney Transplantation In Patients Who Used Cyclosporine Or Tacrolimus [925]
Rosangela Maria Gomes, Augusto Afonso Guerra Júnior, Livia Lovato Pires Lemos, Wallace Breno Barbosa, Francisco Assis Acurcio. (Brazil)

Safety & Effectiveness - Musculo-Skeletal

38. Risk of Venous Thromboembolism Amongst Users of Different Anti-Osteoporosis Drugs: A Multinational Population-Based Cohort Study [926]
Elisa Martin-Merino, Irene Petersen, Samuel Hawley, Arturo Álvarez-Gutierrez, Antonella Delmestri, Ana Llorente-García, Samual Hawley, Arturo Álvarez-Gutierrez, Elisa Martin-Merino, Irene Petersen, Judith van Dalem, Martijn Buijs, Coen Stehouwer, André Klings, Hubert Leufkens, Johanna Driessen, Frank de Vries, Andrea Burden. (Netherlands)

39. Preadmission Use of Prescription Drugs and Risk of Red Blood Cell Transfusion in Elderly Patients Undergoing Hip Fracture Surgery [927]
Alma B Pedersen, Deirdre Cronin-Fenton, Nickolaj R Kristensen, Mette Nørgaard. (Denmark)

40. Fracture-Preventing Benefit of Bisphosphonates by Compliance and Its Timing Following Therapy Start: A Register-Based Study of Postmenopausal Women in Sweden [928]
Anna Westerlund, David Hägg, Tobias Svensson, Fredrik Granath, Helle Kieler. (Sweden)

Safety & Effectiveness - Alimentary Tract and Metabolic

41. Clinical Effectiveness and Safety of Analogue Glargine in Type 1 Diabetes: Systematic Review and Meta-Analysis [929]
Lays Marra, Brian Godman, Vania Araujo, Augusto guerra Junior, Francisco Acurcio, Leonardo Diniz, Juliana Alvarez. (Sweden)

42. Incretin-Based Treatments and the Risk of Pancreatic Cancer in Patients with Type 2 Diabetes [930]
Guillaume Avenin, Marion Bertrand, Celine Druet, Isabelle Yoldjan, Mahmoud Zureick, Rosemary Dray-Spira. (France)

43. The Association of Metformin Exposure and Specific Types of Digestive Cancers Among Diabetic Patients: Real-World Findings from a US EMR Database [931]
William K Mountford, Elise Kaufman, Alexandra Portelli, Caitlin A Knox. (United States)

44. Cardiovascular Risks Associated with Dipeptidyl-Peptidase 4 Inhibitor Compared to Other Diabetes Drugs: A Cohort Study [932]
Maki Komamine, Chiako Ishiguro, Yoshinori Takeuchi, Yoshiaki Uyama. (Japan)

45. Evaluation of Three HbA1c Metrics in Relation to Heart Failure in 94,332 UK Type 2 Diabetes Mellitus Subjects [933]
Claudia Cabrera, Stanko Skrtic, Marita Olsson, Volker Schnecke, Marcus Lind. (Sweden)

46. Pharmacoepidemiological Profiles of Glucose-Lowering Drug Use in Patients with Diabetes and Its Impact on Mortality from All-Cause and Cardiovascular Disease in the U.S. Adults [934]
Longjian Liu, Jinggaofu Shi, Barbara Simon, Howard J Eisen. (United States)

47. Bile Duct and Gallbladder Diseases and the Use of Incretin-Based Drugs in Patients with Type 2 Diabetes [935]
Jean-Luc Faillie, Oriana H Yu, Hui Yin, Dominique Hillaire-Buys, Alan Barkun, Laurent Azoulay. (France)

48. Metformin and Other Glucose-Lowering Drug Initiation and Rates of Community-Based Antibiotic Use and Hospital-Treated Infections in Patients with Type 2 Diabetes: A Danish Nationwide Population-Based Cohort Study [936]
Reimar Wernich Thomsen, Anil Mor, Irene Petersen, Henrik Toft Sorensen. (Denmark)

49. Treatment Discontinuation And Rates Of Hypoglycaemia In Type 2 Diabetes Patients Treated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors or NPH Insulin In Third-Line Therapy [937]
Cristiano S Moura, Sasha Bernatsky, Michal Abramowicz, Hassan Behlouli, Louise Pilote. (Canada)

50. Risk of Hypoglycemia in Users of Sulphonylureas with Renal Impairment: A Population-Based Cohort Study [938]
Judith van Dalem, Martijn Brouwers, Coen Stehouwer, André Klings, Hubert Leufkens, Johanna Driessen, Frank de Vries, Andrea Burden. (Netherlands)

51. Adjusting for the Effect of Switching Basal Insulin Treatment on the Risk of First Severe Hypoglycaemia [939]
Housssem Khanfar, Pas, Korhonen, Sari Mäkipäätä, Fabian Hoti. (Finland)

52. Cancer Risk Among Insulin Users: Comparing Analogues with Human Insulin in the CARING Five-Country Registry Study [940]
Anna But, Marie L De Bruin, Marloes T Bazelier, Vidar Hjellvik, Morten Andersen, Anssi Auvinen, Jakob Starup-Linde, Marjanka K Schmidt, Kari Furu, Frank de Vries, Øystein Karlstad, Nils Ekström, Jari Haukka. (Finland)

53. Comparative Effectiveness of Glinides vs. Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients [941]
Julien Bez, Yohann Mansiaux, Jérémy Jove, Mickael Arnaud, Régis Lassalle, Francesco Salvo, Antoine Pariente. (France)

54. Association Between Type 2 Diabetes Mellitus and Cancer – a Methodological Approach [942]
Jette A Overbeek, Amber AWA van der Heijden, Ron MC Herings, Giel Nijpels. (Netherlands)

55. Association of Type 2 Diabetes And Glucose-Lowering Drugs With Risk Of Recurrence Or Death Following Breast Cancer: A Population-Based Cohort Study [943]
Deirdre Cronin-Fenton, Uffe Heide-Jørgensen, Reimar W Thomsen, Marianne Ewertz, Henrik T Sørensen. (Denmark)
56. Safety and Efficacy of Sofosbuvir with Simeprevir with or without Ribavirin for Hepatitis C Genotype 1 with Severe Renal Impairment: A Meta-Analysis of Cohort Studies [944]
Ruchi Singhal, Pramill Tiwari, Ajay Duseja, Rajiv Ahlawat. (India)

57. Metabolic Syndrome Associated to Antiretroviral Therapy: A Cross-Sectional Analysis [945]
Debora C Hilario, Letícia P Braga, Cassia CP Mendicino, Andreia Q Ribeiro, Cristiane A Menezes de Padua. (Brazil)

Safety & Effectiveness - Anti-infectives

58. Analysis of Regimen Changes Due to Adverse Drug Reactions Associated with Antiretroviral Therapy in HIV Patients [946]
Sareeya Wechwithan. (Thailand)

59. Real-World Effectiveness of HCV Infection from an Irish National HCV Registry [947]
Emma Gray, Aisling O’Leary, Suzanne Norris.

60. The Association Between the Use of Oral Fluoroquinolones and Neuropsychiatric Events: A Self-Controlled Case Series Study [948]
Celine SL Chui, Ian CK Wong, Angel YS Wong, Edwin HM Lee, WC Chang, Eric YH Chen, Esther W Chan. John Snow Award Recipient

61. Incidence of Myelosuppression in Patients with Longer-Term Exposure to Linozole in an Outpatient Claims Database [949]
Vinay Mehta, Thomas Rhodes, Michael Senderak, Carisa De Anda, Chris YH Chen, Esther W Chan.

62. Intravenous Vancomycin and the Risk of Clostridium difficile Infection [950]
Vanessa W Stevens, Karim Khader, Kevin A Brown, Richard E Nelson, Molly Leeceaster, William Ray, Damon Toth, Michael A Rubin. (United States)

63. Clarithromycin Resistance to Helicobacter Pylori: A Prospective Insight from Malaysia [951]
Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari. (Malaysia)

64. Antibiotics and Infection/Colonization by Carbapenem Non-Sensitive P. aeruginosa: A Nested Case-Control Study [952]
Maider Coppy, Camille Jeanne-Leroyer, Marion Saly, Fernelle Noize, Catherine Dumartin, Romuald Riem, Alexandre Boyer, Veronique Dubois, Anne-Marie Rogues. (France)

65. Drug Interactions as a Potential Instrumental Variable: The Example of Effectiveness of Antibiotic Therapy in Exacerbated COPD Patients [953]
Yuanyuan Wang, Anouk JM Jansen, Jens Bos, Eelko Hak. (Netherlands)

66. Clinical Outcome Difference Of The Patient Treated With Generic Piperacillin-Tazobactam And Innovator In Severely Infectious Patients In Medical Intensive Care Units [954]
Chiu-Ju Chen, Tzu-Ayo Chang, Haw-Chyun Lee, Yu-Chin Lily Wang, Wen-Feng Fang, Ching-Ling Tai. (Taiwan)

67. Effectiveness of Adalimumab and Etanercept for the Treatment of Rheumatoid Arthritis in the Public Health System (SUS) Belo Horizonte, Minas Gerais, Brazil [955]
Jéssica B dos Santos, Brian B Godman, Alessandra M Almeida, Francisco de A Acucio, Adriana M Kakehas, Haliton A de Oliveira Junior, Augusto A Guerra Junior, Marion Bennie, Juliana Alvarez. (Sweden)

68. The Associations Between Bulbous Pemphigoid and Drug Use: A Prescription Sequence Symmetry Analysis [956]
Chao-Kai Huo, Edward Chia-Cheng Lai, Chien-Huei Huang, Yea-Huei Kao Yang, Chin-Lan Cheng. (Taiwan)

69. Safety and Efficacy/Effectiveness of 2nd-Line Treatments in Immune Thrombocytopenia (ITP): A Systematic Review of the Literature [957]
Karynsa Cetin, Fiona Callaghan, Jon P Fryzek, Lauren C Bylsma, Carla Bezold, Bhakti Mehta. (United States)

70. Patient Characteristics and Overall Survival (OS) in the Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) Community Setting [958]
Wendy Y Cheng, Raymond Miao, Mei Sheng Duh, Francis Yekeman, Jennifer Sung, Marjolaine Gautier-Loiselle, Jonathan Fortier, Ravinder Dhawan, William K Oh. (United States)

71. Abstract Withdrawn [959]

Safety & Effectiveness - Cardiovascular

72. The Quality of Warfarin Therapy Among Atrial Fibrillation Patients in Finland - Results from the FinWAF Registry [960]
Juha Mehtälä, Pekka Raatikainen, Riitta Lassila, Houssem Khanfir, Pasi Korhonen, Fabian Hoti, Mikael Lehto. (Finland)

73. Antiplatelet and Anticoagulant Prescriptions and Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study [961]
Simon R Sørensen, Thomas P Ahern, Rikke N Pedersen, Peer Christiansen, Bent Ejertsen, Henrik T Sørensen, Deirdre P Cronin-Fenton. (Denmark)

74. Safety And Efficacy Of New Oral Anticoagulants, And Low Molecular Weight Heparins Compared To Aspirin Associated With Total Knee And Hip Replacement [962]
Johannes TH Nielen, Pieter C Dagnelie, Frank de Vries, Pieter Emans, Nicole Veldhorst-Janssen, Ariel Lalmohamed, Tjeerd-Pieter van Staa, Bart van den Bermt, Annelies Boonen. (Netherlands)

75. Outcomes Associated With Non-Adherence To Anti-Hypertensives And Statins [963]
Kathleen Bennett, Mary Connolly, Pedro Okuh, Cahtiona Cahier, MaryJo MacAvin, Mary Teeling. (Ireland)

76. De-Novo Post-Diagnosis Statin Use And Mortality In Women With Stage I-III Breast Cancer [964]
Amelia Smith, Laura Murphy, Linda Sharp, Darran O’Connor, William Gallagher, Kathleen Bennett, Ian Barron. (Ireland)

77. The Association Between Statin Use and Risk of Cancer Among Elderly Medicare Beneficiaries [965]
Jing Yuan, Kevin Z Lu. (United States)

78. Beta Blockers and Cancer Prognosis – the Role of Immortal Time Bias: A Comprehensive Systematic Review and Meta-Analysis [966]
Janick Weberpals, Lina Jansen, Prudence Carr, Michael Hoffmeister, Hermann Brenner. (Germany)

79. Protection Against Colorectal Cancer with Use of Low-Dose Aspirin: Selection Bias Is Unlikely Based on Results Using Three Different Study Designs [967]
Lucia Cea Soriano, Montse Soriano-Gabarró, Luis A García Rodriguez. (Spain)

80. New Use of Statins and the Risk of Achilles or Biceps Tendon Rupture: A Propensity-Score Matched Cohort Study [968]
Julia Spoendlin, J Bradley Layton, Mallika Mundkur, Christian Meier, Susan S Jick, Christoph R Meier.

81. Impact of Treatment with Lipid-Lowering Drugs on Longitudinal and Secular Decrease in Total Cholesterol Levels. The Tromsø Study 1979-2008 [969]
Laila A Hoppstock, Kaare H Bonaa, Anne E Eggen, Sameline Grimsaard, Bjørne K Jacobsen, Maja-Lisa Lochen, Ellisiv B Mathiesen, Inger Njølstad, Tom Wilsgaard. (Norway)
POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

82. Fertility Treatment and the Risk of Cardiovascular Diseases in the Offspring [970]
Annefleur MC Bakker, Eelko Hak, Jens HJ Bos, Catharina CM Schuling-Veninga. (Netherlands)

83. Effectiveness of Ezetimibe on Blood Lipids in Real-Life Clinical Practice [971]
Jean Ferrière, Jean Dallongeville, Lucian Abenhaim, Michel Rossignol, Lamiae Grimaldi-Bensouda. (United Kingdom)

84. Clinical Characteristics, Lipid Treatment and Goal Attainment in a Familial Hypercholesterolemia Cohort in the Netherlands: A Cross Sectional Study [972]
Josephina G Kuiper, Edith H Heintjes, Eline Houben, Femke JA Penning-van Beest, Ron MC Herings. (Netherlands)

85. Modelling Of Average Endpoint Postponement For Cardiovascular Outcomes In Statin Trials [973]
Morten Rix Hansen, Anton Pottegård, Asbjørn Hrøbjartsson, P. G Dampier, René DePonte Christensen, Morten Olsen, Jesper Hallas. (Denmark)

86. Blood Pressure-Lowering Effect of Spironolactone in Hypertensive Patients Without Heart Failure [974]
Michael D Murray, Wanzhu Tu, Shanshan Li, Qing Tang, Anna R Roberts, Julie N Kippenbrock, Rachel E Hasty, Sarah A Lynch, Sarah A Hoover, Howard Pratt. (United States)

87. Effectiveness of Ticagrelor Compared to Clopidogrel in Reducing the Risk of Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease After Percutaneous Coronary Intervention [975]
Hendra Wana Nur’amin, Iwan Hendra, Hendra dh Setiady, Hendra Wana Nur’malin, Iwan Hendra, Hendra Wana Nur’am. (Indonesia)

88. The Comparative Effectiveness of 4th Line Anti-Hypertensive Agents in Patients with Resistant Hypertension: A Meta-Analysis [976]
Sarah-Jo Sinnott, Adrian Root, Rohini Mathur, Kathyn Mansfield, Laurie Tomlinson, Ian J Douglas. (United Kingdom)

89. New Statin Use And Left Ventricular Structure: Estimating Long-Term Associations In The Multi-Ethnic Study of Atherosclerosis (MESA) [977]
Lauren N Strand, Rebekah L Young, Joseph A Delaney, Alain G Bertoni, David A Bluemke, Gregory L Burke, Joao A Lima, Nona Sotodehnia, Bruce M Psaty, Susan R Heckbert, Robyn L McClelland. (United States)

90. Effectiveness Of Preventing Stroke Between Different Rhythm Control Agents For Atrial Fibrillation: Retrospective Cohort Study From A Nationwide And Single-Center Database [978]
Yu-Wen Wang, Po-Yu Chen, Mu-Mei Hu, Jui Wang, Kuo-Liong Chien, Fe-Lin Lin Wu, Zhen-Fang Lin. (Taiwan)

91. The Impact of Comorbidity with Heart Failure on Treatments and Outcomes in Patients with Acute Coronary Syndrome [979]
Yi-Jung Wu, Jui Wang, Kuo-Liong Chien, Zhen-Fang Lin. (Taiwan)

92. Population-Based Effectiveness and Safety of Different Antiplatelet Regimens as Secondary Prevention for Ischemic Stroke/Transient Ischemic Attack [980]
Ali Yasmina, Anthonius de Boer, Vera HM Deneer, Jurrien M ten Berg, Patrick C Souverein, Olaf H Klungel. (Netherlands)

93. Age-Stratified Outcome Of Genotype-Guided Dosing Algorithm For Acenocoumarol And Phenprocoumon [981]
Yumao Zhang, Anthonius de Boer, Talitha I Verhoef, Felix JM van der Meer, Saskia Le Cessie, Vangelia G Manolopoulos, Anke H Maitland-van der Zee. (Netherlands)

94. Incidence of Intracranial Bleeds in New Users and Non-Users of Low-Dose Aspirin in the UK [982]
Lucia Cea Soriano, David Gaist, Montse Soriano-Gabarró, Luis A García Rodríguez. (Spain)

95. An Evaluation of the Effect of Spironolactone on the Risk of New Onset of Diabetes in a Population-Based Study of Patients with Heart Failure [983]
Simon de Denus, Sandra Korol, Michelle White, Eileen O’Meara, Rouleau Jean-Lucien, Dorais Marc, Sylvie Perreault. (Canada)

Manal H Ziadeh, Mehmet Burcu, Elisabeth M Oehrlein, Eleanor M Peretto. (United Kingdom)

97. Rivaroxaban vs. Phenprocoumon Use in Germany and Risk of Bleeding: A Claims Data Analysis Based on 80,000 Patients [985]
Alexander Fassmer, Kathrin Jobski, Ulrike Haug, Tania Verhoef, Felix JM van der Meer, Saskia Le Cessie, Vangelia G Manolopoulos, Anke H Maitland-van der Zee. (Netherlands)

98. Outcomes of Intravenous Corticosteroids in Patients Undergoing Coronary Artery Bypass Grafting Surgery [987]
Macarius M Donneynong, Pauline Levy-Bosco, Joshua J Gagne. (United States)

99. The Impact of Comorbidity and Age on Treatments for Acute Coronary Syndrome [988]
Wei Ho, Jui Wang, Kuo-Liong Chien, Fe-Lin Lin Wu, Zhen-Fang Lin. (Taiwan)

100. Health-Related Quality of Life and Burden of Disease in Patients Suffering from an Acute Coronary Syndrome: Evidences from the Use of Validated Instruments in the PGRx-3 Real World Dataset [989]
Jesus Cuenca, Clementine Nordon, Michel Rossignol, Nicolas Morisot, Jacques Benichou, Nicolas Danchin, Lucien Abenhaim, Lamiae Grimaldi. (Spain)

101. Switching of Angiotensin Receptor Blockers to Angiotensin-Converting Enzyme Inhibitors in Patients with Hypertension: Is It a Cost-Saving Strategy? [990]
Amanj Baker, Li-Chia Chen, Rachel Elliott. (United States)

102. Characteristics of Different Antihypertensive Medication Users in Observational Comparative Effectiveness Studies: A Literature Review [991]
M Sanni Ali, Rolf HH Groenwold, Mikkel Z Ankarfeldt, Erpur Adalsteinsson, Cynthia J Girman, Olaf H Klungel. (Netherlands)

103. Severe Adverse Events and Treatment Discontinuation Among Older Adults Taking Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARB) Following Acute Myocardial Infarction (AMI) [992]
Gang Fang, Izabela E Annis, Nina V Prakash, Tiili Stürmer, Noel Farley, Jennifer G Robinson. (United States)

104. Taking Angiotensin-Converting Enzyme Inhibitors in Patients with Chronic Kidney Disease: Is It a Cost-Saving Strategy? [993]
M Sanni Ali, Rolf HH Groenwold, Mikkel Z Ankarfeldt, Erpur Adalsteinsson, Cynthia J Girman, Olaf H Klungel. (Netherlands)

105. Cholinesterase inhibitors and Risk of Adverse Cardiac Events: Synergic Effects of Cardioselective Drugs in Dementia Patients [994]
Soko Setoguchi, Isaac Iwata, Monera Jia Jia, Reena Hsiang, Yea-Huei Kao Yang, Edward Lai. (United States)

106. Medication Therapy Modifies the Association Between Longitudinal eGFR and Cardiovascular Events Among Adults with CKD [995]
H Lester Kirchner, Sharon Larson, Robert Perkins. (United States)
POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

Safety & Effectiveness - Neurological

107. Risk Of First Hip Fracture Associated With Incident Benzodiazepine And Related Drug Use In Persons With And Without Alzheimer’s Disease [995]
   Laura Saarelainen, Marjaana Koponen, Antti Tanskanen, Anna-Maija Tolppanen, Reijo Sund, Jari Tiihonen, Sirpa Hartikainen, Heidi Taipale. (Finland)

108. Association Between Exposure to Benzodiazepines and Related Drugs and Total Hip Replacement Survivorship in Arthritis: A Population-Based Cohort Study of 246 940 Patients [996]
   Dan Beziz, Sandrine Colas, Cédric Collin, Rosemary Dray-Spira, Mahmoud Zureik. (France)

   David F Niedrig, Lisa Hoppe, Sarah Maechler, Heike Russmann, Stefan Russmann. (Switzerland)

110. Effectiveness and Safety of Smoking Cessation Pharmacotherapy: A Retrospective Cohort Study [998]
   Greg A Carney, Malcolm Maclure, Suzanne M Taylor, Ken Bassett, Colin Dormuth. (Canada)

111. Association Between Buprenorphine/Naloxone Sublingual Tablet And All-Cause Mortality In Patients Receiving Medication Assisted Treatment For Opioid Addiction In UK [999]
   Jinghua He, Sabine M Apelt. (United States)

112. Hypnotic Drug Use and Cardiovascular Events in Treated Hypertensive Patients [1000]
   Kaori Nomura, Yasunari Mano, Mariko Asahi, Shunya Ikeda. (Japan)

113. First-Line Disease Modifying Therapies in Preventing Multiple Sclerosis Relapse – A Nationwide Observational Study in Taiwan [1001]
   Chih-Ho Chou, Tzu-Chieh Lin, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

114. Comparison of the Effectiveness of Duloxetine versus Pregabalin/Gabapentin for Treatment of Diabetic Peripheral Neuropathy [1002]
   CR Shabana, Shamlin M Commen, Sherin John Varghese, PS Sabin, K Geetha. (India)

115. Comparative Safety of Long-Acting Opioids for Non-Cancer Pain [1003]

   Ghaleb Saud Alharbi, Li-Chia Chen, Roger Knaggs.

117. Impact of Pre-Admission Opioid Treatment on One-Year Mortality After Non-Surgical Intensive Care Admission [1005]
   Troels Munch, Christian F Christiansen, Lars Pedersen, Henrik T Sørensen. (Denmark)

118. Is Use of Antiepileptic Drugs Associated with an Increased Cataract Risk? A Case-Control Analysis [1006]
   Claudia Becker, Susan S Jick, Christoph R Meier.

119. Estimating the Association of Adverse Health Outcomes Using Three Anticholinergic Medication Toxicity Scales [1007]
   Kadia Hannah, Heather Anderson, Dong Xu, Robert Valuck. (United States)

120. Psychiatric Medication and School Performance in Primary School Children: An Explorative Study [1008]
   Jurjen van der Schans, Selvike Vardar, Rukyi Cicek, Jens HJ Bos, Pieter J Hoekstra, Tjalling W de Vries, Eelko Hak. (Netherlands)

121. Risk of Parkinson’s Disease In The Users Of Antihypertensive Agents: An Evidence From The Meta-Analysis Observational Studies [1009]
   Amarnath Mullapudi, Dipika Bansal, Kapil Gudala, Chandra sehkar Boya. (India)

122. Risk of Mortality in Patients with Parkinson’S Disease Exposed to Domperidone [1010]
   Judith van Dalem, Andrea Burden, Sander Pouveels, Frank de Vries. (Netherlands)

123. Outcomes of Three Treatment Strategies in Bipolar Disorder Using Conventional Mood Stabilizers and Antipsychotic Drugs [1011]
   Marie Tournier, Anke Neumann, Elodie Pambrun, Alain Weill, Jean-Philippe Chaffiol, François Alla, Bernard Bégaud, Géric Maura, Hélène Verdoux. (France)

124. Use of Antipsychotics and Risk of Recurrent Stroke Events: A Population-Based Retrospective Cohort Study in Taiwan [1012]
   Le Dai, Dan-Wei Choo, Jui Wang, Kuo-Liong Chien, Fe-Lin Lin Wu, Zhen-Fang Lin. (Taiwan)

125. Antipsychotic Use and Risk of Hospitalisation or Death Due to Pneumonia in Persons with and without Alzheimer’s Disease [1013]
   Anna-Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Pia Lavikainen, Reijo Sund, Jari Tiihonen, Sirpa Hartikainen, Heidi Taipale.

126. Antidepressant Use and Outcomes in Combination with Contraindicated Comedication in a Tertiary Care Hospital [1014]
   David F Niedrig, Sabrina T Müller, Carmen Gött, Waldemar Greil, Stefan Russmann. (Switzerland)

127. Applying a Novel Anticholinergic Toxicity Scoring System to a Retrospective Cohort of Managed Care Patients [1015]
   Heather Anderson, Katia Hannah, Dong Xu, Vaughn Culbertson, Robert Valuck.

128. A Novel Molecular-Based Anticholinergic Toxicity Scoring System as a Basis for Assessing Drug-Induced Anticholinergic Burden [1016]
   Dong Xu, Vaughn Culbertson, Heather Anderson, Katia Hannah, Robert Valuck.

129. Tolerability/Safety Profile of Cariprazine in Treating Psychotic Disorders/Bipolar Disorder: A Systematic Review with Meta-Analysis of RCTs [1017]
   Shijian Lao, Ying He, Ian CK Wong, Frank MC Besag, Esther W Chan.

130. The Risk of Depression, Euphoric Mood and Sedation with the Use of Dextromethorphan in Different Indications. Results from a Systematic Review and Meta-Analysis of Randomised Clinical Trials [1018]
   Luis Velez-Nandayapa. (United Kingdom)

131. The Risk of Dizziness with the Use of Dextromethorphan in Different Indications; Not a Rare Risk as Described in Label. Results From a Systematic Review and Meta-Analysis of Randomised Clinical Trials [1019]
   Luis Velez-Nandayapa. (United Kingdom)

Safety & Effectiveness - Respiratory

132. Risk of Myocardial Infarction (MI) Associated with Acute Exacerbations of COPD (AECOPD): Effect Modification by Cardiovascular Drugs [1020]
   Kieran J Rothnie, Hana Müllerová, Liam Smeeth, Neil Pearce, Ian Douglas, Jennifer K Quint. (United Kingdom)
132. Inhaled Corticosteroids and the Risk of Hospitalization for Pneumonia. Results from the OUTPUL Study [1021] 
Silvia Cascini, Nera Agabiti, Lisa Bauleo, Ursula Kirchmayer, Valeria Belleudi, Mirko Di Martino, Riccardo Pistelli, Giulio Formoso, Danilo Fusco, Marina Davoli, OUTPUL Study Group. (Italy)

133. Risk of Cardiovascular Events After Glucocorticoid Treatment: A 24-Year Population-Based Cohort Study [1022] 
Erzsébet Horváth-Puhó, Kristina Laugesen, Uffe Heide-Jørgensen, Jens Otto L Jørgensen, Olaf M Dekkers, Irene Petersen, Henrik T Sørensen. (Denmark)

134. Risk of Idiopathic Pulmonary Fibrosis (IPF) in Patients Exposed to Statins and Other Lipid Lowering Agents [1023] 
Daina B Esposito, Crystal N Holick, Macarius Donneyong, Vibha Desai, Stephan Lanes. (United States)

135. Increased Risk of Stroke with Co-Exposure of Acute Respiratory Infection and NSAIDs Use: A Nationwide Case-Grossover Study [1024] 
Yao-Chun Wen, Fei-Yuan Hsiao, Li-Juan Shen, Cheng-Chung Fang. (Taiwan)

136. LABA Safety in Actual Medical Practice: Results from the Longitudinal, Time-Dependent Analyses of the ASTROLAB Data [1026] 
Stéphanie Lamarque, Séverine Lignot-Real-Life Study [1025] 
Bircher, Susan S Jick, Christoph R Meier, Noel C Frey, Michael Bodmer, Andreas Bircher, Susan S Jick, Christoph R Meier, Xuerong Wen, Karl L Worner, Michael J Casey, Alonso H Santos, Abraham G Hartzema. (United States)

143. Impact Of Anti-Inflammatory Drugs On Risk Of Depression And Anxiety After Intensive Care Requiring Mechanical Ventilation [1032] 
Clara R Medici, Sören D Ostergaard, Henrik T Sørensen, Lars Pedersen, Christian F Christiansen. (Denmark)

144. Utilization of Belatacept in Renal Transplant Recipients in USA [1033] 
Xuerong Wen, Karl L Worner, Michael J Casey, Alonso H Santos, Abraham G Hartzema. (United States)

147. Comparison of Outcomes Following a Switch from a Brand to an Authorized vs. Independent Generic Drug [1036] 
Surendranath Gutta, Yola Moride. (France)

148. Potential Prescribing Omissions Among older US Adults According to START Criteria [1037] 
Richard A Hansen, Jingjing Qian, Richard Berg, James Linneman, Enrique Secoane-Vazquez, Sarah Dutcher, Saeid Raofi, Peggy Peissig. (United States)

149. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Population-Based Case-Control Study [1038] 
Noël C Frey, Michael Bodmer, Andreas Bircher, Susan S Jick, Christophe R Meier, Julia Spoendlin. (Switzerland)

151. Mapping of Existing Disease-Specific Data Sources for The Conduct Of Real-World Studies in Duchenne Muscular Dystrophy (DMD) in North America and Europe [1040] 
Aurore Bergamasco, Chung-Yan Yuen, Tzyuyng D Kou, Yola Moride. (France)

152. Mapping of Existing Disease-Specific Data Sources in Latin America for the Conduct of Real-World Studies [1041] 
Aurore Bergamasco, Teigna Arredondo-Bisono, Gerardo Machnicki, Camilo Obando, Julio Azzael Hernandez-Moran, Alan Andryc, Xiaoying Wu, Louis Pozzo, Surendranath Gutta, Yola Moride. (Canada)

153. Mapping Of Existing Disease-Specific Data Sources For The Conduct Of Pharmacoepidemiologic Studies In China [1042] 
Chung Yan Yuen, Aurore Bergamasco, Teigna Arredondo-Bisono, Yola Moride. (Canada)

154. Assessment and Comparison of Competitiveness Between Clinical Trial Protocols: A Simulation Approach Using Publicly Available Registered Clinical Trials [1043] 
Andrew Wilson, Sergey Krikov, Craig Parker, Allise Kamauu, Rebekah K Paredes, Aaron WC Kamauu.

155. Progress and Future of Medical Information Database Network (MID-NET®) Project [1044] 
Yu Matsuzaki, Fumitaka Takahashi, Mitsune Yamaguchi, Yoshiaki Uyama, On Behalf of MID-NET Project Group. (Japan)

156. A Framework for Rapid Medical Product Safety Assessment: FDA’s Sentinel Toolkit [1045] 
Elizabeth Cavagnaro, Hannah Katcoff, Candace Fuller, Tiffany S Woodworth, Jennifer R Popovic, Nicolas Beau lieu, April Duddy, Eric Gravel, Erick Moyneur, Sengwee Toh, Jeffrey Brown. (United States)

157. Lessons Learned from the Assembly of the SENATOR Drug File [1046] 
Michael McCarthy, Shane Cullinan, Denis O’Mahony, Stephen Byrne. (Ireland)

158. An eResearch Query Definition Library: Methods and Value [1047] 
Maggie Lohnes, Craig Parker, Aaron WC Kamauu.

Irene S Cosmatos, Rebecca J Levin, Michael Bulgrien, Jamie Reifsnnyder.
160. Assessing the Gaps in Turning Data into Insights Using Real World Evidence [1049]
Sharon Hensley Alford, Brandon Fiegoli, Sarah M Miller, Karen E Wells. (United States)

161. Comparative Assessment of US Healthcare Databases and Linkage Capabilities for Pharmacoepidemiology Studies [1050]
Deborah Casso, Karin E Johnson, Syd Phillips, Susan A Oliveria. (United States)

162. Impact of the US ICD-9 to ICD-10 Code Transition on Clinical Research [1051]
Aaron WC Kamauu, Maggie Lohnes, Kyle P Paredes, Scott DuVall. (United States)

163. Leveraging NLP-Assisted Semi-Automated Chart Review for Detecting Rare Clinical Events from Narrative Clinical Notes [1052]
Aaron WC Kamauu, Nicole Bailey, Andrew Wilson, Patrick Alba, Olga Patterson, Scott DuVall.

Panagiotis Antoniou, Eirini Apostolidou, Dimitrios Kouvelas, Panagiotis Bambidis. (Greece)

165. Medication Safety Infrastructure at Saudi Hospitals: A Descriptive Cross-Sectional Pilot Study [1054]
Mohammed Alsultan, Mohamed Alkelya. (Saudi Arabia)

166. Representativeness of Electronic Medical Records to Support Novelty (A Novel Observational Longitudinal Study of Patients with Asthma and/or COPD) [1055]
Xia Wang, Alecka Svereuvs, Josh Hillier, Diana Wong, Paola Nasuti, Harvey Jenner, Alexia McKenney, Aaron Kamauu, Kyle Martin Flickinger, Maria Gerhardsson de Verdier. (United States)

HEOR

167. The Effect of Intensified Anti-Tuberculosis Therapy on Patient’s Health Status (Symptoms, Activity and Respiratory Impact) [1056]
Jair At Thobari, Bryan CG Wibisono, Dyah Perwitasari, Ully A Mulyani. (Indonesia)

168. Patient-Reported Outcomes in Adults Suffering from Acute Coronary Syndrome: A Comprehensive Analysis from the Pharmacoepidemiology General Research eXtension System (PGRx3) [1057]
Jesus Cuervo, Clementine Nordon, Michel Rossignol, Nicolas Morisot, Jacques Benichou, Nicolas Danchin, Lucien Abenhaim, Lamiae Grimaldi. (Spain)

169. Association Between Quality of life and Medication Use for Baby Boomers and Older People, by Cardiovascular Disease Status [1058]
Bee Leng Per, Anne Taylor, Tiffany Gill. (Australia)

170. Do GPs Adhere to the Guidelines? A Study Based on Stats Prescriptions [1059]
Irene Petersen, Federico Ricciardi, Irwin Nazareth, Gianluca Baio. (United Kingdom)

171. Costs Analysis Of Traditional And New Oral Anticoaguulants: A Retrospective Analysis In A Local Health Authority In Northern Italy [1060]
Silvia Lucchi, Alfredo Cocci, Salvatore Mannino. (Italy)

172. The Healthcare Costs of Heart Failure During the Last Five Years of Life: A Retrospective Cohort Study [1061]
William Hollingworth, Mousumi Biswas, Rachel Maishman, Mark Dayer, Theresa McDonagh, Sarah Purdy, Barnett Lee, Chris Rogers, Rachael Williams, Maria Pufulete.

173. Racial Differences in Productivity Loss Attributable to Rheumatoid Arthritis Among Patients Taking Disease-Modifying Antirheumatic Drugs (DMARDs) [1062]
Laurar M Bozzi, Priyanka Gaitonde, Fadia Shaya, Sarah E Tom. (United States)

174. Patient Monitoring – the Hidden Costs of Treatment with Antipsychotics [1063]
Mariette Nederlof, Geert WJ Frederik, Lennart J Stoker, Wouter W van Solinge, Toine CG Eggerts, Elbert R Heerdink. (Netherlands)

175. Assessment of Predictive Ability of SLANSS and ID Pain Questionnaires in Assessing Pain Related Outcomes in Chronic Non-Cancer Neuropathic Pain Conditions [1064]
Rambabu Vatte, Dipika Bansal, Babita Ghai, Kapil Gudala. (India)

176. A Qualitative Study to Develop Patient Materials on Opioid Use in Orthopaedic Surgery [1065]
David Smith, Jennifer Schneider, Jennifer Kuntz, Jill Mesa, Xiuhai Yang, Amanda Petrik, Lynn DeBar. (United States)

177. What Is the Evidence on Financial Toxicity of Cancer Treatment? [1066]
Emre Yucel, Aylin Yucel. (United States)

178. Measuring Outcomes Among Metastatic Prostate Cancer Patients in Administrative Claims Data Using the Center for Medicare and Medicaid Services Oncology Care Model [1067]
Debra E Irwin, Lisa A Palmer. (United States)

179. Quality of Life of Patients with Diabetes Mellitus Types 1 and 2 from a Reference Health Care Center in Minas Gerais, Brazil [1068]
Adriana R Mata, Brian Godman, Juliana Álvares, Leonardo M Diniz, Michael Ruberson, Bárbara R Alvernaz, Augusto A Guerra Júnior, Mariangela Leal Cherchiglia, Eli Iola Gurgel Andreade, Francisco de Assis Acurio. (Sweden)

180. Impact of Patient Counseling on Medication Adherence Behavior and Quality of Life in Diabetics of Telangana Region [1069]
varun Talia, B Rajashkekar, P Anusha, Venkateshwar Rao Jupally, Anvesh Cheera, Sanjeev Kumar Subudhi, Satyanarayana Patnalk. (India)

Charles E Okafor, Obinna I Ekwunife. (Nigeria)

182. Resource Utilization of Adult Patients with Sporadic Angiomyolipoma in the Netherlands [1071]
Francis Vekem, Matthew Magestro, Paul Karner, Jonathan Fortier, Mei Sheng Duh, Bernard A Zonnenberg. (Canada)

183. Costs with Medicines and Services in the Treatment by Patients with Schizophrenia [1072]
Wallace Breno Barbosa, Augusto Afonso Guerra Junior, Rosangela Maria Gomes, Juliana Oliveira Costa, Lívia Lovato Pires Lemos, Francisco Assis Acurio. (Brazil)

184. Some Statistical Considerations in Estimating a Disease Progression Model for Chronic Obstructive Pulmonary Disease (COPD) [1073]
Alex Exuzides, Chris Colby, Andrew H Briggs, Nancy Riesebox, Timothy Baker, Afslai Ismaila. (United States)

185. What Are Patient’s Willing to Pay for Pharmacogenomic Testing? [1074]

186. Policy Options to Lower Prescription Drug Prices in the United States [1075]
G Caleb Alexander, Jeromie Ballreich, G Caleb Alexander, Jeromie Ballreich, Mariana P Socal, Tanja Karmarkar, Antonio Trujillo, Jeremy Green, Joshua Sharfstein, Gerard Anderson. (United States)
POSTER SESSION C: Sunday, August 28 | 8:00am - 1:45pm

187. The Role of Real-World Data in Single Technology Appraisal Submissions in the United Kingdom [1076]
Nathalie A Waser, Sarah M Goring, Sisi Wang, Rei Tao, Ellen E Korol. (Canada)

188. Abstract Withdrawn [1077]

189. Assessment of Pharmacist Interventions of Drug Related Problems Among Patients with Impaired Renal Function [1078]
Savitha R Sanathan, Madhan Ramesh, Manjunath S Shetty. (India)

DUR - Trends

190. New Chronic Disease Medication Prescribing by Nurse Practitioners, Physician Assistants, and Primary Care Physicians: A Cohort Study [1079]
Zachary Marcum, Johanna Bellon, Jie Li, Walid Gellad, Julie Donohue. (United States)

Gillian Bartlett, Brenda MacGibbon. (Canada)

Jason C Hsu, Christine Y Lu. (Taiwan)

Jenny Guadamuz, Caleb Alexander, Dima M Qato.

194. Trends in Medicines Procurement by the Brazilian Federal Government from 2006 to 2013 [1083]
Tatiana Chama Borges Luz, Claudia Garcia Serpa Osorio-de-Castro, Rachel Magarinos-Torres, Bjorn Wettermark. (Brazil)

Yared Santa-Ana-Tellez, Luisa Ibañez, Carlos Durán, Elena Ballarin, Mónica Sabaté, Aukje K Mantel-Teeuwisse, Veronika J Wirtz, Monique Elseviers, Björn Wettermark, Robert H Vander Stichele. (Netherlands)

196. Sale of Phthalate Containing Drugs in Denmark from 2004 to 2012 [1085]
Anne Broe, Zandra N Ennis, Jesper Hallas, Thomas Ahern, Anton Pottegaard, Per Damkier. (Denmark)

197. Use of Proton Pump Inhibitors Among Adults: A Danish Nationwide Drug Utilization Study [1086]
Anton Pottegård, Anne Broe, Jesper Hallas, Ove BS de Muckadell, Annmarie T Lassen, Anders B Lodrup. (Denmark)

198. Utilization Of Tacrolimus And Pimecrolimus In Europe: Results from the JOINT European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE) Study [1087]

DUR - Trends in Alimentary and Metabolic

199. Impact of Safety Warning on Domperidone Prescribing in Ireland [1088]
Mary Teeling, MaryJo MacAvin, Kathleen Bennett. (Ireland)

200. Initiation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease in France Between 2011 and 2013: A Nationwide Study Based on Medico-Administrative Databases [1089]
Pierre-Olivier Blotilère, Jérémie Rudant, Amélie Barré, Antoine Racine, Alain Weill, Franck Carbonnel, François Ailla. (France)

201. Treatment Patterns of Thiopurines in a Danish Population Diagnosed with Inflammatory Bowel Disease: A Drug Utilization Study [1090]
Marie S Kristensen, Thora M Kjærrulf, Lau C Thygesen, Nikoline N Knudsen, Anders Green, Vibeke Andersen, Annette K Erbsoll. (Denmark)

202. Drug Utilization Patterns of Tumor Necrosis Factor Inhibitor Agents in a Population with Inflammatory Bowel Disease from 2009 to 2014 in Denmark [1091]
Thora M Kjærrulf, Marie S Christensen, Annette K Erbsoll, Nikoline N Knudsen, Anders Green, Vibeke Andersen, Lau C Thygesen. (Denmark)

203. Dispensing Patterns of Prescription-Only Antiobesity Preparations in South Africa [1092]
Ilse Truter. (South Africa)

204. Characteristics of Patients Prescribed Prucalopride versus an Active Comparator in England, Wales, and Northern Ireland [1093]
Leah J McGrath, Ana Ruigomez, Estel Plana, Joan Fortuny, Luis-Alberto Garcia-Rodríguez, Cristina Rebordosa, Cristina Varas-Lorenzo, Ryan Ziemiecki, Alicia W Gilsenan, Elizabeth Andrews. (United States)

Nanhee Park, Bo Ram Yang, Joongyub Lee, Nam-Kyong Choi, Ye-Jee Kim, Jong-Mi Seong, Mi-Sook Kim, Kyoung-uen Kwon, Xue-Mei Jin, Byung-Joo Park.

206. Pattern of Use of Incertin-Based Medicines in a Large Sample of the Italian General Population [1095]
Giuseppe Roberto, Francesco Barone Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferraiolo, Francesco Lapi, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini. (Italy)

207. Impact of Pioglitazone Withdrawal in France: A Study Using Data from the National Healthcare Insurance System [1097]
Antoine Pariente, Yohann Mansiaux, Francesco Salvo, Cecile Pageot, Andy Smith, Bernard Bégaud. (France)

Diana H Christensen, Jorgen Rungby, Reimar W Thomsen. (Denmark)

209. Treatment of Polycystic Ovary Syndrome in UK Primary Care 2004-2012 [1099]
Tao Ding, Gianluca Baio, Irene Petersen, Paul Hardiman, Cormac Simmons. (United Kingdom)

DUR - Trends in Anti-infectives

210. Increase In Prescribing Of Systemic Tetracyclines And Isotretinoin For Treatment Of Acne Vulgaris in Norwegian Adolescents From 2005 To 2014 [1100]
Ingvild Odsbu, Randi Selmer, Cecilia Stålsby Lundborg, Hege Salvesen Blix. (Sweden)

211. Retrospective Study on Antibiotics Usage Employing Who ATC DDD Methodology [1101]
Puppala Krishna Geetika, Surulivelraj Mallayasaray, Chiranjay Mukhopadhyay. (India)

212. Travel Time to Pharmacy Influence the Use of Antibiotics in Norway [1102]
Kristian Svendsen, Håvard Kongsård, Pål Haugen, Lars Småbrekke. (Norway)


216. Trends in Utilization of Antibiotics in Norway - Do We Reach the National Goals? [1106] Kari Husabø, Òlaug Fenne, Sissel Torheim, Hege Salvesen Blix, Kari Furu. (Norway)


218. Dispensing Patterns of Anthelmintic Drugs by a Community Pharmacy Group in South Africa [1108] Ilse Truter, Liana Steenkamp. (South Africa)

219. NOACs: Are We Prescribing Appropriately? [1108] Sinead Keohane, Vicki Sandys, Michael Barry. (Ireland)

220. General Pharmacological Treatments Preceding A Primary Chronic Immune Thrombocytopenia Diagnosis [1110] Lukas Löfling, Marie Linder, Charlotte Ekstrand, Honar Cherif, Helle Kieler, Shahram Bahmanyar. (Sweden)

DUR - Trends in GU and Hormones


226. Consumption and Expenditure of Non-Targeted and Targeted Cancer Drugs in Ecuador [1116] Carlos E Durán, Robert Vander Stichele, Thierry Christiaens, Monique Elseviers. (Ecuador)

227. A Comparative Study to Evaluate Treatment Patterns & Resulting Utility in Patients of Head & Neck Cancers Under Private Payment Scheme and Government Reimbursement Scheme [1117] Himanshu Patel, Parthasarathi Gurumurthy, YS Madhavi, MS Vishveshwara, Ramesh Madhan. (India)


DUR - Trends in Cardiovascular

229. Impact of Regulatory Action on Prescribing of Renin-Angiotensin System Blockers in the UK [1119] Craig Allen. (United Kingdom)


DUR - Trends in Cancer

221. Evolving Australian, and Northern European, Utilisation Patterns for Immunosuppressants After Transplantation [1111] Kyle M Gardiner, Susan E Tett, Christine E Staatz. (Australia)

222. Trends in Prevalence of Lung Cancer and Targeted Therapies Utilization for Lung Cancer Treatment in Taiwan (2004-2013) [1112] Jason C Hsu, Chen-Fang Wei, Christine Y Lu. (Taiwan)

223. Differences in Recording of Characteristics Among Patients Prescribed Oral Anticoagulants Using Primary Care and Cardiologist Data in Germany [1122] Shuk-Li Collings, Michelle Johnson, Sebastian Kloss, David Evans, Andrew Maguire, Cinira Lefèvre. (United Kingdom)

224. Differences in Statin Users and Non-Users with Bacteremia [1123] Ajinkya M Pawar, Aisling R Caffrey. (United States)


226. Patterns of Use of Antimicrobial Drugs to Treat Overactive Bladder in Denmark, Sweden and the United Kingdom [1126] Andrea V Margulis, Marie Linder, Alejandro Arana, Anton Pottegård, Ingegård Anveden-Berglund, Christine L Bui, Nina Kristiansen, Shahram Bahmanyar, Lisa J McQuay, Willem Jan Atsma, Kwame Appenteng, Billy Franks, Stefan de Vogel, Milibhor D’Silva, Susana Perez-Guthmann, Jesper Hallas. (Spain)


228. Abstract Withdrawn [1128]

229. Use Of Cyproterone Acetate/Ethinylestradiol In The United Kingdom Prior To And Following Recent Updated Guidance: Prescribing Patterns Using A National Primary Care Database [1129] Lucía Cea Soriano, Alex Asimwwe, Hissba Tus-Saboor Khan, Vita Beckert, Ulrike Wissinger-Graefenhahn, Luis A Garcia Rodriguez.

DUR - Trends in Musculo-Skeletal

241. Use of Emergency Contraceptives in Two European Countries [1131]
Ria Benko, Claudia Furtado, Teresa Risso, Maria Matuz. (Hungary)

242. Characteristics of New Users of Osteoporosis Drugs Changed Over Time, Yet High Compliance with Therapy Remained Stable [1132]
Joann K Ban, Giulia P Consiglio, Bochao B Hao, Marina Simeonova, Andrea M Burden, Suzanne M Cadarette. (Canada)

Nancy Carnide, Shelah Hog-Johnson, Andrea Furlan, Pierre Côté, Mieke Koevoorn. (Canada)

244. Intra-Articular Injection Switching Patterns Among Patients with Knee Osteoarthritis: Data from the Osteoarthritis Initiative [1134]
Shao-Hsien Liu, Catherine E Dubé, Jeffrey B Driban, Timothy E McAlindon, Charles B Eaton, Kate L Lapanne. (United States)

245. Factors Associated with Use of Disease Modifying Agents for Rheumatoid Arthritis in the National Ambulatory Medical Care Survey (NAMCS) [1135]
Priyanka Gaitonde, Laura M Bozzi, Fadia T Shay. (United States)

246. Trends of Allopurinol Use in Norway and in Hungary [1136]
Maria Matuz, Hege Salvesen Blix, Ria Benko, Peter Doro, Gyongyver Soos. (Norway)

DUR - Trends in Neurological

247. Psychotropic Drug Use in Subjects Presenting with a Cancer Diagnosis [1137]
Penichon Marine, Díaz Fabienne, Pambrun Elodie, Fourrier-Reglat Annie, Tournier Marie. (France)

248. Predicting Rehospitalization in Patients Treated with Antipsychotics: A Prospective Observational Study [1138]

249. Persistence of Antipsychotic Medications in Patients with Schizophrenia: A Cross-National Study from the Asian Pharmacoepidemiology Network (AsPEN) [1139]

250. Long-Acting Injectable Antipsychotics: Patterns of Use and Determinants of Treatment Failure in a Northern Italy Area [1140]
Lorenzo Berardi, Ippazio C Antonazzo, Carlo Piccinni, Antonella Piazza, Emanuel Raschi, Elisabetta Poluzzi. (Italy)

251. Incident Use of Benzodiazepines in France from 2006 to 2012: A Population-Based Study [1141]
Anne Bénard-Laribière, Pernelle Noize, Elodie Pambrun, Fabienne Bazin, Hélène Verdoux, Marie Tournier, Bernard Bégaud, Antoine Pariente. (France)

252. Utilization Patterns of Antidepressants in France from 2007 to 2012: A Population-Based Study [1142]
Anne Bénard-Laribière, Antoine Pariente, Elodie Pambrun, Fabienne Bazin, Pernelle Noize, Hélène Verdoux, Bernard Bégaud, Marie Tournier. (France)

253. Trends and Prescription Patterns of Anti-Alzheimer Drugs Used in Japan from 2010 to 2015: A Descriptive Study Based on Pharmacy Claims Databases [1143]
Kimiko Kadohara, Izumi Sato, Yuko Doi, Masaru Arai, Yosuke Fujii, Toshiyuki Matsunaga, Koji Kawakami. (Japan)

254. Evaluation Of Antidepressant Drug Use In Populations In the UK and Quebec [1144]
Therese M Sheppard, William G Dixon, Nadyne Girard, Robyn Tamblyn. (United Kingdom)

255. Use of Antidepressants Under the Financial Crisis in Greece [1145]
Paraskevi Papaioannidou, Maria Michailidou, Achilles Ntatars, Stamata Michailidou. (Greece)

256. Assessment of the Impact of Medical Fee Schedule Revision on Polypharmacy of Psychotropic Agents in Japan [1146]
Rie Nishikino, Chie Ito, Shiho Tsuchiya, Yoshie Onishi. (Japan)

257. Trend and Prescription Patterns of Antipsychotic Medications (APMs) in Asia and US: A Cross-National Comparison Study [1147]

258. Antipsychotic Use in Dementia: A Comparison Between Three European Countries [1148]
Janet Sultana, Francesco Giorgianni, Ingrid Leal, Miram Sturkenboom, Gianluca Trifiro’. (Italy)

259. Antipsychotic Prescription Trend in Hong Kong from 2004 to 2014 [1149]
Shijian Lao, Esther W Chan, Kenneth KC Man, Ian CK Wong.

260. Antipsychotic Prescribing in a Tertiary Hospital Under the Financial Crisis in Greece [1150]
Paraskevi Papaioannidou, Paschalina Kasviki, Nikolaos P Moschopoulos, Ioannis Nimatzoudis. (Greece)

261. Time-to-First Discontinuation in New Users of Second Generation Antipsychotics in Older People [1151]
Henry C Ndulke, Prasad S Nishtala. (New Zealand)

262. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Children and Adolescent Medicaid Beneficiaries, 1999-2010 [1152]
Rene Soria-Saucedo, Xinyue Liu, Juan Hincapie-Castillo, Regina Bussing, Almut G Winterstein. (United States)

263. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Adult Medicaid Beneficiaries, 1999-2010 [1153]
Rene Soria-Saucedo, Xinyue Liu, Juan Hincapie-Castillo, Regina Bussing, Almut G Winterstein. (United States)

264. Comparing the Increase in the Cost of Drug Prices Among Multiple Sclerosis Drugs: Anticipated vs. Market Prices Between 2010-2015 [1154]
Jonathan Campbell, Brandi Vollmer, John Corboy, Timothy Vollmer. (United States)

265. The Nudge, the Push and the Mole: Management of Long-Acting Oxyccodone [1155]
Kevin J Friesen, Shawn C Bugden. (Canada)
266. Exploring Factors linked to In-Patient Hospitalisation Amongst Non-Cancer Pain Patients Prescribed Long-Term Strong Opioids in UK Primary Care [1156]
Muna Adan, Li-Chia Chen, Roger Knaggs. (United Kingdom)

267. Non-Buprenorphine Opioid Utilization Among Patients Using Buprenorphine/Naloxone [1157]
Matthew Daubresse, Brendan Saloner, G Caleb Alexander. (United States)

268. Opioid Utilizations in Patients with Diabetes [1158]
G’yeon Oh, Pratik A Doshi, Daniela C Moga. (United States)

269. Impact of State Laws to Reduce Prescription Drug Abuse on High-Risk Opioid Prescribers [1159]
Hsien-Yen Chang, Tatyana Lyapustina, Lainie Rutkow, Matthew Daubresse, Matt Richey, Mark Faut, Elizabeth A Stuart, G Caleb Alexander. (United States)

270. Drugs Used in Intentional Drug Overdose: Findings from the National Self-Harm Registry Ireland [1160]
Caroline Emer Daly, Eve Griffin, Roger Webb, Ella Arensman. (Ireland)

DUR - Trends in Respiratory
271. Asthma Hospitalization Differences Between Generics and Brand of Montelukast [1161]
Yasser Albogami, Abraham Hartzema. (United States)

Yasser Albogami, Abraham Hartzema. (United States)

273. The Role of Patient Characteristics in Dosage Form of ICSLABA Prescriptions [1163]
Kristine E Lynch, Jill S Helmke, Olga V Efimova, Scott L DuVall. (United States)

Daniel P Henriksen, Anders Christiansen, Jesper R Davidsen, Christian B Laursen, Per Damkier, Jesper Hallas, Anton Pottegård. (Denmark)

Pili Ferrer, Mónica Sabaté, Elena Ballarín, Xavier Vidal, Sven Schmiedl, Olaf H Klungel, Luisa Ibáñez. (Spain)

276. Characteristics of New Users of Aclidinium Bromide in the United Kingdom [1166]
Cristina Rebordosa, Cristina Varas-Lorenzo, Jordi Castellsague, Estel Plana, Christine Bui, Jaume Aguado, Esther Garcia Gil, Susana Perez-Gutthann. (Spain)

277. Predictors for the Prescription of Aclidinium Bromide as Compared to Tiotropium Bromide Using German Claims Data [1167]
Nadine Wentzell, Bianca Kollhorst, Tania Schink.

278. Patterns of Roflumilast Use for the Treatment of COPD Across Three Distinct Populations: Findings from the Roflumilast PASS Study [1168]

279. COPD Patients Initiating Roflumilast in Sweden, Germany and the United States: Findings from the Roflumilast PASS Study [1169]
Fabian Hoti, Vasilii Mushnikov, Juha Mehtälä, Nadine Wentzell, Bianca Kollhorst, Tania Schink, Pasi Korhonen, Gunnar Johansson, Edeltraut Garbe. (Finland)

280. Treatment of Patients with Pulmonary Tuberculosis in China [1170]
Minfu He, Jian Du, Yongjing Zhang, Yuhong Liu, Liang Li. (China)

Kristine E Lynch, Benjamin Viernes, Olga V Efimova, Jill Helmke, Scott L DuVall. (United States)

282. Hospitalization and Length of Stay Among Patients with Non-Valvular Atrial Fibrillation Taking Dabigatran or Warfarin: A Population-Based Cohort Study [860]
Wallis CY Lau, Xue Li, Ian CK Wong, Esther W Chan. (Hong Kong)

283. Discrete Event Simulation for Facilitating Between-Study Comparisons [879]
Mehdi Najafzadeh, Sebastian Schneeweiss, Nitesh Choudhry, Shirley Wang, Joshua Gagne. (United States)

End Session C
### FRIDAY, AUGUST 26

#### Meascan de Meds: Utilization and Trends

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>10:30am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>10:45am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>11:00am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>11:15am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>11:30am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>11:45am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### BRACE Yourself

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td></td>
<td>10:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>10:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>11:00am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>11:15am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>11:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>11:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Adverse Events of Cardiovascular Treatment: Head to Toe

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td></td>
<td>10:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>10:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>11:00am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>11:15am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td>11:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>11:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Pregnancy and Beyond

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td></td>
<td>10:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>10:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>11:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>22</td>
<td></td>
<td>11:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>11:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>11:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Keeping an I in Opioid Use

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td></td>
<td>10:30am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>26</td>
<td></td>
<td>10:45am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>27</td>
<td></td>
<td>11:00am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>11:15am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>29</td>
<td></td>
<td>11:30am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td>11:45am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Data Lost and Found

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td></td>
<td>10:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>32</td>
<td></td>
<td>10:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>33</td>
<td></td>
<td>11:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>34</td>
<td></td>
<td>11:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>35</td>
<td></td>
<td>11:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>36</td>
<td></td>
<td>11:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Bittersweet: Trends and Treatments in Diabetes

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td></td>
<td>1:30pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>38</td>
<td></td>
<td>1:45pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>37</td>
<td></td>
<td>2:00pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>40</td>
<td></td>
<td>2:15pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>41</td>
<td></td>
<td>2:30pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>42</td>
<td></td>
<td>2:45pm</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Cancer: Around the World in Databases

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td></td>
<td>1:30pm</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>44</td>
<td></td>
<td>1:45pm</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>45</td>
<td></td>
<td>2:00pm</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
</tbody>
</table>
**FRIDAY, AUGUST 26 Cont.**

**Exploring Innovative Methods to Conduct Validation Using United States Medicare Administrative Claims Data**

- **Poster Session A: Spotlight Session-Adherence**
  - 80 A 12:15pm-1:15pm Third Floor Poster
  - 81 B 12:15pm-1:15pm Third Floor Poster
  - 82 C 12:15pm-1:15pm Third Floor Poster
  - 83 D 12:15pm-1:15pm Third Floor Poster
  - 84 E 12:15pm-1:15pm Third Floor Poster
  - 85 F 12:15pm-1:15pm Third Floor Poster
  - 86 G 12:15pm-1:15pm Third Floor Poster
  - 87 H 12:15pm-1:15pm Third Floor Poster

**Poster Session A: Spotlight Session-Databases**

- 89 I 12:15pm-1:15pm Third Floor Poster
- 90 J 12:15pm-1:15pm Third Floor Poster
- 91 K 12:15pm-1:15pm Third Floor Poster
- 92 L 12:15pm-1:15pm Withdrawn by Author
- 93 M 12:15pm-1:15pm Third Floor Poster
- 94 N 12:15pm-1:15pm Third Floor Poster
- 95 O 12:15pm-1:15pm Third Floor Poster

**Poster Session A: Spotlight Session-Devices**

- 96 P 12:15pm-1:15pm Third Floor Poster
- 97 Q 12:15pm-1:15pm Third Floor Poster
- 98 R 12:15pm-1:15pm Third Floor Poster
- 99 S 12:15pm-1:15pm Third Floor Poster
- 100 T 12:15pm-1:15pm Third Floor Poster
- 101 U 12:15pm-1:15pm Third Floor Poster
- 102 V 12:15pm-1:15pm Third Floor Poster
- 103 W 12:15pm-1:15pm Third Floor Poster

**Poster Session A: Spotlight Session-Pediatrics**

- 104 X 12:15pm-1:15pm Third Floor Poster
- 105 Y 12:15pm-1:15pm Third Floor Poster
- 106 Z 12:15pm-1:15pm Third Floor Poster
- 107 AA 12:15pm-1:15pm Third Floor Poster
- 108 BB 12:15pm-1:15pm Third Floor Poster
- 109 CC 12:15pm-1:15pm Third Floor Poster
- 110 DD 12:15pm-1:15pm Third Floor Poster
- 111 EE 12:15pm-1:15pm Third Floor Poster

**Poster Session A: Burden of Disease - Alimentary & Metabolic**

- 112 1 8:00am-6:00pm The Forum Poster
- 113 2 8:00am-6:00pm The Forum Poster
- 114 3 8:00am-6:00pm The Forum Poster
- 115 4 8:00am-6:00pm The Forum Poster
- 116 5 8:00am-6:00pm The Forum Poster
- 117 6 8:00am-6:00pm The Forum Poster
- 118 7 8:00am-6:00pm The Forum Poster
- 119 8 8:00am-6:00pm The Forum Poster
- 120 9 8:00am-6:00pm The Forum Poster
- 121 10 8:00am-6:00pm The Forum Poster
- 122 11 8:00am-6:00pm The Forum Poster
- 123 12 8:00am-6:00pm The Forum Poster
- 124 13 8:00am-6:00pm The Forum Poster
- 125 14 8:00am-6:00pm The Forum Poster

**Poster Session A: Burden of Disease - Infection**

- 126 15 8:00am-6:00pm The Forum Poster
- 127 16 8:00am-6:00pm The Forum Poster
- 128 17 8:00am-6:00pm The Forum Poster
- 129 18 8:00am-6:00pm The Forum Poster
- 130 19 8:00am-6:00pm The Forum Poster
- 131 20 8:00am-6:00pm The Forum Poster
- 132 21 8:00am-6:00pm The Forum Poster
- 133 22 8:00am-6:00pm The Forum Poster

**Poster Session A: Burden of Disease - Cancer**

- 134 23 8:00am-6:00pm The Forum Poster
- 135 24 8:00am-6:00pm The Forum Poster
- 136 25 8:00am-6:00pm The Forum Poster
- 137 26 8:00am-6:00pm The Forum Poster
- 138 27 8:00am-6:00pm The Forum Poster
- 139 28 8:00am-6:00pm The Forum Poster
- 140 29 8:00am-6:00pm The Forum Poster
- 141 30 8:00am-6:00pm The Forum Poster

**Poster Session A: Burden of Disease - Hematological and Cardiovascular**

- 142 31 8:00am-6:00pm The Forum Poster
- 143 32 8:00am-6:00pm The Forum Poster
- 144 33 8:00am-6:00pm The Forum Poster
- 145 34 8:00am-6:00pm The Forum Poster
- 146 35 8:00am-6:00pm The Forum Poster
- 147 36 8:00am-6:00pm The Forum Poster
- 148 37 8:00am-6:00pm The Forum Poster
- 149 38 8:00am-6:00pm The Forum Poster
- 150 39 8:00am-6:00pm The Forum Poster
- 151 40 8:00am-6:00pm The Forum Poster
- 152 41 8:00am-6:00pm The Forum Poster
- 153 42 8:00am-6:00pm The Forum Poster
- 154 43 8:00am-6:00pm The Forum Poster
- 155 44 8:00am-6:00pm The Forum Poster
- 156 45 8:00am-6:00pm The Forum Poster

**Poster Session A: Burden of Disease - Neurological**

- 157 46 8:00am-6:00pm The Forum Poster
- 158 47 8:00am-6:00pm The Forum Poster
- 159 48 8:00am-6:00pm The Forum Poster
- 160 49 8:00am-6:00pm The Forum Poster
- 161 50 8:00am-6:00pm The Forum Poster
- 162 51 8:00am-6:00pm The Forum Poster
- 163 52 8:00am-6:00pm The Forum Poster
- 164 53 8:00am-6:00pm The Forum Poster
- 165 54 8:00am-6:00pm The Forum Poster
- 166 55 8:00am-6:00pm The Forum Poster
- 167 56 8:00am-6:00pm The Forum Poster
- 168 57 8:00am-6:00pm The Forum Poster
- 169 58 8:00am-6:00pm The Forum Poster
- 170 59 8:00am-6:00pm The Forum Poster
- 171 60 8:00am-6:00pm The Forum Poster
- 172 61 8:00am-6:00pm The Forum Poster
- 173 62 8:00am-6:00pm The Forum Poster
- 174 63 8:00am-6:00pm The Forum Poster
- 175 64 8:00am-6:00pm The Forum Poster
- 176 65 8:00am-6:00pm The Forum Poster
- 177 66 8:00am-6:00pm The Forum Poster
- 178 67 8:00am-6:00pm The Forum Poster
<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>179</td>
<td>67</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>180</td>
<td>68</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>181</td>
<td>69</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>182</td>
<td>70</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>183</td>
<td>71</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>184</td>
<td>72</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>185</td>
<td>73</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>186</td>
<td>74</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session A: Burden of Disease - Respiratory**

- 187 75 8:00am - 6:00pm The Forum Poster
- 188 76 8:00am - 6:00pm The Forum Poster
- 189 77 8:00am - 6:00pm The Forum Poster
- 190 78 8:00am - 6:00pm The Forum Poster
- 191 79 8:00am - 6:00pm The Forum Poster
- 192 80 8:00am - 6:00pm The Forum Poster
- 193 81 8:00am - 6:00pm The Forum Poster
- 194 82 8:00am - 6:00pm The Forum Poster
- 195 83 8:00am - 6:00pm The Forum Poster
- 196 84 8:00am - 6:00pm The Forum Poster
- 197 85 8:00am - 6:00pm The Forum Poster
- 198 86 8:00am - 6:00pm The Forum Poster
- 199 87 8:00am - 6:00pm The Forum Poster
- 200 88 8:00am - 6:00pm The Forum Poster
- 201 89 8:00am - 6:00pm The Forum Poster
- 202 90 8:00am - 6:00pm The Forum Poster
- 203 91 8:00am - 6:00pm The Forum Poster
- 204 92 8:00am - 6:00pm The Forum Poster
- 205 93 8:00am - 6:00pm The Forum Poster

**Poster Session A: Burden of Disease - Other**

- 206 94 8:00am - 6:00pm The Forum Poster
- 207 95 8:00am - 6:00pm The Forum Poster
- 208 96 8:00am - 6:00pm The Forum Poster
- 209 97 8:00am - 6:00pm The Forum Poster
- 210 98 8:00am - 6:00pm Withdrawn by Author
- 211 99 8:00am - 6:00pm The Forum Poster
- 212 100 8:00am - 6:00pm The Forum Poster
- 213 101 8:00am - 6:00pm The Forum Poster
- 214 102 8:00am - 6:00pm The Forum Poster

**Poster Session A: Medical Devices**

- 215 103 8:00am - 6:00pm The Forum Poster
- 216 104 8:00am - 6:00pm The Forum Poster
- 217 105 8:00am - 6:00pm The Forum Poster
- 218 106 8:00am - 6:00pm The Forum Poster
- 219 107 8:00am - 6:00pm The Forum Poster
- 220 108 8:00am - 6:00pm The Forum Poster
- 221 109 8:00am - 6:00pm The Forum Poster
- 222 110 8:00am - 6:00pm The Forum Poster
- 223 111 8:00am - 6:00pm The Forum Poster
- 224 112 8:00am - 6:00pm The Forum Poster
- 225 113 8:00am - 6:00pm The Forum Poster
- 226 114 8:00am - 6:00pm The Forum Poster
- 227 115 8:00am - 6:00pm The Forum Poster
- 228 116 8:00am - 6:00pm The Forum Poster
- 229 117 8:00am - 6:00pm The Forum Poster
- 230 118 8:00am - 6:00pm The Forum Poster
- 231 119 8:00am - 6:00pm The Forum Poster

**Poster Session A: Analytical Methods**

- 232 120 8:00am - 6:00pm Poster Session A: Clinical Trial Methodology
- 233 121 8:00am - 6:00pm Poster Session A: Confounding/Bias
- 234 122 8:00am - 6:00pm Poster Session A: Data Linkage
- 235 123 8:00am - 6:00pm Poster Session A: Measurement & Validation Methods
- 236 124 8:00am - 6:00pm Poster Session A: Study Design

**Poster Session A: Study Design**

- 284 172 8:00am - 6:00pm The Forum Poster
### FRIDAY, AUGUST 26 Cont.

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>285</td>
<td>173</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>286</td>
<td>174</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>287</td>
<td>175</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>288</td>
<td>176</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>289</td>
<td>177</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>290</td>
<td>178</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>291</td>
<td>179</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>292</td>
<td>180</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn</td>
<td>Author</td>
</tr>
<tr>
<td>293</td>
<td>181</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn</td>
<td>Author</td>
</tr>
</tbody>
</table>

**Poster Session A: Pediatrics**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>294</td>
<td>182</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>295</td>
<td>183</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn</td>
<td>Author</td>
</tr>
<tr>
<td>296</td>
<td>184</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>297</td>
<td>185</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>298</td>
<td>186</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>299</td>
<td>187</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn</td>
<td>Author</td>
</tr>
<tr>
<td>300</td>
<td>188</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>301</td>
<td>189</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>302</td>
<td>190</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>303</td>
<td>191</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>304</td>
<td>192</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>305</td>
<td>193</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>306</td>
<td>194</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>307</td>
<td>195</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>308</td>
<td>196</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session A: Adherence**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>309</td>
<td>197</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>310</td>
<td>198</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>311</td>
<td>199</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>312</td>
<td>200</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>313</td>
<td>201</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn</td>
<td>Author</td>
</tr>
<tr>
<td>314</td>
<td>202</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>315</td>
<td>203</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>316</td>
<td>204</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>317</td>
<td>205</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>318</td>
<td>206</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>319</td>
<td>207</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>320</td>
<td>208</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>321</td>
<td>209</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>322</td>
<td>210</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>323</td>
<td>211</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>324</td>
<td>212</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>325</td>
<td>213</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>326</td>
<td>214</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>327</td>
<td>215</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session A: Use of Medicines - Alimentary & Metabolic**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>328</td>
<td>216</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>329</td>
<td>217</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>330</td>
<td>218</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>331</td>
<td>219</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>332</td>
<td>220</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>333</td>
<td>221</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>334</td>
<td>222</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session A: Use of Medicines - Hematological and Cardiovascular**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>335</td>
<td>223</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>336</td>
<td>224</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>Pub. #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>-------------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>396</td>
<td>284</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>397</td>
<td>285</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>398</td>
<td>286</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>399</td>
<td>287</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>400</td>
<td>288</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>401</td>
<td>289</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>690</td>
<td>290</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**FRIDAY, AUGUST 26 Cont.**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>396</td>
<td>284</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>397</td>
<td>285</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>398</td>
<td>286</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>399</td>
<td>287</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>400</td>
<td>288</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>401</td>
<td>289</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>690</td>
<td>290</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**SATURDAY, AUGUST 27**

**Psychotropics in Pregnancy**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>402</td>
<td></td>
<td>8:00am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>403</td>
<td></td>
<td>8:15am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>404</td>
<td></td>
<td>8:30am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>405</td>
<td></td>
<td>8:45am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>406</td>
<td></td>
<td>9:00am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>407</td>
<td></td>
<td>9:15am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Pay Attention to Pain: ADHD and Pain Treatment DUS**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>408</td>
<td></td>
<td>8:00am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>409</td>
<td></td>
<td>8:15am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>410</td>
<td></td>
<td>8:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>411</td>
<td></td>
<td>8:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>412</td>
<td></td>
<td>9:00am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>413</td>
<td></td>
<td>9:15am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Psychotropic Trends on Populations from a Multinational Perspective**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>414</td>
<td></td>
<td>8:00am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>415</td>
<td></td>
<td>8:15am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>416</td>
<td></td>
<td>8:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>417</td>
<td></td>
<td>8:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>418</td>
<td></td>
<td>9:00am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>419</td>
<td></td>
<td>9:15am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**A Sticky Subject: Diabetes Safety**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>420</td>
<td></td>
<td>8:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>421</td>
<td></td>
<td>8:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>422</td>
<td></td>
<td>8:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>423</td>
<td></td>
<td>8:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>424</td>
<td></td>
<td>9:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>425</td>
<td></td>
<td>9:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Broken & Torn**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>426</td>
<td></td>
<td>8:00am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>427</td>
<td></td>
<td>8:15am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>428</td>
<td></td>
<td>8:30am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>429</td>
<td></td>
<td>8:45am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>430</td>
<td></td>
<td>9:00am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
<tr>
<td>431</td>
<td></td>
<td>9:15am</td>
<td>Liffey Hall 1</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Identification and Validation of Outcomes**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>432</td>
<td></td>
<td>8:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>433</td>
<td></td>
<td>8:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>434</td>
<td></td>
<td>8:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>435</td>
<td></td>
<td>8:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>436</td>
<td></td>
<td>9:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>437</td>
<td></td>
<td>9:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
</tbody>
</table>
### SATURDAY, AUGUST 27 Cont.

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>478</td>
<td></td>
<td></td>
<td>Wicklow Hall 2</td>
<td>Symposium</td>
</tr>
</tbody>
</table>

**What's in a Code? Algorithm Validation in Drug Safety Studies**

**The Epidemiological Approach to Rare Disease Research: Challenges and Opportunities**

**The Role of Evidence Synthesis in Drug Safety Evaluation and Regulation**

**A Discussion of Data Requirements and Methodologic Considerations for Evaluating the Real-World Effectiveness and Safety of Biosimilar Medicines**

### Poster Session B: Spotlight Session-AsPEN

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>482 A</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>483 B</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>484 C</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>485 D</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>486 E</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>487 F</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>488 G</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>489 H</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Spotlight Session-BRACE**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>490 I</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>491 J</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>492 K</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>493 L</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>494 M</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>495 N</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>496 O</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>497 P</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Spotlight Session-DUR**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>498 Q</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>499 R</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>500 S</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>501 T</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>502 U</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>503 V</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>505 X</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Spotlight Session-Meds in Pregnancy**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>506 Y</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>507 Z</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>508 AA</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>509 BB</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>510 CC</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>511 DD</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>512 EE</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>513 FF</td>
<td>11:45am -12:45pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: BRACE**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>514 1</td>
<td>8:00am -6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>515 2</td>
<td>8:00am -6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>516 3</td>
<td>8:00am -6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>517 4</td>
<td>8:00am -6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>
### Poster Session B: Changing Drug Utilization

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>587</td>
<td>74</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>588</td>
<td>75</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>589</td>
<td>76</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>590</td>
<td>77</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>591</td>
<td>78</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>592</td>
<td>79</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>593</td>
<td>80</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>594</td>
<td>81</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>595</td>
<td>82</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>596</td>
<td>83</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>597</td>
<td>84</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>598</td>
<td>85</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>599</td>
<td>86</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>600</td>
<td>87</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>601</td>
<td>88</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>602</td>
<td>89</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session B: Drug Utilization and Policy

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>603</td>
<td>90</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>604</td>
<td>91</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>605</td>
<td>92</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>606</td>
<td>93</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>607</td>
<td>94</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>608</td>
<td>95</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>609</td>
<td>96</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>610</td>
<td>97</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>611</td>
<td>98</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>612</td>
<td>99</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>613</td>
<td>100</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session B: Geriatric Pharmacoepidemiology

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>614</td>
<td>101</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>615</td>
<td>102</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>616</td>
<td>103</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>617</td>
<td>104</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>618</td>
<td>105</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>619</td>
<td>106</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>620</td>
<td>107</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>621</td>
<td>108</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>622</td>
<td>109</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>623</td>
<td>110</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
<tr>
<td>624</td>
<td>111</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>625</td>
<td>112</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>626</td>
<td>113</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>627</td>
<td>114</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>628</td>
<td>115</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>629</td>
<td>116</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>630</td>
<td>117</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>631</td>
<td>118</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>632</td>
<td>119</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>633</td>
<td>120</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session B: Pharmacovigilance

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>688</td>
<td>175</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>689</td>
<td>176</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>Pub. #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-------------------</td>
<td>------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>SATURDAY, AUGUST 27 Cont.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>691</td>
<td>177</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>692</td>
<td>178</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>693</td>
<td>179</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
<tr>
<td>694</td>
<td>180</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>695</td>
<td>181</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>696</td>
<td>182</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>697</td>
<td>183</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>698</td>
<td>184</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>699</td>
<td>185</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>700</td>
<td>186</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>701</td>
<td>187</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>702</td>
<td>188</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>703</td>
<td>189</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>704</td>
<td>190</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>705</td>
<td>191</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>706</td>
<td>192</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>707</td>
<td>193</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>708</td>
<td>194</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>709</td>
<td>195</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>710</td>
<td>196</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>711</td>
<td>197</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>712</td>
<td>198</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>713</td>
<td>199</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>714</td>
<td>200</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>715</td>
<td>201</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>716</td>
<td>202</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>717</td>
<td>203</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>718</td>
<td>204</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Pharmacovigilance by Geography**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>719</td>
<td>205</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>720</td>
<td>206</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>721</td>
<td>207</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>722</td>
<td>208</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>723</td>
<td>209</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>724</td>
<td>210</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>725</td>
<td>211</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>726</td>
<td>212</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>727</td>
<td>213</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>728</td>
<td>214</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>729</td>
<td>215</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>730</td>
<td>216</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>731</td>
<td>217</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>732</td>
<td>218</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>733</td>
<td>219</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>734</td>
<td>220</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>735</td>
<td>221</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>736</td>
<td>222</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Pharmacovigilance - Alimentary and Metabolic**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>737</td>
<td>223</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>738</td>
<td>224</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>739</td>
<td>225</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>740</td>
<td>226</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>741</td>
<td>227</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>742</td>
<td>228</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>743</td>
<td>229</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>744</td>
<td>230</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Pharmacovigilance - Other Therapeutic**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>778</td>
<td>264</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>779</td>
<td>265</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
<tr>
<td>780</td>
<td>266</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>781</td>
<td>267</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>782</td>
<td>268</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>783</td>
<td>269</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>784</td>
<td>270</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>785</td>
<td>271</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>786</td>
<td>272</td>
<td>8:00am - 6:00pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
<tr>
<td>787</td>
<td>273</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>788</td>
<td>274</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>789</td>
<td>275</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>790</td>
<td>276</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>841</td>
<td>277</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>884</td>
<td>278</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session B: Other Safety & Effectiveness**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1029</td>
<td>279</td>
<td>8:00am - 6:00pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>
**SUNDAY, AUGUST 28**

### From Eve to...

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>791</td>
<td></td>
<td>8:30am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>792</td>
<td></td>
<td>8:45am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>793</td>
<td></td>
<td>9:00am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>794</td>
<td></td>
<td>9:15am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>795</td>
<td></td>
<td>9:30am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
<tr>
<td>796</td>
<td></td>
<td>9:45am</td>
<td>The Liffey A</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### My Achy Breaky Heart: Diabetes and CVD

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>797</td>
<td></td>
<td>8:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>798</td>
<td></td>
<td>8:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>1096</td>
<td></td>
<td>9:00am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>800</td>
<td></td>
<td>9:15am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>801</td>
<td></td>
<td>9:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>802</td>
<td></td>
<td>9:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Keeping Up - A Potpourri

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>803</td>
<td></td>
<td>8:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>804</td>
<td></td>
<td>8:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>805</td>
<td></td>
<td>9:00am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>806</td>
<td></td>
<td>9:15am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>807</td>
<td></td>
<td>9:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>808</td>
<td></td>
<td>9:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Adverse Outcomes and Infectious Diseases

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>809</td>
<td></td>
<td>8:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>810</td>
<td></td>
<td>8:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>811</td>
<td></td>
<td>9:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>812</td>
<td></td>
<td>9:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>813</td>
<td></td>
<td>9:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>814</td>
<td></td>
<td>9:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Implications for Patients, Industry and Regulators

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>831</td>
<td></td>
<td>8:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>832</td>
<td></td>
<td>8:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>833</td>
<td></td>
<td>9:00am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>834</td>
<td></td>
<td>9:15am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>835</td>
<td></td>
<td>9:30am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
<tr>
<td>836</td>
<td></td>
<td>9:45am</td>
<td>The Liffey B</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Adverse Outcomes of Glucocorticoid and Immunomodulator Use

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>837</td>
<td></td>
<td>8:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>838</td>
<td></td>
<td>8:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>839</td>
<td></td>
<td>9:00am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>840</td>
<td></td>
<td>9:15am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>841</td>
<td></td>
<td>9:30am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>842</td>
<td></td>
<td>9:45am</td>
<td>Wicklow Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Disease Burden from Clinical Databases

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>843</td>
<td></td>
<td>8:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>844</td>
<td></td>
<td>8:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>845</td>
<td></td>
<td>9:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>846</td>
<td></td>
<td>9:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>847</td>
<td></td>
<td>9:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>848</td>
<td></td>
<td>9:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>849</td>
<td></td>
<td>10:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>850</td>
<td></td>
<td>10:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Moving Forward

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>851</td>
<td></td>
<td>10:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>852</td>
<td></td>
<td>10:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>853</td>
<td></td>
<td>11:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>854</td>
<td></td>
<td>11:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>855</td>
<td></td>
<td>11:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>856</td>
<td></td>
<td>11:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Adverse Outcomes of Glucocorticoid and Immunomodulator Use

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>857</td>
<td></td>
<td>11:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>858</td>
<td></td>
<td>11:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>859</td>
<td></td>
<td>12:00am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>860</td>
<td></td>
<td>12:15am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>861</td>
<td></td>
<td>12:30am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
<tr>
<td>862</td>
<td></td>
<td>12:45am</td>
<td>Liffey Hall 2</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Is it Safe Enough?

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>863</td>
<td></td>
<td>13:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>864</td>
<td></td>
<td>13:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>865</td>
<td></td>
<td>13:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>866</td>
<td></td>
<td>13:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>867</td>
<td></td>
<td>14:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>868</td>
<td></td>
<td>14:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Practice of Epidemiology in Pregnancy Studies

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>869</td>
<td></td>
<td>14:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>870</td>
<td></td>
<td>14:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>871</td>
<td></td>
<td>15:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>872</td>
<td></td>
<td>15:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>873</td>
<td></td>
<td>15:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>874</td>
<td></td>
<td>15:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>875</td>
<td></td>
<td>16:00am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>876</td>
<td></td>
<td>16:15am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>877</td>
<td></td>
<td>16:30am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>878</td>
<td></td>
<td>16:45am</td>
<td>The Auditorium</td>
<td>Oral</td>
</tr>
<tr>
<td>Pub. #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>-------------------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>869</td>
<td>A</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>870</td>
<td>B</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>871</td>
<td>C</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>872</td>
<td>D</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>873</td>
<td>E</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>874</td>
<td>F</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Spotlight Session-CER**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>875</td>
<td>G</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>876</td>
<td>H</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>877</td>
<td>I</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>878</td>
<td>J</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>880</td>
<td>L</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Spotlight Session-Biologics**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>881</td>
<td>M</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>882</td>
<td>N</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>883</td>
<td>O</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>888</td>
<td>P</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>885</td>
<td>Q</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>886</td>
<td>R</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
<tr>
<td>887</td>
<td>S</td>
<td>12:15pm - 1:15pm</td>
<td>Third Floor</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Biologics**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>889</td>
<td>1</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>890</td>
<td>2</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>891</td>
<td>3</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>892</td>
<td>4</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>893</td>
<td>5</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>894</td>
<td>6</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>895</td>
<td>7</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Vaccines**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>896</td>
<td>8</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>897</td>
<td>9</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>898</td>
<td>10</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>899</td>
<td>11</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>900</td>
<td>12</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>901</td>
<td>13</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>902</td>
<td>14</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>903</td>
<td>15</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>904</td>
<td>16</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Safety & Effectiveness - Cancer**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>905</td>
<td>17</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>906</td>
<td>18</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>907</td>
<td>19</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>908</td>
<td>20</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>909</td>
<td>21</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>910</td>
<td>22</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Safety & Effectiveness - GU & Hormones**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>911</td>
<td>23</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>912</td>
<td>24</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>913</td>
<td>25</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>914</td>
<td>26</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>915</td>
<td>27</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>916</td>
<td>28</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>917</td>
<td>29</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>918</td>
<td>30</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: Safety & Effectiveness - Cardiovascular**

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>960</td>
<td>72</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>961</td>
<td>73</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>962</td>
<td>74</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>963</td>
<td>75</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>964</td>
<td>76</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>965</td>
<td>77</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>966</td>
<td>78</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>967</td>
<td>79</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>968</td>
<td>80</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>969</td>
<td>81</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>970</td>
<td>82</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>971</td>
<td>83</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>972</td>
<td>84</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>
### Poster Session C: Other Safety & Effectiveness

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1028</td>
<td>140</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1030</td>
<td>141</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1031</td>
<td>142</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1032</td>
<td>143</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1033</td>
<td>144</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1034</td>
<td>145</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1035</td>
<td>146</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1036</td>
<td>147</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1037</td>
<td>148</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1038</td>
<td>149</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1039</td>
<td>150</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1040</td>
<td>151</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1041</td>
<td>152</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1042</td>
<td>153</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session C: Informatics

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1043</td>
<td>154</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1044</td>
<td>155</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1045</td>
<td>156</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1046</td>
<td>157</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1047</td>
<td>158</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1048</td>
<td>159</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1049</td>
<td>160</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1050</td>
<td>161</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1051</td>
<td>162</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1052</td>
<td>163</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1053</td>
<td>164</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1054</td>
<td>165</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1055</td>
<td>166</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session C: HEOR

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1056</td>
<td>167</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1057</td>
<td>168</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1058</td>
<td>169</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1059</td>
<td>170</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1060</td>
<td>171</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1061</td>
<td>172</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1062</td>
<td>173</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1063</td>
<td>174</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1064</td>
<td>175</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1065</td>
<td>176</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1066</td>
<td>177</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1067</td>
<td>178</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1068</td>
<td>179</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1069</td>
<td>180</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1070</td>
<td>181</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1071</td>
<td>182</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1072</td>
<td>183</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1073</td>
<td>184</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1074</td>
<td>185</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1075</td>
<td>186</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1076</td>
<td>187</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1077</td>
<td>188</td>
<td>8:00am - 1:45pm</td>
<td>Withdrawn by Author</td>
<td>Poster</td>
</tr>
<tr>
<td>1078</td>
<td>189</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Poster Session C: DUR - Trends

<table>
<thead>
<tr>
<th>Pub. #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1079</td>
<td>190</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1080</td>
<td>191</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1081</td>
<td>192</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1082</td>
<td>193</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1083</td>
<td>194</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1084</td>
<td>195</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>Pub. #</td>
<td>Poster #</td>
<td>Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>----------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>1085</td>
<td>196</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1086</td>
<td>197</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
<tr>
<td>1087</td>
<td>198</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
<td>Poster</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Alimentary and Metabolic**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1088</td>
<td>199</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1089</td>
<td>200</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1090</td>
<td>201</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1091</td>
<td>202</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1092</td>
<td>203</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1093</td>
<td>204</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1094</td>
<td>205</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1095</td>
<td>206</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1096</td>
<td>207</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1097</td>
<td>208</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1098</td>
<td>209</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Anti-infectives**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1100</td>
<td>210</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1101</td>
<td>211</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1102</td>
<td>212</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1103</td>
<td>213</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1104</td>
<td>214</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1105</td>
<td>215</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1106</td>
<td>216</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1107</td>
<td>217</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1108</td>
<td>218</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1109</td>
<td>219</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1110</td>
<td>220</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Cancer**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1111</td>
<td>221</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1112</td>
<td>222</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1113</td>
<td>223</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1114</td>
<td>224</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1115</td>
<td>225</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1116</td>
<td>226</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1117</td>
<td>227</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1118</td>
<td>228</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Cardiovascular**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1119</td>
<td>229</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1120</td>
<td>230</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1121</td>
<td>231</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1122</td>
<td>232</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1123</td>
<td>233</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1124</td>
<td>234</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in GU and Hormones**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1125</td>
<td>235</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1126</td>
<td>236</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1127</td>
<td>237</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1128</td>
<td>238</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1129</td>
<td>239</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1130</td>
<td>240</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Musculo-Skeletal**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1131</td>
<td>241</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1132</td>
<td>242</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1133</td>
<td>243</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1134</td>
<td>244</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1135</td>
<td>245</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Neurological**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1136</td>
<td>246</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>

**Poster Session C: DUR - Trends in Respiratory**

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1161</td>
<td>271</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1162</td>
<td>272</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1163</td>
<td>273</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1164</td>
<td>274</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1165</td>
<td>275</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1166</td>
<td>276</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1167</td>
<td>277</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1168</td>
<td>278</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1169</td>
<td>279</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1170</td>
<td>280</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>1171</td>
<td>281</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>860</td>
<td>282</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
<tr>
<td>879</td>
<td>283</td>
<td>8:00am - 1:45pm</td>
<td>The Forum</td>
</tr>
</tbody>
</table>
Advertisers Index

- Amgen .......................................................... 41
- Analysis Group ........................................... 18
- Bayer Pharma ............................................. 29
- BHE Boston Health Economics .................... 52
- Boehringer Ingelheim .................................... 21
- Clinical Practice Research Datalink (CPRD) ...... 53
- Department of Clinical Epidemiology,
  Aarhus University Hospital .......................... 37
- Eli Lilly & Company ..................................... 15
- EPID Research ............................................. 31
- Evalytica .................................................. 50
- Evidera ..................................................... 9
- HealthCore ............................................... 13
- IMS Health GmbH & Co. ............................. 58
- Kantar Health ............................................. 54
- Mapi Group ................................................ 19
- Merck and Company ................................. 17
- Numerus ................................................... 23
- Optum ...................................................... 46
- Pfizer ....................................................... 32
- Quintiles ................................................... 25
- RTI Health Solutions ................................ 48
- Takeda ...................................................... 36
- The Degge Group and DGI, LLC .................. 56
- Truven Health Analytics ........................... 56
- Wiley Publications .................................... 110
Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

Free online access for ISPE members via the society website

Congratulations to The Ronald D. Mann Best Article of 2015 Awards Winners

First Prize
Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case–crossover study
Hung-Lin Chen and Fei-Yuan Hsiao
Volume 24, Issue 8, August 2015, Pages: 841-848

Honorable Mention:
Exposure to systemic antibacterial medications during pregnancy and risk of childhood cancer
Natalie C. Momen, Jørn Olsen, Mika Gissler, Helle Kieler, Bengt Haglund and Jiong Li
Volume 24, Issue 8, August 2015, Pages: 821-829

Honorable Mention:
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting
Joshua A. Roth, Katharine Bradley, Kenneth E. Thummel, David L. Veenstra and Denise Boudreau
Volume 24, Issue 6, June 2015, Pages: 619-627

For more information on these top papers and other journal features, please visit

www.pdsjournal.org

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2016 Volume: 25 • Frequency: Monthly
YOU ARE INVITED TO SUBMIT AN ABSTRACT

ISPE invites you to submit an abstract for an oral/poster presentation, workshop or symposium at the 33rd ICPE in Halifax, Nova Scotia. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and will allow you to experience Halifax's dynamic and lively personality.

GUIDELINES FOR SUBMISSIONS

The deadline for receipt of all abstracts is February 15, 2017. Please visit pharmacoepi.org, for submission guidelines. The online submission site will be operational by mid-December 2016.

Questions about abstract submissions should be directed to infor@pharmacoepi.org. Note, submissions will not be accepted until the online submission site is open in December 2016.

REVIEWING/REGISTRATION

The ISPE Scientific Program Committee will review all abstracts in April 2017. All submitters will be notified by email in early June 2017. All presenters and panelists (workshop/symposia) must register to attend the 2017 ICPE.

SCHOLARSHIPS & STUDENT AWARDS

ISPE will award a limited number of scholarships to help defray conference expenses. Information will be posted on pharmacoepi.org.

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The Scientific Program Committee oversees the selection of awards, which will be presented at the 2017 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

SPONSORSHIPS, EXHIBITS & ACADEMIC SHOWCASE

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on pharmacoepi.org/meetings/33ICPE.

SAVE THE DATES!

August 23-27, 2017
Halifax Convention Centre
Halifax, Nova Scotia

Please visit pharmacoepi.org/meetings/33ICPE for updated conference information.
WE'RE ABOUT SPACE.

The Forum

Liffey Hall 2
Liffey Hall 1
Foyer
Wicklow Hall 2
Wicklow Hall 1
Foyer
Liffey Boardroom 4
Liffey Boardroom 3
Liffey Boardroom 2
Wicklow Meeting Room 5
Wicklow Meeting Room 4
Wicklow Meeting Room 3
Wicklow Meeting Room 2
Wicklow Meeting Room 1
Ecocem Meeting Room
Liffey Meeting Room 5
Liffey Meeting Room 4
Liffey Meeting Room 3
Liffey Meeting Room 2
Liffey Meeting Room 1
Liffey Boardroom 1
Liffey Boardroom 3
The Liffey
The Forum

WHEN I DIE DUBLIN WILL BE WRITTEN IN MY HEART

James Joyce

The Convention Center Dublin

32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management
The Convention Center Dublin

pharmacoepi.org